Gene editing systems targeting UBE3a-ATS and uses thereof

WO2026217760A3PCT designated stage Publication Date: 2026-11-19ARBOR BIOTECHNOLOGIES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/022989
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-10-30
Filing Date
2026-04-09
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Angelman syndrome is caused by mutations in the maternal copy of the E3 ubiquitin ligase UBE3A gene, leading to a loss of function and severe neurodevelopmental disorders, and existing treatments fail to effectively activate the paternal UBE3A gene to compensate for this loss.

Method used

Development of gene editing systems targeting the UBE3A antisense transcript (UBE3A-ATS) gene using CRISPR nucleases and guide RNAs to disrupt the UBE3A-ATS gene, specifically in the cluster 2 exonic and intronic regions, enhancing UBE3A protein production in neurons.

Benefits of technology

The gene editing systems successfully disrupt the UBE3A-ATS gene, increasing UBE3A protein production, thereby alleviating Angelman syndrome phenotypes such as ataxia, absence of speech, and intellectual disability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026022989_19112026_PF_FP_ABST
    Figure US2026022989_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The disclosure is directed, in part to a gene editing system for genetic editing of a E3 ubiquitin ligase UBE3A antisense transcript (UBE3A-ATS) gene, comprising: (i) a CRISPR nuclease; and (ii) a guide RNA specific to the UBE3A-ATS gene sequence. The present disclosures further provide uses the gene editing system for editing a UBE3A-ATS gene in a cell.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No. 063586-568001WO

[0002] GENE EDITING SYSTEMS TARGETING UBE3A-ATS AND USES THEREOF

[0003] CROSS REFERENCE TO RELATED APPLICATIONS

[0004] This application claims the benefit of the filing dates of U.S. Provisional Application No. 63 / 786,782, filed April 10, 2025, U.S. Provisional Application No. 63 / 908,110, filed October 30, 2025, and U.S. Provisional Application No. 64 / 016,827, filed March 25, 2026, the entire contents of each of which are incorporated by reference herein.

[0005] SEQUENCE LISTING

[0006] The instant application contains a Sequence Listing which has been filed electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on April 9, 2026, is named 063586-568001WO_Seq-Listing_ST26.xml and is 1,018,521 bytes in size.

[0007] FIELD

[0008] The disclosure relates to gene editing systems targeting the UBE3A-ATS gene.

[0009] BACKGROUND

[0010] Angelman syndrome is a genetic disorder caused by mutations in the maternal copy of the E3 ubiquitin ligase UBE3A gene (UBE3A). Loss of E3 ubiquitin ligase function in mature neurons due to these mutations leads to a severe neurodevelopmental disorder, whose symptoms include ataxia, absence of speech, seizures, and intellectual disability. The UBE3 A antisense transcript is expressed exclusively from the paternal allele and disruption of the UBE3A-ATS gene will unsilence the UBE3A paternal allele, making up for the loss of maternal UBE3A gene expression.

[0011] Therefore, activating the paternal copy of the UBE3 A gene in mature neurons could benefit patients with Angelman syndrome.

[0012] SUMMARY

[0013] The present disclosure is based, at least in part, on the development of gene editing systems for genetic editing a UBE3A antisense transcript gene (UBE3A-ATS gene), e.g., in the cluster 2 exonic region or in the intronic region of the UBE3A-ATS gene. The gene editing systems provided herein successfully disrupted the UBE3 A antisense transcript from the edited UBE3A-ATS gene, thereby enhancing production of active UBE3A protein in neuron cells.Attorney Docket No. 063586-568001WO

[0014] Such gene editing systems would be effective in treating Angelman syndrome, which is associated with loss of function of UBE3A protein in neuron cells. Accordingly, provided herein are gene editing systems targeting the UBE3A-ATS gene and uses thereof for alleviating Angelman syndrome phenotypes.

[0015] In some aspects, the present disclosure features a gene editing system for genetic editing a UBE3A antisense transcript gene (UBE3A-ATS gene), the gene editing system comprising: (a) a CRISPR nuclease or a first nucleic acid encoding the CRISPR nuclease; and (b) a guide RNA or a second nucleic acid encoding the guide RNA. The guide RNA comprises a spacer sequence that is specific to a target sequence in a UBE3 A antisense transcript gene (UBE3A-ATS gene), and a scaffold sequence recognizable by the CRISPR nuclease. In some instances, the target sequence is adjacent to a protospacer adjacent motif (PAM) comprising the motif of 5’-NTTN-3’, for example, 5’-NTTR-3’, in which each N independently is A, T, G, or C, and R is A or G. The PAM being located 5’ to the target sequence. In other instances, the target sequence is adjacent to a PAM comprising the motif of 5’-NGG-3’, in which N is A, T, G, or C. The PAM is located 3’ to the target sequence.

[0016] In some embodiments, the target sequence is located in a cluster 2 exonic region (chrl5: 25,266,431-25,278,884) of the UBE3A-ATS gene. For example, the target sequence can be located in Exon 5. Exemplary target sequences within the cluster 2 exonic region are provided in Table 4, each of which is within the scope of the present disclosure.

[0017] In other embodiments, the target sequence is located in the intronic region (chrl5: 25,278,885 to 25,333,728) of the UBE3A-ATS gene. In some examples, the target sequence is located in segment 1 of the intronic region (chrl5: 25,278,885 to 25,296,525). In some examples, the target sequence is located in segment 2 of the intronic region (chrl5: 25,296,526 to 25,316,526). In other examples, the target sequence is located in segment 3 of the intronic region (chrl5: 25,316,526 to 25,333,728). Exemplary target sequences within the intronic region are provided in Table 6 and Table 7, each of which is within the scope of the present disclosure.

[0018] In some embodiments, the guide RNA provided herein comprises a spacer sequence specific to any of the target sequences provided herein. Examples are provided in Table 4, Table 6, and Table 7.

[0019] In some examples, the target sequence is set forth as 5’-AACCAGGATTTAAGGATGCC-3’ (SEQ ID NO: 455). In some instances, the corresponding spacer sequence may comprise 5’- AACCAGGAUUUAAGGAUGCC -3’ (SEQ ID NO: 457). In other examples, the target sequence is set forth as 5’- GTATGAGAGATGCTGTTCTA-3’Attorney Docket No. 063586-568001WO

[0020] (SEQ ID NO: 709). In some instances, the corresponding spacer sequence may comprise 5’-GUAUGAGAGAUGCUGUUCUA-3’ (SEQ ID NO: 711). In yet other examples, the target sequence is set forth as 5’- TCCTCCTCCCCTTAGATAAG-3’ (SEQ ID NO: 183). In some instances, the corresponding spacer sequence may comprise 5’-UCCUCCUCCCCUUAGAUAAG-3’ (SEQ ID NO: 185). In still other examples, the target sequence is set forth as 5’-TATATATAATTGAGGGCCAC-3’ (SEQ ID NO: 927). In some instances, the corresponding spacer sequence may comprise 5’-UAUAUAUAAUUGAGGGCCAC-3’ (SEQ ID NO: 929).

[0021] In some embodiments, the CRISPR nuclease involved in the gene editing system disclosed herein comprises an amino acid sequence at least 90% identical to SEQ ID NO: 1. In some instances, the CRISPR nuclease may further comprise one or more nuclear localization signals (NLS), one or more peptide likers, or a combination thereof. Such a CRISPR nuclease recognizes the PAM motif 5’-NTTN-3’, in which each N independent is any one of A, C, G, and T. The scaffold sequence recognizable by such a CRISPR nuclease may comprise a sequence that is at least 80% identical to SEQ ID NO: 7. In one example, the scaffold sequence comprises the sequence of SEQ ID NO: 7.

[0022] In some instances, the CRISPR nuclease is a variant of SEQ ID NO: 1 comprising one or more mutations at positions D581, G624, F626, N840, P868, 1926, V1030, E1035, and / or S1046 of SEQ ID NO: 1, for example, D581R, G624R, F626R, N840R, P868T, I926R, V1030G, E1035R, S1046G, or a combination thereof. In one example, the CRISPR nuclease comprises mutations at positions D581, D911, 1926, and V1030, for example, amino acid substitutions of D581R, D911R, I926R, and V1030G. In another example, the CRISPR nuclease comprises mutations at positions D581, 1926, and V1030, for example, amino acid substitutions of D581R, I926R, and V1030G. In yet another example, the CRISPR nuclease comprises mutations at positions D581, 1926, V1030, and S1046, for example, amino acid substitutions of D581R, I926R, V1030G, and S1046G. In still another example, the CRISPR nuclease comprises mutations at positions D581, G624, F626, 1926, V1030, E1035, and S1046, for example, amino acid substitutions of D581R, G624R, F626R, I926R, V1030G, E1035R, and S1046G. In yet another example, the CRISPR nuclease comprises mutations at positions D581, G624, F626, P868, 1926, V1030, E1035, and S1046, for example, amino acid substitutions of D581R, G624R, F626R, P868T, I926R, V1030G, E1035R, and S1046G. In another example, the CRISPR nuclease comprises mutations at positions D581, G624, F626, N840, P868, 1926, V1030, E1035, and S1046, for example, amino acid substitutions of D581R, G624R, F626R, N840R, P868T, I926R, V1030G, E1035R, and S1046G.Attorney Docket No. 063586-568001WO

[0023] In one specific example, the CRISPR nuclease comprises the amino acid sequence of SEQ ID NO: 3. In another specific example, the CRISPR nuclease comprises the amino acid sequence of SEQ ID NO: 1153. Such a CRISPR nuclease may further comprise one or more nuclear localization signals (NLS), one or more peptide likers, or a combination thereof.

[0024] In some instances, the CRISPR nuclease involved in the gene editing system disclosed herein may comprise an amino acid sequence at least 90% identical to SEQ ID NO: 4. Such a CRISPR nuclease may further comprise one or more NLSs, one or more peptide linkers or a combination thereof. In some examples, the CRISPR nuclease comprises the amino acid sequence of SEQ ID NO: 5 and optionally one or more NLSs and / or peptide linkers. The PAM specific to the CRISPR is 5’-NTTR-3’, in which N is any one of A, C, G, and T and R is A or G. The scaffold sequence recognizable by the CRISPR may comprise a sequence that is at least 80% identical to SEQ ID NO: 8. In one example, the scaffold sequence comprises the sequence of SEQ ID NO: 8.

[0025] In some instances, the CRISPR nuclease involved in the gene editing system disclosed herein may comprise an amino acid sequence at least 90% identical to SEQ ID NO: 6. Such a CRISPR nuclease may further comprise one or more NLSs, one or more peptide linkers or a combination thereof. In some examples, the CRISPR nuclease may comprise the amino acid sequence of SEQ ID NO: 6. The PAM specific to such a CRISPR nuclease is 5’-NGG-3’, in which N is any one of A, C, G, and T. The scaffold sequence recognizable by the CRISPR nuclease may be at least 80% identical to SEQ ID NO: 9. In one example, the scaffold sequence comprises the sequence of SEQ ID NO: 9.

[0026] Exemplary guide RNAs are provided in Table 4, Table 6, or Table 7, each of which is within the scope of the present disclosure. In one example, the guide RNA comprises the sequence of SEQ ID NO: 458. In another example, the guide RNA comprises the sequence of SEQ ID NO: 712. In yet another example, the guide RNA comprises the sequence of SEQ ID NO: 186. In still another example, the guide RNA comprises the sequence of SEQ ID NO: 930.

[0027] In some embodiments, the gene editing system provided herein comprises the first nucleic acid encoding the CRISPR nuclease. In some instances, the first nucleic acid is codon optimized. In some examples, the first nucleic acid encoding the CRISPR nuclease and the second nucleic acid encoding the guide RNA. In some instances, the first nucleic acid and the second nucleic acid are located on one or more vectors. In some examples, at least one of the one or more vectors is a viral vector. In some specific examples, the first nucleic acid and the second nucleic acid are located on one viral vector, which optionally is adeno-associated virus (AAV) vectors.Attorney Docket No. 063586-568001WO

[0028] In some aspects, provided herein is a gene editing system for genetic editing a UBE3 A antisense transcript gene (UBE3A-ATS gene), the gene editing system comprising a genetically modified viral particle, which comprises a viral capsid encapsulating a viral genome. The viral genome comprises a first nucleotide sequence encoding a CRISPR nuclease or a complementary sequence thereof and a second nucleotide sequence encoding a guide RNA or a complementary sequence thereof. The guide RNA comprises a spacer sequence that is specific to a target sequence in a UBE3A antisense transcript gene (UBE3A-ATS gene), and a scaffold sequence recognizable by the CRISPR nuclease. In some instances, the target sequence is adjacent to a protospacer adjacent motif (PAM) comprising the motif of 5’-NTTN-3’, for example, 5’-NTTR-3’, in which each N independently is A, T, G, or C, and R is A or G. The PAM being located 5’ to the target sequence. In other instances, the target sequence is adjacent to a PAM comprising the motif of 5’-NGG-3’, in which N is A, T, G, or C. The PAM is located 3’ to the target sequence. In some instances, the target sequence is located in a cluster 2 exonic region (chrl5: 25,266,431-25,278,884). In other instances, the target sequence is located in an intronic region (chrl5: 25,278,885 to 25,333,728) of the UBE3A-ATS gene.

[0029] The gene editing system provided above may comprise any of the CRISPR nucleases disclosed herein. Alternatively, or in addition, the target sequence specific to the guide RNA in the above gene editing system can be any one disclosed herein. Further, the gene editing system may comprise any of the guide RNAs disclosed herein.

[0030] In some embodiments, the genetically modified viral particle is an engineered AAV viral particle, for example, an AAV particle comprising AAV2 capsid or AAV9 capsid. In some examples, the viral particle is an engineered AAV viral particle comprising AAV9 capsid. In some specific examples, the AAV9 capsid comprises blood-brain barrier (BBB)-penetrant capsid proteins. In some embodiments, the genetically modified viral genome is a genetically modified adeno-associated viral (AAV) genome, which comprises inverted terminal repeats (ITRs) at both 5’ and 3’ ends. In some instances, the ITRs are AAV2 ITRs.

[0031] In some examples, the genetically engineered viral genome comprises the first nucleotide sequence and a complementary sequence of the second nucleotide sequence. In other examples, the genetically engineered viral genome comprises a complementary sequence of the first nucleotide sequence and the second nucleotide sequence. In some instances, in the genetically modified viral genome, the first nucleotide sequence encoding the CRISPR nuclease polypeptide is in operable linkage to a first promoter and the second nucleotide encoding the gRNA is in operable linkage to a second promoter. In some specific examples, the first promoter and the second promoter are different promoters and / or wherein the first andAttorney Docket No. 063586-568001WO

[0032] second promoters are in opposite orientation. In one example, the first promoter is a human synapsin promoter and the second promoter is a U6 promoter.

[0033] In some instances, the first nucleotide sequence may further comprise a polyA signal sequence. Alternatively, or in addition, the complementary sequence of the second nucleotide sequence encoding the gRNAmay further comprise a transcription terminator sequence downstream to the gRNA-coding sequence.

[0034] In some examples, the first nucleotide sequence encodes the CRISPR nuclease comprising the amino acid sequence of SEQ ID NO: 1153. In one specific example, the first nucleotide sequence comprises the nucleotide sequence of SEQ ID NO: 1154. In some instances, the CRISPR nuclease further comprises a peptide linker of SEQ ID NO: 1158 and an NLS of SEQ ID NO: 1156.

[0035] In one specific example, the genetically modified viral genome comprises (a) from 5’ to 3’, a human synapsin promoter, a nucleotide sequence encoding the CRISPR nuclease polypeptide (e.g., any of those disclosed herein), a polyA signal sequence, a nucleotide sequence complementary to the coding sequence of the guide RNA (e.g., comprises the nucleotide sequence of SEQ ID NO: 458, 712, 186, or 930) and a nucleotide sequence complementary to a U6 promoter. In another specific example, the genetically modified viral genome comprises a complementary sequence of (a).

[0036] In some instances, the genetically modified viral genome disclosed herein comprises AAV2 inverted terminal repeats at both the 5’ end and the 3’ end.

[0037] Also provided herein are pharmaceutical compositions comprising any of the gene editing systems disclosed herein.

[0038] In some other aspects, the present disclosure features a guide RNA comprising a spacer sequence that is specific to a target sequence in a UBE3 A antisense transcript gene (UBE3A-ATS gene). In some instances, the target sequence is adjacent to a protospacer adjacent motif (PAM) comprising the motif of 5’-NTTN-3’, for example, 5’-NTTR-3’, in which each N independently is A, T, G, or C, and R is A or G, the PAM being located 5’ to the target sequence. In other instances, the target sequence is adjacent to a PAM comprising the motif a 5’-NGG-3’, in which N is A, T, G, or C, the PAM being located 3’ to the target sequence. In some instances, the target sequence is located in the Cluster 2 exonic region (chrl5:

[0039] 25,266,431-25,278,884), for example, in Exon 5. In other instances, the target sequence is located in the intronic region (chrl5: 25,278,885 to 25,333,728) of the UBE3A-ATS gene, for example, in segment 1 of the intronic region (chrl5: 25,278,885 to 25,296,525); in segment 2 of the intronic region (chr!5: 25,296,526 to 25,316,526); or in segment 3 of the intronic regionAttorney Docket No. 063586-568001WO

[0040] (chrl5: 25,316,526 to 25,333,728).

[0041] In some examples, the target sequence is set forth as 5’-AACCAGGATTTAAGGATGCC-3’ (SEQ ID NO: 455). In some instances, the corresponding spacer sequence may comprise 5’- AACCAGGAUUUAAGGAUGCC -3’ (SEQ ID NO: 457). In other examples, the target sequence is set forth as 5’- GTATGAGAGATGCTGTTCTA-3’ (SEQ ID NO: 709). In some instances, the corresponding spacer sequence may comprise 5’-GUAUGAGAGAUGCUGUUCUA-3’ (SEQ ID NO: 711). In yet other examples, the target sequence is set forth as 5’- TCCTCCTCCCCTTAGATAAG-3’ (SEQ ID NO: 183). In some instances, the corresponding spacer sequence may comprise 5’-UCCUCCUCCCCUUAGAUAAG-3’ (SEQ ID NO: 185). In still other examples, the target sequence is set forth as 5’-TATATATAATTGAGGGCCAC-3’ (SEQ ID NO: 927). In some instances, the corresponding spacer sequence may comprise 5’-UAUAUAUAAUUGAGGGCCAC-3’ (SEQ ID NO: 929). Exemplary target sequences and spacer sequences are provided in Table 4, Table 6, or Table 7.

[0042] Any of the guide RNAs provided herein further comprises a scaffold sequence. In some examples, the scaffold sequence comprises a sequence that is at least 80% identical to any one of SEQ IDNOs: 7-9.

[0043] Exemplary guide RNAs are provided in Table 4, Table 6, or Table 7, each of which is within the scope of the present disclosure. In one example, the guide RNA comprises the nucleotide sequence of SEQ ID NO: 458. In another example, the guide RNA comprises the nucleotide sequence of SEQ ID NO: 712. In yet another example, the guide RNA comprises the nucleotide sequence of SEQ ID NO: 186. In still another example, the guide RNA comprises the nucleotide sequence of SEQ ID NO: 930.

[0044] Further, the present disclosure provides a method of treating Angelman Syndrome comprising administering to a subject in need thereof an effective amount of any of the gene editing systems disclosed herein or the pharmaceutical composition comprising such. Also provided herein are any of the gene editing systems provided herein for use in treating Angelman Syndrome or uses of such a gene editing system for manufacturing a medicament for use in treating the disease.

[0045] Moreover, the present disclosure provides a method for editing a UBE3A-ATS gene in a cell, comprising contacting the cell with any of the gene editing systems disclosed herein. In some instances, the cell is a neuronal cell. In some instances, the cell is cultured in vitro. In other instances, the contacting step is performed by administering the gene editing system to a subject comprising the cell.Attorney Docket No. 063586-568001WO

[0046] In yet other aspects, the present disclosure features a viral vector, comprising a first nucleic acid comprising a nucleotide sequence encoding a CRISPR nuclease (e.g., any of those disclosed herein) and a second nucleic acid comprising a nucleotide sequence encoding a guide RNA targeting a human UBE3A antisense transcript gene (UBE3A-ATS gene) (e.g., any of the guide RNAs disclosed herein). The first nucleic acid is in operable linkage to a first promoter and the second nucleic acid is in operable linkage to a second promoter; the first and second promoter optionally being in opposite orientation and different from each other. In some examples, the viral vector may be an AAV vector further comprising a 5’ end inverted terminal repeat (ITR) and a 3 ’ end ITR.

[0047] In some instances, the first nucleic acid further comprises a polyA signal sequence. Alternatively, or in addition, the second nucleic acid further comprises a transcription terminator sequence downstream to the encoding sequence for the gRNA. In some instances, the first promoter is a human synapsin promoter and the second promoter is a U6 promoter.

[0048] In some examples, the CRISPR nuclease comprises the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 1153. In some specific examples, the nucleotide sequence encoding the CRISPR nuclease comprises SEQ ID NO: 1151, 1152, or 1154. Alternatively, or in addition, the gRNA comprises the nucleotide sequence of SEQ ID NO: 458, 712, 186, or 930.

[0049] In one example, the viral vector comprises, from 5’ to 3’, a human synapsin promoter, a nucleotide sequence encoding the CRISPR nuclease, which cany be any of those disclosed herein, a polyA signal sequence, a nucleotide sequence complementary to a coding sequence for the guide RNA, and a nucleotide sequence complementary to a U6 promoter; optionally wherein viral vector further comprise a complementary sequence of a transcription terminator 5’ of the complementary sequence of the gRNA coding sequence.

[0050] Also within the scope of the present disclosure is a kit comprising (i) any of the guide RNAs disclosed herein or a nucleic acid encoding the guide RNA and / or (ii) a CRISPR nuclease or a nucleic acid encoding the CRISPR nuclease such as those disclosed herein. In some examples, the kit may comprise one or more components of the gene editing system disclosed herein, the viral particle disclosed herein, or the viral vector disclosed herein.

[0051] Additional embodiments are provided below:

[0052] Embodiment 1 : A gene editing system comprising: (a) a guide RNA or a first nucleic acid encoding the guide RNA, wherein the guide RNA comprises a spacer sequence that is specific to a target sequence in a UBE3A antisense transcript gene (UBE3A-ATS gene), wherein: (i) the target sequence is adjacent to a protospacer adjacent motif (PAM) comprising the motif of 5’-NTTN-3’, 5’-NTTR-3’, wherein N is A, T, G, or C, and R is A or G, andAttorney Docket No. 063586-568001WO

[0053] wherein the PAM is located 5’ to the target sequence, and (ii) the target sequence is located in the cluster 2 exonic region (chrl5: 25,266,431-25,278,884) or the intronic region (chrl5: 25,278,885 to 25,333,728) of the UBE3A-ATS gene; and (b) a CRISPR nuclease or a second nucleic acid encoding the CRISPR nuclease.

[0054] Embodiment 2: The gene editing system of Embodiment 1, wherein the PAM comprises the motif NTTN.

[0055] Embodiment 3: The gene editing system of Embodiment 1, wherein the PAM comprises the motif NTTR.

[0056] Embodiment 4: The gene editing system of any one of Embodiments 1-3, wherein the target sequence is located in exon 5 of the UBE3A-ATS gene.

[0057] Embodiment 5: The gene editing system of any one of Embodiments 1-3, wherein the target sequence is located in the cluster 2 exonic region of the UBE3A-ATS gene.

[0058] Embodiment 6: The gene editing system of any one of Embodiments 1-3, wherein the target sequence comprises any one or more of the target sequences set forth in Table 4.

[0059] Embodiment 7: The gene editing system of any one of Embodiments 1-3, wherein the target sequence is located in the intronic region of the UBE3A-ATS gene.

[0060] Embodiment 8: The gene editing system of any one of Embodiments 1-3 and 7, wherein the target sequence is located in segment 1 of the intronic region (chrl5: 25,278,885 to 25.296.525).

[0061] Embodiment 9: The gene editing system of any one of Embodiments 1-3 and 7, wherein the target sequence is located in segment 2 of the intronic region (chrl5: 25,296,526 to 25.316.526).

[0062] Embodiment 10: The gene editing system of any one of Embodiments 1-3 and 7, wherein the target sequence is not located in segment 3 of the intronic region (chrl5:

[0063] 25,316,526 to 25,333,728).

[0064] Embodiment 11: The gene editing system of any one of Embodiments 1-3 and 7-10, wherein the target sequence comprises any one or more of the target sequences set forth in Table 6

[0065] Embodiment 12: The gene editing system of any one of Embodiments 1-11, wherein the RNA further comprises a scaffold sequence.

[0066] Embodiment 13: The gene editing system of Embodiment 12, wherein the scaffold sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 7-9.

[0067] Embodiment 14: The gene editing system of any one of Embodiments 1-13, wherein the guide RNA does not comprise a tracr sequence.Attorney Docket No. 063586-568001WO

[0068] Embodiment 15: The gene editing system of Embodiment 1, 5 or 7, wherein the guide RNA comprises a spacer sequence that is any one of the spacer sequences provided in Table 4 and Table 6.

[0069] Embodiment 16: The gene editing system of any one of Embodiments 1, 5, 7, or 15, wherein the guide RNA comprises a sequence set forth in any one of the spacer sequences set forth in Table 4 or Table 6.

[0070] Embodiment 17: The gene editing system of any one of Embodiments 1-16, wherein the CRISPR nuclease comprises at least 80% identity to the sequence of SEQ ID NO: 3 or SEQ ID NO: 5.

[0071] Embodiment 18: The gene editing system of any one of Embodiments 1-17, wherein the CRISPR nuclease comprises the sequence of SEQ ID NO: 3 or SEQ ID NO: 5.

[0072] Embodiment 19: The gene editing system of any one of Embodiments 1-18, wherein the first nucleic acid is codon optimized.

[0073] Embodiment 20: The gene editing system of any one of Embodiments 1-19, wherein the nucleic acid encoding the guide RNA and the nucleic acid encoding the CRISPR nuclease are located on one or more vectors.

[0074] Embodiment 21 : The gene editing system of Embodiment 20, wherein at least one of the one or more vectors is a viral vector.

[0075] Embodiment 22: The gene editing system of any one of Embodiments 1-21, wherein one or more vectors comprise the first nucleic acid encoding the guide RNA and / or the second nucleic acid encoding the CRISPR nuclease.

[0076] Embodiment 23: The gene editing system of Embodiment 22, wherein the first nucleic acid encoding the guide RNA and the second nucleic acid encoding the CRISPR nuclease are located one or more vectors.

[0077] Embodiment 24: The gene editing system of Embodiment 23, wherein the one or more vectors comprise one or more viral vectors.

[0078] Embodiment 25: The gene editing system of Embodiment 24, wherein the one or more viral vectors are one or more adeno-associated virus (AAV) vectors.

[0079] Embodiment 26: A vector comprising the gene editing system of any one of Embodiments 1-25.

[0080] Embodiment 27: A vector comprising the guide RNA of any one of Embodiments 30-47.

[0081] Embodiment 28: The vector of Embodiment 27 further comprising a second nucleic acid encoding a CRISPR nuclease.Attorney Docket No. 063586-568001WO

[0082] Embodiment 29: A composition comprising the vector of any one of Embodiments 26- 28.

[0083] Embodiment 30: A guide RNA comprising a spacer sequence that is specific to a target sequence in a UBE3A antisense transcript gene (UBE3A-ATS gene), wherein: (i) the target sequence is adjacent to a protospacer adjacent motif (PAM) comprising the motif of 5’-NTTN-3’or 5’-NTTR-3’, wherein N is A, T, G, or C, and R is A or G, and wherein the PAM is located 5’ to the target sequence, or the target sequence is adjacent to a PAM comprising the motif a 5’-NGG-3’, wherein N is A, T, G, or C, and wherein the PAM is located 3’ to the target sequence, and (ii) the target sequence is located in the Cluster 2 exonic region (chrl5:

[0084] 25,266,431-25,278,884) or the intronic region (chrl5: 25,278,885 to 25,333,728) of the UBE3A-ATS gene.

[0085] Embodiment 31 : The guide RNA of Embodiment 30, wherein the PAM comprises the motif NTTN.

[0086] Embodiment 32: The guide RNA of Embodiment 30, wherein the PAM comprises the motif NTTR.

[0087] Embodiment 33: The guide RNA of any one of Embodiments 30-32, wherein the target sequence is located in exon 5 of the UBE3A-ATS gene.

[0088] Embodiment 34: The guide RNA of any one of Embodiments 30-32, wherein the target sequence is located in the cluster 2 exonic region of the UBE3A-ATS gene.

[0089] Embodiment 35: The guide RNA of any one of Embodiments 30-32, wherein the target sequence comprises any one or more of the target sequences set forth in Table 4.

[0090] Embodiment 36: The guide RNA of any one of Embodiments 30-32, wherein the target sequence is located in the intronic region of the UBE3A-ATS gene.

[0091] Embodiment 37: The guide RNA of any one of Embodiments 30-32 and 36, wherein the target sequence is located in segment 1 of the intronic region (chrl5: 25,278,885 to 25.296.525).

[0092] Embodiment 38: The guide RNA of any one of Embodiments 30-32 and 36, wherein the target sequence is located in segment 2 of the intronic region (chrl5: 25,296,526 to 25.316.526).

[0093] Embodiment 39: The guide RNA of any one of Embodiments 30-32 and 36, wherein the target sequence is not located in segment 3 of the intronic region (chrl5: 25,316,526 to 25,333,728).

[0094] Embodiment 40: The guide RNA of any one of Embodiments 30-32 and 36-39, wherein the target sequence comprises any one or more of the target sequences set forth inAttorney Docket No. 063586-568001WO

[0095] Table 6

[0096] Embodiment 41 : The guide RNA of any one of Embodiments 30-40, wherein the RNA further comprises a scaffold sequence.

[0097] Embodiment 42: The guide RNA of Embodiment 41, wherein the scaffold sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 7-9.

[0098] Embodiment 43: The guide RNA of any one of Embodiments 30-42, wherein the guide RNA does not comprise a tracr sequence.

[0099] Embodiment 44: The guide RNA of Embodiment 30, 34 or 36, wherein the guide RNA comprises a spacer sequence that is any one of the spacer sequences provided in Table 4 and Table 6

[0100] Embodiment 45: The guide RNA of any one of Embodiments 30, 34, 36, or 44, wherein the guide RNA comprises a sequence set forth in Table 4 or Table 6.

[0101] Embodiment 46: The guide RNA of Embodiment 30, wherein the guide RNA comprises a spacer sequence having the sequence: UCCUCCUCCCCUUAGAUAAG (SEQ ID NO: 185), AACCAGGAUUUAAGGAUGCC (SEQ ID NO: 457), GUAUGAGAGAUGCUGUUCUA (SEQ ID NO: 711), or UAUAUAUAAUUGAGGGCCAC (SEQ ID NO: 929).

[0102] Embodiment 47: A guide RNA set forth in any one of FIGs. 1-11.

[0103] Embodiment 48: A composition comprising: i) the guide RNA of any one of Embodiments 30-42, or ii) a nucleic acid encoding the guide RNA of any one of Embodiments 30-42, wherein the guide RNA comprises a sequence of any one of the spacer sequences provided in Table 4 or Table 6 or the nucleic acid encoding the guide RNA comprises any one of the target sequences provided in Table 4 or Table 6.

[0104] Embodiment 49: A method of treating Angelman Syndrome comprising administering to a subject the gene editing system of any one of Embodiments 1-25.

[0105] Embodiment 50: A method of editing a UBE3A-ATS gene in a cell, comprising administering to the cell the gene editing system of any one of Embodiments 1-25.

[0106] Embodiment 51: The method of Embodiment 50, wherein the cell is a neuronal cell. Embodiment 52: The method of any one of Embodiment 49-51, wherein the method decreases RNA transcript levels of the UBE3A-ATS gene relative to levels of UBE3A-ATS transcript in a neuron that has not administered the gene editing system of any one of Embodiments 1-25.

[0107] Embodiment 53: The method of any one of Embodiments 49-52, wherein the method increases RNA transcript levels of UBE3A in the neuron relative to levels of UBE3A transcriptAttorney Docket No. 063586-568001WO

[0108] in a neuron that has not been administered the gene editing system of any one of Embodiments 1-25.

[0109] Embodiment 54: The method of any one of Embodiments 49-53, wherein the method increases RNA transcript levels of UBE3A in the neuron by at least 10% relative to levels of UBE3 A transcript in a neuron that has not been administered the gene editing system of any one of Embodiments 1-25.

[0110] Embodiment 55: The method of any one of Embodiments 49-53, wherein the method increases the protein levels of UBE3A in the neuron relative to levels of UBE3A protein in a neuron that has not been administered the gene editing system of any one of Embodiments 1-25.

[0111] Embodiment 56: The method of Embodiment 51, wherein the method increases protein levels of UBE3A in the neuron by at least 20% relative to levels of UBE3A protein in a neuron that has not been administered the gene editing system of any one of Embodiments 1-25.

[0112] Embodiment 57: The method of any one of Embodiments 49-56, wherein the method reduces hyperexcitability in the neuron relative to a neuron that has not been administered the gene editing system of any one of Embodiments 1-25.

[0113] Embodiment 58: The method of any one of Embodiments 49-56, wherein the method reduces the mean firing rate of the neuron relative to a neuron that has not been administered the gene editing system of any one of Embodiments 1-25.

[0114] Embodiment 59: The method of any one of Embodiments 49-58, wherein the gene editing system is administered using a viral vector.

[0115] Embodiment 60: The method of Embodiment 59, wherein the viral vector is a lentiviral vector or an adeno-associated virus (AAV) vector.

[0116] Embodiment 61 : A composition comprising one or more components of the gene editing system set forth in any one of Embodiments 1-25.

[0117] Embodiment 62: A pharmaceutical composition comprising the gene editing system set forth in any one of Embodiments 1-25 and a pharmaceutically acceptable carrier.

[0118] Embodiment 63: A kit comprising (i) the guide RNA or first nucleic acid encoding the guide RNA and / or (ii) the CRISPR nuclease or second nucleic acid encoding the CRISPR nuclease of the gene editing system set forth in any one of Embodiments 1-25.

[0119] Embodiment 64: The kit of Embodiment 63, wherein the kit comprises a first nucleic acid encoding the gRNA and a second nucleic acid encoding the CRISPR nuclease of the gene editing system set forth in any one of Embodiments 1-25.

[0120] The details of one or more embodiments of the invention are set forth in the descriptionAttorney Docket No. 063586-568001WO

[0121] below. Other features or advantages of the present invention will be apparent from the following drawings and detailed description of several embodiments, and also from the appended claims.

[0122] BRIEF DESCRIPTION OF DRAWINGS FIG. 1 is a schematic depicting the UBE3A-ATS gene and the two regions targeted in this disclosure.

[0123] FIG. 2 is a diagram showing the % indels of UBE3A-ATS Cluster 2 Exons in HEK293T cells following delivery of plasmid-encoded Nuclease C2 and Nuclease DI and guide RNAs. Mean + SEM of two biological replicates, each with three technical replicates, is depicted for guides that produced at least 20% indels. Nuclease C2 guides are shown in blue and Nuclease DI guides are shown in green.

[0124] FIG. 3 shows a schematic depicting the UBE3A-ATS intronic region, divided into 3 segments.

[0125] FIG. 4 shows Cas9 guide targeting UBE3A-ATS via RNP Electroporation.

[0126] FIG. 5 is a diagram showing the % indels of UBE3A-ATS intronic regions in HEK293T cells following delivery of RNP complex (nuclease + guide) via electroporation. Mean + SEM of two biological replicates, each with three technical replicates.

[0127] FIG. 6A is a diagram showing the UBE3 A mRNA expression in human glutamatergic neurons following treatment with nuclease + Cluster 2 guides.

[0128] FIG. 6B is a diagram showing indel % in human glutamatergic neurons following treatment with nuclease + Cluster 2 guides. Mean + SEM is depicted for guides tested in neurons.

[0129] FIG. 7A is a diagram showing the UBE3 A mRNA expression in human glutamatergic neurons following treatment with nuclease + intronic guides.

[0130] FIG. 7B is a diagram showing indel % in human glutamatergic neurons following treatment with nuclease + intronic guides. Negative control (non-targeting guide) is used. Mean + SEM is depicted for guides tested in neurons.

[0131] FIG. 8 shows the correlation between indel % (x-axis) and UBE3 A mRNA expression fold-change (y-axis).

[0132] FIG. 9 shows the correlation between indel % (x-axis) and UBE3 A mRNA expression fold-change (y-axis).

[0133] FIGs. 10A-10C show that disrupting UBE3A-ATS restores UBE3A protein expression and reverses hypersynchrony phenotype. FIG. 10A shows UBE3A protein expression, 21 daysAttorney Docket No. 063586-568001WO

[0134] after editing. FIG. 10B shows network activity of edited neurons cultured on MEA with reduction of synchrony observed in UBE3A-ATS guide treated cells vs non-targeting guide. FIG. IOC shows the area under curve statistical analysis of network activity time course, oneway ANOVA (pO.OOOl).

[0135] FIG. 11 shows correlation between recovery of UBE3A protein and reversal of hypersynchrony phenotype.

[0136] FIG. 12 shows UBE3 A protein expression recovery relative to a non-targeting guide control following treatment with top nuclease / guide candidates. Both neurotypical neurons and Angelman neurons treated with research-grade ASO are included as benchmarks. Values are expressed as fold change relative to control.

[0137] FIGs. 13A-13D shows in vivo recovery of UBE3A protein in a humanized UBE3A-ATS mouse model using an exemplary gene editing system disclosed herein with an AAV delivery vehicle. FIG. 13A: a diagram illustrating an exemplary AAV vector for delivering the gene editing system. FIG. 13B: UBE3A-ATS gene editing efficiency with two guide RNAs as indicated in both wild-type humanized mice (WT / hsATS) and Angelman humanized mice (AS / hsATS). FIG. 13C: UBE3A protein levels in wild-type humanized mice (WT / hsATS) and Angelman humanized mice (AS / hsATS) treated by the gene editing system. FIG. 13D:

[0138] Recovery level of UBE3A protein in Angelman humanized mice (AS / hsATS) treated by the gene editing system.

[0139] DETAILED DESCRIPTION

[0140] Angelman syndrome is a genetic disorder caused by a mutation in the maternal copy of the E3 ubiquitin ligase UBE3 A gene (UBE3A). In mature neurons, only the maternal copy of the UBE3 A gene is expressed; the paternal copy of the UBE3 A gene is epigenetically silenced by a long non-coding RNA. The long non-coding RNA (also called a “long non-coding antisense”) is called UBE3A-ATS and is encoded by the UBE3A-ATS gene. Without intending to be bound by theory, disrupting the UBE3A-ATS gene relieves the repression of paternal UBE3A allele expression.

[0141] The present disclosure relates to compositions and methods for disrupting the UBE3A-ATS gene using a CRISPR nuclease and one or more guide RNAs (also called “RNA guides”).

[0142] I. Gene Editing Systems Targeting UBE3A-ATS

[0143] Aspects of the present disclosure provide gene editing systems targeting the UBE3 A-ATS gene, for example, within the cluster 2 exonic region or within the intronic region. InAttorney Docket No. 063586-568001WO

[0144] some embodiments, the gene editing system provided herein for genetic editing of an E3 ubiquitin ligase antisense transcript (UBE3A-ATS) gene comprises (i) a CRISPR nuclease or a nucleic acid encoding a CRISPR nuclease and (ii) one or more guide RNAs disclosed herein or one or more nucleic acids encoding the one or more guide RNAs disclosed herein. In some embodiments, the gene editing system comprises two or more guide RNAs each targeting a region within the UBE3A-ATS.

[0145] A. CRISPR nucleases

[0146] CRISPR nuclease as used herein refers to an RNA-guided endonuclease in a CRISPR editing system that is capable of cleaving DNA at specific sites guided by a guide RNA. In some embodiments, a CRISPR nuclease is a Type V CRISPR nuclease. In some embodiments, a CRISPR nuclease is or comprises a Casl2 nuclease. In some embodiments, a CRISPR nuclease is or comprises a Casl2i nuclease. In some embodiments, a CRISPR nuclease is or comprises a Casl2i2 nuclease. In some embodiments, a CRISPR nuclease is or comprises a C2 nuclease. In some embodiments, a CRISPR nuclease is or comprises a DI nuclease. In some embodiments, a CRISPR nuclease is a Type II CRISPR nuclease. In some embodiments, a CRISPR nuclease is or comprises a Cas9 nuclease. In some embodiments, a CRISPR nuclease is a variant nuclease comprising one or more amino acid substitutions relative to a wildtype CRISPR nuclease.

[0147] In some embodiments, the CRISPR nuclease used in the gene editing system disclosed herein comprises the amino acid sequence of any one of SEQ ID NOs: 1-6 and 1153, corresponding to Nucleases C, Cl, C2, C3, D, DI, and Cas9, respectively. See Table 1 below.

[0148] In some embodiments, the CRISPR nuclease is Nuclease C. In some embodiments, the CRISPR nuclease used in the gene editing system disclosed herein comprises the amino acid sequence of SEQ ID NO: 1. In other embodiments, the CRISPR nuclease may comprise an amino acid sequence that is at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1.

[0149] In some embodiments, the CRISPR nuclease provided herein may be a variant of Nuclease C, for example, Nuclease Cl, Nuclease C2, or Nuclease C3. The variant Nuclease C may comprise one or more amino acid substitutions relative to SEQ ID NO: 1, for example, at positions D581, 1926, V1030, and optionally further at positions G624, F626, P868, E1035, and S1046 in SEQ ID NO: 1. In some instances, the original amino acid residue in SEQ IDAttorney Docket No. 063586-568001WO

[0150] NO: 1 at the just-noted positions (e.g., D581, G624, F626, 1926, and / or E1035 positions) may be replaced by R or a conservative substitution thereof (e.g., K). Alternatively, or in addition, the original amino acid residue in SEQ ID NO: 1 at the noted positions (e.g., V1030 and / or SI 046) may be replaced with G or a conservative substitution thereof such as A. Further, the original amino acid residue at position P868 of SEQ ID NO: 1 may be replaced with T or a conservative substitution thereof such as S. Alternatively, or in addition, the original amino acid residue at position N840 of SEQ ID NO: 1 may be replaced with R or a conservative substitution thereof such as K.

[0151] In some examples, the variant Nuclease C comprises D581R, I926R, and V1030G relative to SEQ ID NO: 1. In another example, the variant Casl2i2 nuclease comprises D581R, G624R, F626R, P868T, I926R, V1030G, E1035R, and S1046G relative to SEQ ID NO: 1. In yet another example, the variant Casl2i2 nuclease comprises D581R, G624R, F626R, N840R, P868T, I926R, V1030G, E1035R, and S1046G relative to SEQ ID NO: 1. Additional Nuclease C variants can be found, e.g., in WO2021 / 202800, the relevant disclosures of which are incorporated by reference for the subject matter and purpose referenced herein.

[0152] In some instances, the CRISPR nuclease is Nuclease Cl. In one example, the CRISPR nuclease used in the gene editing system disclosed herein comprises the amino acid sequence of SEQ ID NO: 2. In other examples, the CRISPR nuclease may comprise an amino acid sequence that is at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 2.

[0153] In some instances, the CRISPR nuclease is Nuclease C2. In one example, the CRISPR nuclease used in the gene editing system disclosed herein comprises the amino acid sequence of SEQ ID NO: 3. In other examples, the CRISPR nuclease may comprise an amino acid sequence that is at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 3.

[0154] In some instances, the CRISPR nuclease is Nuclease C3. In one example, the CRISPR nuclease used in the gene editing system disclosed herein comprises the amino acid sequence of SEQ ID NO: 1153. In other examples, the CRISPR nuclease may comprise an amino acid sequence that is at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1153.

[0155] In other embodiments, the CRISPR nuclease is Nuclease D. In one example, theAttorney Docket No. 063586-568001WO

[0156] CRISPR nuclease used in the gene editing system disclosed herein comprises the amino acid sequence of SEQ ID NO: 4. In other examples, the CRISPR nuclease may comprise an amino acid sequence that is at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 4.

[0157] In some embodiments, the CRISPR nuclease is Nuclease DI (a variant of Nuclease D). In one example, the CRISPR nuclease used in the gene editing system disclosed herein comprises the amino acid sequence of SEQ ID NO: 5. In other examples, the CRISPR nuclease may comprise an amino acid sequence that is at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 5.

[0158] In yet other embodiments, the CRISPR nuclease is a Cas9 nuclease. In one example, the CRISPR nuclease used in the gene editing system disclosed herein comprises the amino acid sequence of SEQ ID NO: 6. In other examples, the CRISPR nuclease may comprise an amino acid sequence that is at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 6.

[0159] The “percent identity” (a.k.a., sequence identity) of two nucleic acids or of two amino acid sequences can be determined using any method known in the art, such as the algorithm of Karlin and Altschul Proc. Natl. Acad. Sci. USA 87:2264-68, 1990, modified as in Karlin and Altschul Proc. Natl. Acad. Sci. USA 90:5873-77, 1993. For example, the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. J. Mol. Biol. 215:403-10, 1990 can be used. BLAST nucleotide searches can be performed, for example, with the NBLAST program, score=100, wordlength- 12. BLAST protein searches can be performed, for example, with the XBLAST program, score=50, word length=3. Gapped BLAST can be utilized, for example, as described in Altschul et al., Nucleic Acids Res. 25(17):3389-3402, 1997, to address gaps between sequences. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. As a nonlimiting example, the percent identity between nucleic acid sequences or between amino acid sequences can be determined manually by inspection of the aligned sequences or by using software programs or algorithms (e.g., BLAST, ALIGN, CLUSTAL) using standard parameters.Attorney Docket No. 063586-568001WO

[0160] In some instances, the CRISPR nuclease of the present disclosure has enzymatic activity, e.g., nuclease or endonuclease activity similar to SEQ ID NO: 1, and comprises an amino acid sequence that differs from the amino acid sequences of SEQ ID NO: 1 by 50, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 amino acid residue(s) when aligned using any of the previously described alignment methods or other alignment methods known in the art.

[0161] In some instances, the CRISPR nuclease of the present disclosure has enzymatic activity, e.g., nuclease or endonuclease activity similar to SEQ ID NO: 2, and comprises an amino acid sequence that differs from the amino acid sequences of SEQ ID NO: 2 by 50, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 amino acid residue(s) when aligned using any of the previously described alignment methods or other alignment methods known in the art.

[0162] In some instances, the CRISPR nuclease of the present disclosure has enzymatic activity, e.g., nuclease or endonuclease activity similar to SEQ ID NO: 3, and comprises an amino acid sequence that differs from the amino acid sequences of SEQ ID NO: 16 by 50, 40, 35. 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 amino acid residue(s) when aligned using any of the previously described alignment methods or other alignment methods known in the art.

[0163] In some instances, the CRISPR nuclease of the present disclosure has enzymatic activity, e.g., nuclease or endonuclease activity similar to SEQ ID NO: 1153, and comprises an amino acid sequence that differs from the amino acid sequences of SEQ ID NO: 1153 by 50, 40. 35. 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 amino acid residue(s) when aligned using any of the previously described alignment methods or other alignment methods known in the art.

[0164] In some instances, the CRISPR nuclease of the present disclosure has enzymatic activity, e.g., nuclease or endonuclease activity similar to SEQ ID NO: 4, and comprises an amino acid sequence that differs from the amino acid sequences of SEQ ID NO: 4 by 50, 40, 35. 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 amino acid residue(s) when aligned using any of the previously described alignment methods or other alignment methods known in the art.

[0165] In some instances, the CRISPR nuclease of the present disclosure has enzymatic activity, e.g., nuclease or endonuclease activity similar to SEQ ID NO: 5, and comprises an amino acid sequence that differs from the amino acid sequences of SEQ ID NO: 5 by 50, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 amino acidAttorney Docket No. 063586-568001WO

[0166] residue(s) when aligned using any of the previously described alignment methods or other alignment methods known in the art.

[0167] In some instances, the CRISPR nuclease of the present disclosure has enzymatic activity, e.g., nuclease or endonuclease activity similar to SEQ ID NO: 6, and comprises an amino acid sequence that differs from the amino acid sequences of SEQ ID NO: 6 by 50, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 amino acid residue(s) when aligned using any of the previously described alignment methods or other alignment methods known in the art.

[0168] In some instances, the CRISPR nuclease may comprise one or more conservative amino acid substitutions as compared with any one of SEQ ID NOs: 1-6. As used herein, a “conservative amino acid substitution” refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

[0169] Table 1. Amino Acid Sequences of Exemplary CRISPR Nucleases.

[0170] Nuclease Amino Acid Sequence SEQ ID NO:

[0171] C MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGIT 1 PEIVRFSTEQEKQQQDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFE EYYGGTASDAIKQYFSASIGESYYWNDCRQQYYDLCRELGVEVSDL THDLEILCREKCLAVATESNQNNSIISVLFGTGEKEDRSVKLRITKKILE AISNLKEIPKNVAPIQEIILNVAKATKETFRQVYAGNLGAPSTLEKFIAK DGQKEFDLKKLQTDLKKVIRGKSKERDWCCQEELRSYVEQNTIQYD LWAWGEMFNKAHTALKIKSTRNYNFAKQRLEQFKEIQSLNNLLVVK KLNDFFDSEFFSGEETYTICVHHLGGKDLSKLYKAWEDDPADPENAI VVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQQLDRY KSQKANPSVLGNQGFTWTNAVILPEKAQRNDRPNSLDLRIWLYLKLR HPDGRWKKHHIPFYDTRFFQEIYAAGNSPVDTCQFRTPRFGYHLPKLT DQTAIRVNKKHVKAAKTEARIRLAIQQGTLPVSNLKITEISATINSKGQ VRIPVKFDVGRQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQY HKELGCFVRFISSGDIVSITENRGNQFDQLSYEGLAYPQYADWRKKA SKFVSLWQITKKNKKKEIVTVEAKEKFDAICKYQPRLYKFNKEYAYL LRDIVRGKSLVELQQIRQEIFRFIEQDCGVTRLGSLSLSTLETVKAVKG IIYSYFSTALNASKNNPISDEQRKEFDPELFALLEKLELIRTRKKKQKV ERIANSLIQTCLENNIKFIRGEGDLSTTNNATKKKANSRSMDWLARG VFNKIRQLAPMHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRWAAIP VKDIGDWVLRKLSQNLRAKNIGTGEYYHQGVKEFLSHYELQDLEEE LLKWRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHK VATGAVSIVFDQKQVWVCNADHVAAANIALTVKGIGEQSSDEENPDG

[0172]

[0173] SRIKLQLTSAttorney Docket No. 063586-568001WO

[0174] Cl MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGIT 2 PEIVRFSTEQEKQQQDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFE EYYGGTASDAIKQYFSASIGESYYWNDCRQQYYDLCRELGVEVSDL THDLEILCREKCLAVATESNQNNSIISVLFGTGEKEDRSVKLRITKKILE AISNLKEIPKNVAPIQEIILNVAKATKETFRQVYAGNLGAPSTLEKFIAK DGQKEFDLKKLQTDLKKVIRGKSKERDWCCQEELRSYVEQNTIQYD LWAWGEMFNKAHTALKIKSTRNYNFAKQRLEQFKEIQSLNNLLVVK KLNDFFDSEFFSGEETYTICVHHLGGKDLSKLYKAWEDDPADPENAI VVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQQLDRY KSQKANPSVLGNQGFTWTNAVILPEKAQRNDRPNSLDLRIWLYLKLR HPDGRWKKHHIPFYDTRFFQEIYAAGNSPVDTCQFRTPRFGYHLPKLT DQTAIRVNKKHVKAAKTEARIRLAIQQGTLPVSNLKITEISATINSKGQ VRIPVKFRVGRQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQY HKELGCFVRFISSGDIVSITENRGNQFDQLSYEGLAYPQYADWRKKA SKFVSLWQITKKNKKKEIVTVEAKEKFDAICKYQPREYKFNKEYAYL LRDIVRGKSLVELQQIRQEIFRFIEQDCGVTRLGSLSLSTLETVKAVKG IIYSYFSTALNASKNNPISDEQRKEFDPELFALLEKLELIRTRKKKQKV ERIANSLIQTCLENNIKFIRGEGDLSTTNNATKKKANSRSMDWLARG VFNKIRQLAPMHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRWAAIP VKDIGDWVLRKLSQNLRAKNRGTGEYYHQGVKEFLSHYELQDLEEE LLKWRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHK VATGAVSIVFDQKQVWVCNADHVAAANIALTGKGIGEQSSDEENPDG SRIKLQLTS

[0175] C2 MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGIT 3 PEIVRFSTEQEKQQQDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFE EYYGGTASDAIKQYFSASIGESYYWNDCRQQYYDLCRELGVEVSDL THDLEILCREKCLAVATESNQNNSIISVLFGTGEKEDRSVKLRITKKILE AISNLKEIPKNVAPIQEIILNVAKATKETFRQVYAGNLGAPSTLEKFIAK DGQKEFDLKKLQTDLKKVIRGKSKERDWCCQEELRSYVEQNTIQYD LWAWGEMFNKAHTALKIKSTRNYNFAKQRLEQFKEIQSLNNLLVVK KLNDFFDSEFFSGEETYTICVHHLGGKDLSKLYKAWEDDPADPENAI VVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQQLDRY KSQKANPSVLGNQGFTWTNAVILPEKAQRNDRPNSLDLRIWLYLKLR HPDGRWKKHHIPFYDTRFFQEIYAAGNSPVDTCQFRTPRFGYHLPKLT DQTAIRVNKKHVKAAKTEARIRLAIQQGTLPVSNLKITEISATINSKGQ VRIPVKFRVGRQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQY HKELRCRVRFISSGDIVSITENRGNQFDQLSYEGLAYPQYADWRKKA SKFVSLWQITKKNKKKEIVTVEAKEKFDAICKYQPREYKFNKEYAYL LRDIVRGKSLVELQQIRQEIFRFIEQDCGVTRLGSLSLSTLETVKAVKG IIYSYFSTALNASKNNPISDEQRKEFDPELFALLEKLELIRTRKKKQKV ERIANSLIQTCLENNIKFIRGEGDLSTTNNATKKKANSRSMDWLARG VFNKIRQLATMHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRWAAIP VKDIGDWVLRKLSQNLRAKNRGTGEYYHQGVKEFLSHYELQDLEEE LLKWRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHK VATGAVSIVFDQKQVWVCNADHVAAANIALTGKGIGRQSSDEENPDG GRIKLQLTS

[0176] Codon- ATGAGCTCTGCCATCAAGAGCTACAAGTCCGTGCTGCGGCCCAAC 1151 optimized GAGCGGAAGAACCAGCTGCTGAAGTCCACCATCCAGTGCCTGGA coding GGACGGCTCTGCCTTCTTCTTCAAGATGCTCCAGGGGCTGTTTGGC sequence GGCATCACCCCCGAGATCGTGCGCTTCTCCACCGAGCAGGAGAAG

[0177] A for C2 CAGCAGCAGGACATCGCCCTGTGGTGCGCCGTGAACTGGTTCCGG CCCGTGAGTCAGGACAGCCTGACTCACACCATTGCCAGCGACAAC CTGGTGGAGAAGTTTGAGGAGTACTACGGAGGCACCGCCTCCGAC GCCATCAAGCAGTACTTCTCCGCCAGCATCGGCGAGAGCTACTACT

[0178]

[0179] GGAACGACTGCCGCCAGCAGTACTACGACCTGTGCAGGGAGCTGGAttorney Docket No. 063586-568001WO

[0180] GCGTGGAGGTGAGCGACCTGACCCACGACCTGGAGATCCTGTGCA GGGAGAAGTGCCTGGCCGTGGCCACCGAGTCCAACCAGAACAAC TCCATCATCTCCGTGCTGTTCGGCACCGGAGAGAAGGAGGACCGC AGCGTGAAGCTGCGGATCACCAAGAAGATCCTGGAGGCCATCTCC AACCTGAAGGAGATCCCCAAGAACGTGGCCCCCATCCAGGAGATC ATCCTGAACGTGGCCAAGGCCACCAAGGAGACCTTCCGCCAGGTG TACGCTGGCAACCTGGGCGCTCCCTCCACCCTGGAGAAGTTCATT GCCAAGGATGGCCAGAAGGAGTTCGATCTGAAGAAGCTGCAGAC CGACCTGAAGAAGGTGATCCGGGGCAAGAGCAAGGAGCGCGACT GGTGCTGCCAGGAGGAGCTGCGCTCCTACGTGGAGCAGAACACC ATCCAGTACGACCTGTGGGCCTGGGGCGAGATGTTCAACAAGGCC CACACCGCCCTGAAGATCAAGAGCACCCGGAACTACAACTTCGCC AAGCAGCGCCTGGAGCAGTTCAAGGAGATCCAGAGCCTGAACAA CCTGCTGGTGGTGAAGAAGCTGAACGACTTCTTCGACAGCGAGTT CTTCAGCGGCGAGGAGACATACACCATCTGCGTGCACCATCTGGG CGGCAAGGACCTGTCCAAGCTGTACAAGGCTTGGGAGGACGATCC TGCCGACCCAGAGAACGCCATCGTGGTGCTGTGCGACGACCTGAA GAACAACTTCAAGAAGGAGCCCATCCGCAACATCCTGCGGTACAT CTTCACCATCCGGCAGGAGTGCAGCGCCCAGGACATCCTGGCCGC TGCCAAGTACAATCAGCAGCTGGACCGCTACAAGAGCCAGAAGGC CAACCCCAGCGTGCTGGGCAACCAGGGGTTCACCTGGACCAACG CCGTGATCCTGCCCGAGAAGGCCCAGCGGAACGATCGGCCTAACA GCCTGGATCTGCGCATCTGGCTGTACCTGAAGCTGCGGCACCCCG ACGGCAGGTGGAAGAAGCACCACATCCCCTTCTACGACACCCGGT TCTTCCAGGAGATCTACGCCGCAGGCAACAGCCCCGTGGACACCT GCCAGTTCCGGACCCCCCGGTTCGGATACCACCTGCCCAAGCTGA CCGACCAGACCGCCATTCGCGTGAACAAGAAGCACGTGAAGGCC GCCAAGACCGAGGCCCGGATCCGGCTGGCCATCCAGCAGGGCACC CTGCCCGTGTCCAACCTGAAGATCACCGAGATCAGCGCCACCATC AACAGCAAGGGCCAGGTGCGGATCCCGGTGAAGTTCAGGGTGGG CCGGCAGAAGGGCACCCTGCAGATCGGCGACCGGTTCTGCGGCTA CGACCAGAACCAGACCGCCTCCCACGCCTACAGCCTGTGGGAGGT GGTGAAGGAGGGGCAGTACCACAAGGAGCTGCGCTGCCGGGTGC GGTTCATCAGCTCCGGCGACATCGTGTCCATCACCGAGAACCGGG GGAACCAGTTCGACCAGCTGTCCTACGAGGGCCTGGCCTATCCCC AGTACGCCGACTGGCGGAAGAAGGCCAGCAAGTTCGTGAGCCTG TGGCAGATCACCAAGAAGAACAAGAAGAAGGAGATCGTGACCGT GGAGGCCAAGGAGAAGTTCGACGCCATCTGCAAGTACCAGCCTCG GCTGTACAAGTTCAACAAGGAGTACGCCTACCTGCTGCGGGACAT CGTGCGCGGCAAGTCCCTGGTGGAGCTGCAGCAGATCCGGCAGG AGATCTTCCGCTTCATCGAGCAGGATTGCGGCGTGACCAGGCTGG GCTCCCTGAGCCTGAGCACGCTGGAGACCGTGAAGGCCGTGAAG GGCATCATCTACAGCTACTTCTCCACCGCCCTGAACGCCTCCAAGA ACAACCCCATCTCCGACGAGCAGCGCAAGGAGTTCGACCCCGAGC TGTTTGCCCTGCTGGAGAAGCTGGAGCTGATCAGGACCCGGAAGA AGAAGCAGAAGGTGGAGCGGATCGCCAACTCCCTGATCCAGACCT GCCTGGAGAACAACATCAAGTTCATCCGGGGGGAGGGCGATCTGT CCACCACCAACAACGCCACCAAGAAGAAGGCCAACAGCCGCAGC ATGGACTGGCTGGCCAGGGGCGTGTTCAACAAGATCCGCCAGCTG GCCACCATGCACAACATCACCCTGTTCGGCTGCGGCTCCCTGTACA CCAGCCACCAGGACCCCCTGGTGCACAGGAACCCCGACAAGGCC ATGAAGTGCCGGTGGGCCGCCATCCCCGTGAAGGACATCGGGGAC TGGGTGCTGCGGAAGCTGAGCCAGAACCTGCGGGCCAAGAATCG CGGCACAGGCGAGTACTACCACCAGGGGGTGAAGGAGTTCCTGTC

[0181]

[0182] CCACTACGAGCTGCAGGACCTGGAGGAGGAGCTGCTGAAGTGGCAttorney Docket No. 063586-568001WO

[0183] GGAGCGACAGGAAGTCCAACATCCCCTGCTGGGTGCTGCAGAACC GCCTGGCCGAGAAGCTGGGCAACAAGGAGGCCGTGGTGTACATC CCCGTGCGCGGCGGCCGGATCTACTTCGCCACCCACAAGGTGGCC ACCGGCGCCGTGAGCATCGTGTTCGACCAGAAGCAGGTGTGGGTG TGCAACGCCGACCACGTGGCCGCCGCCAACATCGCCCTGACCGGC AAGGGCATCGGCCGCCAGTCCTCCGACGAGGAGAACCCCGACGG CGGCCGGATCAAGCTGCAGCTGACCAGC

[0184] Codon- ATGAGCTCCGCCATCAAGAGCTACAAGAGCGTGCTGCGGCCCAAC 1152 optimized GAGCGGAAGAACCAGCTGCTGAAGAGCACCATCCAGTGCCTGGA coding GGACGGCAGCGCCTTCTTCTTCAAGATGCTGCAGGGCCTGTTCGG sequence CGGCATCACCCCCGAGATCGTGCGGTTCAGCACCGAGCAGGAGAA

[0185] B for C2 GCAGCAGCAGGACATCGCCCTGTGGTGCGCCGTGAACTGGTTCCG GCCCGTGAGCCAGGACAGCCTGACCCACACCATCGCCAGCGACA ACCTGGTGGAGAAGTTCGAGGAGTACTACGGCGGCACCGCCAGC GACGCCATCAAGCAGTACTTCAGCGCCAGCATCGGCGAGAGCTAC TACTGGAACGACTGCCGGCAGCAGTACTACGACCTGTGCCGGGAG CTGGGCGTGGAGGTGAGCGACCTGACCCACGACCTGGAGATCCTG TGCCGGGAGAAGTGCCTGGCCGTGGCCACCGAGAGCAACCAGAA CAACAGCATCATCAGCGTGCTGTTCGGCACCGGCGAGAAGGAGGA CCGCAGCGTGAAGCTGCGGATCACCAAGAAGATCCTGGAGGCCAT CAGCAACCTGAAGGAGATCCCCAAGAACGTGGCCCCCATCCAGGA GATCATCCTGAACGTGGCCAAGGCCACCAAGGAGACCTTCCGCCA GGTGTACGCCGGCAACCTGGGCGCCCCCAGCACCCTGGAGAAGTT CATCGCCAAGGACGGCCAGAAGGAGTTCGACCTGAAGAAGCTGC AGACCGACCTGAAGAAGGTGATCCGGGGCAAGAGCAAGGAGCGG GACTGGTGCTGCCAGGAGGAGCTGCGCTCCTACGTGGAGCAGAA CACCATCCAGTACGACCTGTGGGCCTGGGGCGAGATGTTCAACAA GGCCCACACCGCCCTGAAGATCAAGAGCACCCGGAACTACAACTT CGCCAAGCAGCGGCTGGAGCAGTTCAAGGAGATCCAGAGCCTGA ACAACCTGCTGGTGGTGAAGAAGCTGAACGACTTCTTCGACAGCG AGTTCTTCAGCGGCGAGGAGACCTACACCATCTGCGTGCACCACC TGGGCGGCAAGGACCTGTCCAAGCTGTACAAGGCCTGGGAGGAC GACCCCGCCGACCCCGAGAACGCCATCGTGGTGCTGTGCGACGAC CTGAAGAACAACTTCAAGAAGGAGCCCATCCGCAACATCCTGCGG TACATCTTCACCATCCGGCAGGAGTGCAGCGCCCAGGACATCCTG GCCGCCGCCAAGTACAACCAGCAGCTGGACCGGTACAAGAGCCA GAAGGCCAACCCCAGCGTGCTGGGCAACCAGGGCTTCACCTGGA CCAACGCCGTGATCCTGCCCGAGAAGGCCCAGCGGAACGACCGG CCCAACAGCCTGGACCTGCGGATCTGGCTGTACCTGAAGCTGCGG CACCCCGACGGCCGGTGGAAGAAGCACCACATCCCCTTCTACGAC ACCCGGTTCTTCCAGGAGATCTACGCCGCCGGCAACAGCCCCGTG GACACCTGCCAGTTCCGGACCCCCCGGTTCGGCTACCACCTGCCC AAGCTGACCGACCAGACCGCCATCCGGGTGAACAAGAAGCACGT GAAGGCCGCCAAGACCGAGGCCCGGATCCGGCTGGCCATCCAGC AGGGCACCCTGCCCGTGTCCAACCTGAAGATCACCGAGATCAGCG CCACCATCAACAGCAAGGGCCAGGTGCGGATCCCCGTGAAGTTCC GGGTGGGCCGGCAGAAGGGCACCCTGCAGATCGGCGACCGGTTC TGCGGCTACGACCAGAACCAGACCGCCTCCCACGCCTACAGCCTG TGGGAGGTGGTGAAGGAGGGCCAGTACCACAAGGAGCTGCGGTG CCGGGTGCGGTTCATCAGCAGCGGCGACATCGTGAGCATCACCGA GAACCGGGGCAACCAGTTCGACCAGCTGTCCTACGAGGGCCTGGC CTACCCCCAGTACGCCGACTGGCGGAAGAAGGCCAGCAAGTTCGT GAGCCTGTGGCAGATCACCAAGAAGAACAAGAAGAAGGAGATCG TGACCGTGGAGGCCAAGGAGAAGTTCGACGCCATCTGCAAGTACC

[0186]

[0187] AGCCCCGGCTGTACAAGTTCAACAAGGAGTACGCCTACCTGCTGCAttorney Docket No. 063586-568001WO

[0188] GCGACATCGTGCGCGGCAAGAGCCTGGTGGAGCTGCAGCAGATCC GGCAGGAGATCTTCCGGTTCATCGAGCAGGACTGCGGCGTGACCC GGCTGGGCAGCCTGAGCCTGAGCACCCTGGAGACCGTGAAGGCC GTGAAGGGCATCATCTACAGCTACTTCAGCACCGCCCTGAACGCC AGCAAGAACAACCCCATCAGCGACGAGCAGCGGAAGGAGTTCGA CCCCGAGCTGTTCGCCCTGCTGGAGAAGCTGGAGCTGATCCGGAC CCGGAAGAAGAAGCAGAAGGTGGAGCGGATCGCCAACAGCCTGA TCCAGACCTGCCTGGAGAACAACATCAAGTTCATCCGGGGCGAGG GCGACCTGAGCACCACCAACAACGCCACCAAGAAGAAGGCCAAC AGCCGGAGCATGGACTGGCTGGCCCGGGGCGTGTTCAACAAGATC CGGCAGCTGGCCACCATGCACAACATCACCCTGTTCGGCTGCGGC AGCCTGTACACCAGCCACCAGGACCCCCTGGTGCACCGCAACCCC GACAAGGCCATGAAGTGCCGCTGGGCCGCCATCCCCGTGAAGGAC ATCGGCGACTGGGTGCTGCGGAAGCTGTCCCAGAACCTGCGGGCC AAGAACCGGGGCACCGGCGAGTACTACCACCAGGGCGTGAAGGA GTTCCTGAGCCACTACGAGCTGCAGGACCTGGAGGAGGAGCTGCT GAAGTGGCGGAGCGACCGGAAGAGCAACATCCCCTGCTGGGTGC TGCAGAACCGGCTGGCCGAGAAGCTGGGCAACAAGGAGGCCGTG GTGTACATCCCCGTGCGCGGCGGCCGGATCTACTTCGCCACCCACA AGGTGGCCACCGGCGCCGTGAGCATCGTGTTCGACCAGAAGCAG GTGTGGGTGTGCAACGCCGACCACGTGGCCGCCGCCAACATCGCC CTGACCGGCAAGGGCATCGGCCGGCAGTCCAGCGACGAGGAGAA CCCCGACGGCGGCCGGATCAAGCTGCAGCTGACCAGC

[0189] C3 MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGIT 1153 PEIVRFSTEQEKQQQDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFE EYYGGTASDAIKQYFSASIGESYYWNDCRQQYYDLCRELGVEVSDL THDLEILCREKCLAVATESNQNNSIISVLFGTGEKEDRSVKLRITKKILE AISNLKEIPKNVAPIQEIILNVAKATKETFRQVYAGNLGAPSTLEKFIAK DGQKEFDLKKLQTDLKKVIRGKSKERDWCCQEELRSYVEQNTIQYD LWAWGEMFNKAHTALKIKSTRNYNFAKQRLEQFKEIQSLNNLLVVK KLNDFFDSEFFSGEETYTICVHHLGGKDLSKLYKAWEDDPADPENAI VVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQQLDRY KSQKANPSVLGNQGFTWTNAVILPEKAQRNDRPNSLDLRIWLYLKLR HPDGRWKKHHIPFYDTRFFQEIYAAGNSPVDTCQFRTPRFGYHLPKLT DQTAIRVNKKHVKAAKTEARIRLAIQQGTLPVSNLKITEISATINSKGQ VRIPVKFRVGRQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQY HKELRCRVRFISSGDIVSITENRGNQFDQLSYEGLAYPQYADWRKKA SKFVSLWQITKKNKKKEIVTVEAKEKFDAICKYQPREYKFNKEYAYL LRDIVRGKSLVELQQIRQEIFRFIEQDCGVTRLGSLSLSTLETVKAVKG IIYSYFSTALNASKNNPISDEQRKEFDPELFALLEKLELIRTRKKKQKV ERIANSLIQTCLENNIKFIRGEGDLSTTRNATKKKANSRSMDWLARG VFNKIRQLATMHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRWAAIP VKDIGDWVLRKLSQNLRAKNRGTGEYYHQGVKEFLSHYELQDLEEE LLKWRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHK VATGAVSIVFDQKQVWVCNADHVAAANIALTGKGIGRQSSDEENPDG GRIKLQLTS

[0190] Codon ATGAGCTCCGCCATCAAGAGCTACAAGAGCGTGCTGCGGCCCAAC 1154 optimized GAGCGGAAGAACCAGCTGCTGAAGAGCACCATCCAGTGCCTGGA coding GGACGGCAGCGCCTTCTTCTTCAAGATGCTGCAGGGCCTGTTCGG sequence CGGCATCACCCCCGAGATCGTGCGGTTCAGCACCGAGCAGGAGAA for C3 GCAGCAGCAGGACATCGCCCTGTGGTGCGCCGTGAACTGGTTCCG GCCCGTGAGCCAGGACAGCCTGACCCACACCATCGCCAGCGACA ACCTGGTGGAGAAGTTCGAGGAGTACTACGGCGGCACCGCCAGC GACGCCATCAAGCAGTACTTCAGCGCCAGCATCGGCGAGAGCTAC

[0191]

[0192] TACTGGAACGACTGCCGGCAGCAGTACTACGACCTGTGCCGGGAGAttorney Docket No. 063586-568001WO

[0193] CTGGGCGTGGAGGTGAGCGACCTGACCCACGACCTGGAGATCCTG TGCCGGGAGAAGTGCCTGGCCGTGGCCACCGAGAGCAACCAGAA CAACAGCATCATCAGCGTGCTGTTCGGCACCGGCGAGAAGGAGGA CCGCAGCGTGAAGCTGCGGATCACCAAGAAGATCCTGGAGGCCAT CAGCAACCTGAAGGAGATCCCCAAGAACGTGGCCCCCATCCAGGA GATCATCCTGAACGTGGCCAAGGCCACCAAGGAGACCTTCCGCCA GGTGTACGCCGGCAACCTGGGCGCCCCCAGCACCCTGGAGAAGTT CATCGCCAAGGACGGCCAGAAGGAGTTCGACCTGAAGAAGCTGC AGACCGACCTGAAGAAGGTGATCCGGGGCAAGAGCAAGGAGCGG GACTGGTGCTGCCAGGAGGAGCTGCGCTCCTACGTGGAGCAGAA CACCATCCAGTACGACCTGTGGGCCTGGGGCGAGATGTTCAACAA GGCCCACACCGCCCTGAAGATCAAGAGCACCCGGAACTACAACTT CGCCAAGCAGCGGCTGGAGCAGTTCAAGGAGATCCAGAGCCTGA ACAACCTGCTGGTGGTGAAGAAGCTGAACGACTTCTTCGACAGCG AGTTCTTCAGCGGCGAGGAGACCTACACCATCTGCGTGCACCACC TGGGCGGCAAGGACCTGTCCAAGCTGTACAAGGCCTGGGAGGAC GACCCCGCCGACCCCGAGAACGCCATCGTGGTGCTGTGCGACGAC CTGAAGAACAACTTCAAGAAGGAGCCCATCCGCAACATCCTGCGG TACATCTTCACCATCCGGCAGGAGTGCAGCGCCCAGGACATCCTG GCCGCCGCCAAGTACAACCAGCAGCTGGACCGGTACAAGAGCCA GAAGGCCAACCCCAGCGTGCTGGGCAACCAGGGCTTCACCTGGA CCAACGCCGTGATCCTGCCCGAGAAGGCCCAGCGGAACGACCGG CCCAACAGCCTGGACCTGCGGATCTGGCTGTACCTGAAGCTGCGG CACCCCGACGGCCGGTGGAAGAAGCACCACATCCCCTTCTACGAC ACCCGGTTCTTCCAGGAGATCTACGCCGCCGGCAACAGCCCCGTG GACACCTGCCAGTTCCGGACCCCCCGGTTCGGCTACCACCTGCCC AAGCTGACCGACCAGACCGCCATCCGGGTGAACAAGAAGCACGT GAAGGCCGCCAAGACCGAGGCCCGGATCCGGCTGGCCATCCAGC AGGGCACCCTGCCCGTGTCCAACCTGAAGATCACCGAGATCAGCG CCACCATCAACAGCAAGGGCCAGGTGCGGATCCCCGTGAAGTTCC GGGTGGGCCGGCAGAAGGGCACCCTGCAGATCGGCGACCGGTTC TGCGGCTACGACCAGAACCAGACCGCCTCCCACGCCTACAGCCTG TGGGAGGTGGTGAAGGAGGGCCAGTACCACAAGGAGCTGCGGTG CCGGGTGCGGTTCATCAGCAGCGGCGACATCGTGAGCATCACCGA GAACCGGGGCAACCAGTTCGACCAGCTGTCCTACGAGGGCCTGGC CTACCCCCAGTACGCCGACTGGCGGAAGAAGGCCAGCAAGTTCGT GAGCCTGTGGCAGATCACCAAGAAGAACAAGAAGAAGGAGATCG TGACCGTGGAGGCCAAGGAGAAGTTCGACGCCATCTGCAAGTACC AGCCCCGGCTGTACAAGTTCAACAAGGAGTACGCCTACCTGCTGC GCGACATCGTGCGCGGCAAGAGCCTGGTGGAGCTGCAGCAGATCC GGCAGGAGATCTTCCGGTTCATCGAGCAGGACTGCGGCGTGACCC GGCTGGGCAGCCTGAGCCTGAGCACCCTGGAGACCGTGAAGGCC GTGAAGGGCATCATCTACAGCTACTTCAGCACCGCCCTGAACGCC AGCAAGAACAACCCCATCAGCGACGAGCAGCGGAAGGAGTTCGA CCCCGAGCTGTTCGCCCTGCTGGAGAAGCTGGAGCTGATCCGGAC CCGGAAGAAGAAGCAGAAGGTGGAGCGGATCGCCAACAGCCTGA TCCAGACCTGCCTGGAGAACAACATCAAGTTCATCCGGGGCGAGG GCGACCTGAGCACCACCAGAAACGCCACCAAGAAGAAGGCCAAC AGCCGGAGCATGGACTGGCTGGCCCGGGGCGTGTTCAACAAGATC CGGCAGCTGGCCACCATGCACAACATCACCCTGTTCGGCTGCGGC AGCCTGTACACCAGCCACCAGGACCCCCTGGTGCACCGCAACCCC GACAAGGCCATGAAGTGCCGCTGGGCCGCCATCCCCGTGAAGGAC ATCGGCGACTGGGTGCTGCGGAAGCTGTCCCAGAACCTGCGGGCC AAGAACCGGGGCACCGGCGAGTACTACCACCAGGGCGTGAAGGA

[0194]

[0195] GTTCCTGAGCCACTACGAGCTGCAGGACCTGGAGGAGGAGCTGCTAttorney Docket No. 063586-568001WO

[0196] GAAGTGGCGGAGCGACCGGAAGAGCAACATCCCCTGCTGGGTGC TGCAGAACCGGCTGGCCGAGAAGCTGGGCAACAAGGAGGCCGTG GTGTACATCCCCGTGCGCGGCGGCCGGATCTACTTCGCCACCCACA AGGTGGCCACCGGCGCCGTGAGCATCGTGTTCGACCAGAAGCAG GTGTGGGTGTGCAACGCCGACCACGTGGCCGCCGCCAACATCGCC CTGACCGGCAAGGGCATCGGCCGGCAGTCCAGCGACGAGGAGAA CCCCGACGGCGGCCGGATCAAGCTGCAGCTGACCAGC D MIKSIQLKVKGECPITKDVINEYKEYYNNCSDWIKNNLTSITIGEMAK 4 FLQSLSDKEVAYISMGLSDEWKDKPLYHLFTKKYHTKNADNLLYYYI KEKNLDGYKGNTLNISNTSFRQFGYFKLVVSNYRTKIRTLNCKIKRK KIDADSTSEDIEMQVMYEIIKYSLNKKSDWDNFISYIENVENPNIDNIN RYKLLRECFCENENMIKNKLELLSVEQLKKFGGCIMKPHINSMTINIQ DFKIEEKENSLGFILHLPLNKKQYQIELLGNRQIKKGTKEIHETLVDIT NTHGENIVFTIKNDNEYIVFSYESEFEKEEVNFAKTVGLDVNFKHAFF VTSEKDNCHLDGYINLYKYLLEHDEFTNLLTEDERKDYEELSKVVTF CPFENQLLFARYNKMSKFCKKEQVLSKLLYALQKKLKDENRTKEYIY VSCVNKLRAKYVSYFILKEKYYEKQKEYDIEMGFVDDSTESKESMD KRRTEYPFRNTPVANELLSKLNNVQQDINGCLKNIINYIYKIFEQNGY KVVALENLENSNFEKKQVLPTIKSLLKYHKLENQNVNDIKASDKVKE YIENGYYELMTNENNEIVDAKYTEKGAMKVKNANFFNLMMKSLHF ASVKDEFVLLSNNGKTQIALVPSEFTSQMDSTDHCLYMKKNDKGKL VKADKKEVRTKQERHINGLNADFNAANNIKYIVENEVWRGIFCTRP KKTEYNVPSLDTTKKGPSAILNMLKKIEAIKVLETEK DI MIKSIQLKVKGECRITKDVINEYKEYYNNCSRWIKNNLTSITIGEMAK 5 FLQSLSDKEVAYRSMGLSDEWKDKPLYHLFTKKYHTKNADNLLYYY IKEKNLDGYKGNTLNISNTSFRQFGYFKLVVSNYRTKIRTLNCKIKRK KIDADSTSEDIEMQVMYEIIKYSLNKKSDWDNFISYIENVENPNIDNIN RYKLLRECFCENENMIKNKLELLSVEQLKKFGGCIMKPHINSMTINIQ DFKIEEKENSLGFILHLPLNKKQYQIELLGNRQIKKGTKEIHETLVDIT NTHGENIVFTIKNDNEYIVFSYRSEFEKEEVNFAKTVGLDVNFKHAFF VGSEKDNCHLDGYINLYKYLLEHDEFTNLLTEDERKDYEELSKVVTF CPFENQLLFARYNKMSKFCKKEQVLSKLLYALQKKLKDENRTKEYIY VSCVNKLRAKYVSYFILKEKYYEKQKEYDIEMGFVDDSTESKESMD KRRTEYPFRNTPVANELLSKLNNVQQDINGCLKNIINYIYKIFEQNGY KVVALENLENSNFEKKQVLPTIKSLLKYHKLENQNVNDIKASDKVKE YIENGYYELMTNENNEIVDAKYTEKGAMKVKNANFFNLMMKSLHF ASVKDEFVLLSNNGKTQIALVPSEFTSQMDSTDHCLYMKKNDKGKL VKADKKEVRTKQERHINGLNADFNAANNIKYIVENEVWRGIFCTRP KKTEYNVPSLDTTKKGPSAILNMLKKIGAIKVLETEK

[0197] Cas9 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNL 6

[0198] IGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLV DSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQT YNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFG NLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQY ADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTL LKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEK MDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY PFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTK VKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKI ECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL TLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLIN

[0199]

[0200] GIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQAttorney Docket No. 063586-568001WO

[0201] GDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEK LYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEWKKMKNYWRQLLNAKLITQRKFDNLTK AERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTA LIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIM NFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQ VNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPT VAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKG YKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYV NFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVIL ADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTT

[0202]

[0203] IDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

[0204] Table 2: CRISPR Nuclease PAM and gRNA Scaffold Sequences

[0205] Nuclease(s) PAM Scaffold

[0206] C NTTN AGAAAUCCGUCUUUCAUUGACGG (SEQ ID NO: 7) Cl (wherein N

[0207] C2 can be A,

[0208] C3 C, T, or G)

[0209] D NTTR CUUGUUGUAUAUGUCCUUUUAUAGGUAUUAAACAAC DI (where R (SEQ ID NO: 8)

[0210] can be A

[0211] or G)

[0212] Cas9 NGG GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUA (wherein N GUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGU can be A, GC

[0213]

[0214] C, T, or G) (SEQ ID NO: 9)

[0215] Any of the CRISPR nuclease polypeptides disclosed herein may further comprise one or more functional motifs in addition to the nuclease domain. For example, the CRISPR nuclease polypeptide comprises at least one (e.g., two, three, four, five, six, or more, identical or different) nuclear localization signal (NLS). In some embodiments, the CRISPR nuclease polypeptide comprises at least one (e.g., two, three, four, five, six, or more, identical or different) nuclear export signal (NES). In some embodiments, the CRISPR nuclease polypeptide comprises at least one (e.g., two, three, four, five, six, or more) NLS and at least one (e.g., two, three, four, five, six, or more) NES. In some examples, the CRISPR nuclease polypeptide may comprise one NLS at the C-terminus. In other examples, the CRISPR nuclease polypeptide may comprise one NLS at the N-terminus and one NLS at the C-terminus. In some instances, the N-terminus and C-terminus NLS motifs can be identical. Suitable NLS motifs known in the art can be used in the CRISPR nuclease polypeptidesAttorney Docket No. 063586-568001WO

[0216] disclosed herein. Examples of the NLS and peptide linker fragments, as well as other functional elements, are provided in Table 8 below.

[0217] Table 8. Exemplary Functional Fragments

[0218] Description Sequence SEQ ID NO.

[0219] SV40 NLS KRTADGSEFESPKKKRKV 1155 Nucleoplasmin NLS KRP AAT KKAGQ AKKKK 1156 (npNLS)

[0220] XTEN linker SGGSSGGSSGSETPGTSESATPESSGGSSGGSS 1157 Peptide linker SAGGGGSGGGGSGGGGSG 1158 bGH Poly A signal CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCC 1159

[0221] GTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTC CTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTC ATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAG GATTGGGAAGAGAATAGCAGGCATGCTGGGGA AAV2 ITR (left) CTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGC 1160

[0222] CCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAG CGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCT AAV2 ITR (right) AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCT 1161

[0223] CGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGC GACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAG

[0224] TranscriptionTTTTTTGCG

[0225]

[0226] Terminator

[0227] Any of the CRISPR nuclease polypeptides disclosed herein may have its native N- terminus methionine residue removed, for example, when an exogenous functional fragment (e.g., an NLS or a peptide linker) is linked to the N-terminus of the CRISPR nuclease polypeptide.

[0228] B. Guide RNAs

[0229] Aspects of the present disclose provide guide RNAs targeting a UBE3A-ATS gene. In some embodiments, a guide RNA targets a region within the cluster 2 exonic region (chrl5: 25,266,431-25,278,884) of a UBE3A-ATS gene. In some embodiments, a guide RNA is a guide RNA that targets a region of a UBE3A-ATS gene located within an intronic region of the UBE3A-ATS gene. In some embodiments, a guide RNA targets a target sequence located in segment 1 (chrl5: 25,278,885 to 25,296,525) of the intronic region of the UBE3A-ATS gene. In some embodiments, the gene editing system described herein comprises two or more guide RNAs targeting a UBE3A-ATS gene. In some embodiments, a guide RNA targets a target sequence located in segment 2 (chrl5: 25,296,526 to 25,316,526) of the intronic region of the UBE3A-ATS gene. In some embodiments, a guide RNA targets a target sequence located inAttorney Docket No. 063586-568001WO

[0230] segment 3 (25,316,526 to 25,333,728) of the intronic region of the UBE3A-ATS gene. In some embodiments, the gene editing system described herein comprises two or more guide RNAs targeting a UBE3A-ATS gene. In some embodiments, the gene editing system described herein comprises two or more guide RNAs targeting a UBE3A-ATS gene.

[0231] The guide RNA may direct the CRISPR nuclease contained in the gene editing system as described herein to a UBE3A-ATS target sequence. Two or more guide RNAs may direct two or more separate CRISPR nucleases as described herein to two or more UBE3A-ATS target sequences. In some embodiments, the two or more separate CRISPR nucleases may comprise the same amino acid sequence.

[0232] Those skilled in the art reading the below examples of particular kinds of guide RNAs will understand that, in some embodiments, a guide RNA is UBE3A-ATS target-specific. That is, the guide RNA binds specifically a UBE3A-ATS target sequence (e.g., within a cell such as a neuron) and not to non-targeted sequences (e.g., non-specific DNA or random sequences within the same cell).

[0233] In some embodiments, the guide RNA comprises a spacer sequence followed by a scaffold sequence in the 5’ to 3’ direction. In some embodiments, the guide RNA comprises a scaffold sequence followed by a spacer sequence in the 5’ to 3’ direction. In some embodiments the scaffold sequence comprises a direct repeat sequence. In some embodiments the scaffold sequence consists a direct repeat sequence.

[0234] In some examples, the guide RNA comprises a first scaffold sequence followed by a spacer sequence and a second scaffold sequence, referring to the sequences in the 5’ to 3’ direction. In some examples, the first and second scaffold sequences of such a guide RNA are identical. In other examples, the first and second scaffold sequences of such a guide RNA are different. In some instances, the guide RNA disclosed herein may further comprise a linker sequence, a 5’ end and / or 3’ end protection fragment (see disclosures herein), or a combination thereof.

[0235] In some embodiments, the spacer sequence and the scaffold sequence(s) of the guide RNA are present within the same RNA molecule. For example, the spacer and scaffold sequences are linked directly to one another. Alternatively, a short linker is present between the spacer and scaffold sequences, e.g., an RNA linker of 1, 2, or 3 nucleotides in length. In other examples, the spacer sequence and the scaffold sequence(s) of the guide RNA are present in separate molecules, which are joined to one another by base pairing interactions.

[0236] A guide RNA provided herein may comprise a spacer sequence specific to a target sequence within a UBE3A-ATS gene, the target sequence being adjacent to a protospacerAttorney Docket No. 063586-568001WO

[0237] adjacent motif (PAM) comprising (i) the motif of 5’-NTTN-3’ or 5’-NTTR-3’ (N being any of A, T, G, and C; and R being A or G) or (ii) the motif of 5’-NGG-3’ (N being any of A, T, G, and C). In some embodiments, the PAM comprises the motif of 5’-NTTN-3’ or 5’-NTTR-3’, wherein N is A, T, G, or C, and R is A or G, and the PAM is located 5’ to the target sequence. In some embodiments, the PAM comprises the motif of 5’-NGG-3’ (N being any of A, T, G, and C), and the PAM is located 3’ to the target sequence.

[0238] As used herein, the term “protospacer adjacent motif’ or “PAM” refers to a DNA sequence adjacent to a target sequence (e.g., a UBE3A-ATS target sequence) to which a complex comprising a guide RNA (e.g., a UBE3A-ATS -targeting Guide RNA) and a CRISPR nuclease binds. In a double- stranded DNA molecule, the strand containing the PAM motif is called the “PAM-strand” and the complementary strand is called the “non-PAM strand.” The guide RNA binds to a site in the non-PAM strand that is complementary to a target sequence disclosed herein.

[0239] As used herein, the term “target sequence” refers to a DNA fragment adjacent to a PAM motif (on the PAM strand). The complementary region of the target sequence is on the non-PAM strand. A target sequence may be immediately adjacent to the PAM motif. Alternatively, the target sequence and the PAM may be separated by a small sequence segment (e.g., up to 5 nucleotides, for example, up to 4, 3, 2, or 1 nucleotide). A target sequence may be located at the 3’ end of the PAM motif or at the 5’ end of the PAM motif, depending upon the CRISPR nuclease that recognizes the PAM motif, which is known in the art. In some embodiments, a target sequence is located at the 3’ end of a PAM motif for a CRISPR nuclease disclosed herein. In some embodiments, a target sequence is located at the 5’ end of a PAM motif for a Cas9 nuclease (e.g., 5’-NGG-3’ (N being any of A, T, G, and C) located 3’ to the target sequence). In some embodiments, the target sequence is a sequence within a UBE3A-ATS gene.

[0240] As used herein, the term “adjacent to” refers to a nucleotide or amino acid sequence in close proximity to another nucleotide or amino acid sequence. In some embodiments, a nucleotide sequence is adjacent to another nucleotide sequence if no nucleotides separate the two sequences (i.e., immediately adjacent). In some embodiments, a nucleotide sequence is adjacent to another nucleotide sequence if a small number of nucleotides separate the two sequences (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides). In some embodiments, a first sequence is adjacent to a second sequence if the two sequences are separated by about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides. In some embodiments, a first sequence is adjacent to a second sequence if the two sequences are separated by up to 2 nucleotides, up to 5 nucleotides, up to 8 nucleotides, up to 10 nucleotides,Attorney Docket No. 063586-568001WO

[0241] up to 12 nucleotides, or up to 15 nucleotides. In some embodiments, a first sequence is adjacent to a second sequence if the two sequences are separated by 2-5 nucleotides, 4-6 nucleotides, 4-8 nucleotides, 4-10 nucleotides, 6-8 nucleotides, 6-10 nucleotides, 6-12 nucleotides, 8-10 nucleotides, 8-12 nucleotides, 10-12 nucleotides, 10-15 nucleotides, or 12-15 nucleotides.

[0242] Further aspects of the present disclose provide compositions comprising two or more guides disclosed herein.

[0243] Spacer Sequence

[0244] As used herein, the term “spacer” or “spacer sequence” is a portion in a guide RNA that is the RNA equivalent of a target sequence (a DNA sequence) in the gene for editing (here UBE3A-ATS). The spacer contains a sequence capable of binding to the non -PAM strand via base-pairing at the site complementary to the target sequence (in the PAM strand). Such a spacer is also known as being specific to the target sequence. In some instances, the spacer may be at least 75% identical to the target sequence (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%), except for the RNA-DNA sequence difference. In some instances, the spacer may be 100% identical to the target sequence except for the RNA-DNA sequence difference.

[0245] In some embodiments, a spacer sequence comprises a sequence that is at least 80% (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or is 100%) identical to a spacer sequence set forth in Table 4, Table 6, or Table 7.

[0246] In some embodiments, the spacer sequence is at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or is 100%) identical to:

[0247] UCCUCCUCCCCUUAGAUAAG (SEQ ID NO: 185), AACCAGGAUUUAAGGAUGCC (SEQ ID NO: 457), GUAUGAGAGAUGCUGUUCUA (SEQ ID NO: 711), or UAUAUAUAAUUGAGGGCCAC (SEQ ID NO: 929).

[0248] PAM

[0249] In some embodiments, the target sequence is adjacent to a protospacer adjacent motif (PAM). In some embodiments, the PAM comprises (i) the motif of 5’-NTTN-3’ or 5’-NTTR-3’ (N being any of A, T, G, and C; and R being A or G) or (ii) the motif of 5’-NGG-3’ (N being any of A, T, G, and C). In some embodiments, the PAM comprises the motif of 5’-NTTN-3’ or 5’-NTTR-3’, wherein N is A, T, G, or C, and R is A or G, and the PAM is locatedAttorney Docket No. 063586-568001WO

[0250] 5’ to the target sequence. In some embodiments, the PAM comprises the motif of 5’-NGG-3’ (N being any of A, T, G, and C), and the PAM is located 3’ to the target sequence. In some embodiments, the PAM sequence comprises a PAM sequence corresponding to a Cas9 nuclease.

[0251] In some embodiments, the PAM strand is a coding (e.g., sense) strand. In other embodiments, the PAM strand is a non-coding (e.g., antisense strand). Since a guide RNA binds the non-PAM strand via base-pairing, the non-PAM strand is also known as the target strand, while the PAM strand is also known as the non-target strand.

[0252] In some embodiments, the PAM sequence is a sequence provided in Table 2 or a portion thereof.

[0253] Scaffold Sequence

[0254] In some embodiments, the guide RNA comprises a scaffold sequence. A scaffold sequences is recognizable by the CRISPR nuclease. In some embodiments, the scaffold sequence comprises a direct repeat sequence. In some embodiments, the scaffold sequence of the guide RNA has a length of between 12-100, 13-75, 14-50, or 15-40 nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides). In some embodiments, the scaffold sequence length of the guide RNA is at least 21 nucleotides, or is from 21 to 37 nucleotides (e.g., 23, 24, 25, 30, 35, or 36 nucleotides). In some embodiments, the scaffold sequence length of the guide RNA is 22 nucleotides. In some embodiments, the scaffold sequence length of the guide RNA is 23 nucleotides. In some embodiments, the scaffold sequence length of the guide RNA is 36 nucleotides.

[0255] In some embodiments, the scaffold sequence comprises a sequence provided in Table 2 or a portion thereof. In some embodiments, the scaffold sequence comprises:

[0256] (i) AGAAAUCCGUCUUUC AUUGACGG (SEQ ID NO : 7),

[0257] (ii) CUUGUUGUAUAUGUCCUUUUAUAGGUAUUAAACAAC (SEQ ID NO:

[0258] 8),

[0259] (iii) or a portion thereof.

[0260] A skilled person would understand that the scaffold sequence used for a particular guide RNA in a gene editing system could be dependent on the CRISPR nuclease in the gene editing system.

[0261] Additional scaffold sequence for use in constructing the guide RNAs provided herein can be found, e.g., in WO2019178427, W02021202800, W02021050534, WO2022192391 or W02024020567, the relevant disclosures of each of which are incorporated by reference hereinAttorney Docket No. 063586-568001WO

[0262] for the subject matter and purpose referenced herein.

[0263] Some CRISPR nucleases, such as Type II nucleases (e.g. : Cas9), require a transactivating CRISPR RNA (tracr RNA). In some embodiments, the disclosure provides CRISPR nucleases that do not require a tracr RNA. In some embodiments, the disclosure provides CRISPR nucleases, such as Cas9, that require a tracr RNA. In some embodiments, the tracr RNA comprises all or a portion of a wildtype tracr RNA sequence. In some embodiments the scaffold sequence comprises a tracr RNA. In some embodiments the scaffold sequence compri ses : gttttagagctaGAAAtagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgc (SEQ ID NO: 9)

[0264] Exemplary RNA Guides

[0265] Aspects of the present disclosure provide guide RNAs that comprise a specific combination of a scaffolds and a spacer described herein. In some embodiments, the sequence of a guide RNA is at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or is 100%) identical to a guide RNA sequence provided in Table 4, Table 6, or Table 7.

[0266] In some embodiments, a guide RNA comprises a spacer sequence that is at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or is 100%) identical to a spacer RNA sequence provided in Table 4, Table 6, or Table 7. In some embodiments, the spacer sequence is at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or is 100%) identical to:

[0267] UCCUCCUCCCCUUAGAUAAG (SEQ ID NO: 185), AACCAGGAUUUAAGGAUGCC (SEQ ID NO: 457), GUAUGAGAGAUGCUGUUCUA (SEQ ID NO: 711), or UAUAUAUAAUUGAGGGCCAC (SEQ ID NO: 929).

[0268] Modifications

[0269] The RNA guides provided herein may include one or more covalent modifications with respect to a reference sequence, in particular the parent polyribonucleotide, which are included within the scope of the present disclosure.

[0270] Exemplary modifications can include any modification to the sugar, the nucleobase, the internucleoside linkage (e.g., to a linking phosphate / to a phosphodiester linkage / to the phosphodiester backbone), and any combination thereof. Some of the exemplary modifications provided herein are described in detail below.Attorney Docket No. 063586-568001WO

[0271] The RNA guide may include any useful modification, such as to the sugar, the nucleobase, or the internucleoside linkage (e.g., to a linking phosphate / to a phosphodiester linkage / to the phosphodiester backbone). One or more atoms of a pyrimidine nucleobase may be replaced or substituted with optionally substituted amino, optionally substituted thiol, optionally substituted alkyl (e.g., methyl or ethyl), or halo (e.g., chloro or fluoro). In certain embodiments, modifications (e.g., one or more modifications) are present in each of the sugar and the internucleoside linkage. Modifications may be modifications of ribonucleic acids (RNAs) to deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs) or hybrids thereof).

[0272] Additional modifications are described herein.

[0273] In some embodiments, the modification may include a chemical or cellular induced modification. For example, some nonlimiting examples of intracellular RNA modifications are described by Lewis and Pan in “RNA modifications and structures cooperate to RNA guideprotein interactions” from Nat Reviews Mol Cell Biol, 2017, 18:202-210.

[0274] Different sugar modifications, nucleotide modifications, and / or internucleoside linkages (e.g., backbone structures) may exist at various positions in the sequence. One of ordinary skill in the art will appreciate that the nucleotide analogs or other modification(s) may be located at any position(s) of the sequence, such that the function of the sequence is not substantially decreased. The sequence may include from about 1% to about 100% modified nucleotides (either in relation to overall nucleotide content, or in relation to one or more types of nucleotide, i.e., any one or more of A, G, U or C) or any intervening percentage (e.g., from 1% to 20%>, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%, from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%, from 90% to 100%, and from 95% to 100%).

[0275] In some embodiments, sugar modifications (e.g., at the 2’ position or 4’ position) or replacement of the sugar at one or more ribonucleotides of the sequence may, as well as backbone modifications, include modification or replacement of the phosphodiester linkages. Specific examples of a sequence include, but are not limited to, sequences including modifiedAttorney Docket No. 063586-568001WO

[0276] backbones or no natural intemucleoside linkages such as internucleoside modifications, including modification or replacement of the phosphodiester linkages. Sequences having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this application, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In particular embodiments, a sequence will include ribonucleotides with a phosphorus atom in its intemucleoside backbone.

[0277] Modified sequence backbones may include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates such as 3 ’-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates such as 3 ’-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3’-5’ linkages, 2’-5’ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3’-5’ to 5’-3’ or 2’-5’ to 5’-2’. Various salts, mixed salts and free acid forms are also included. In some embodiments, the sequence may be negatively or positively charged.

[0278] The modified nucleotides, which may be incorporated into the sequence, can be modified on the intemucleoside linkage (e.g., phosphate backbone). Herein, in the context of the polynucleotide backbone, the phrases “phosphate” and “phosphodiester” are used interchangeably. Backbone phosphate groups can be modified by replacing one or more of the oxygen atoms with a different substituent. Further, the modified nucleosides and nucleotides can include the wholesale replacement of an unmodified phosphate moiety with another intemucleoside linkage as described herein. Examples of modified phosphate groups include, but are not limited to, phosphorothioate, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoramidates, phosphorodiamidates, alkyl or aryl phosphonates, and phosphotriesters. Phosphorodithioates have both non-linking oxygens replaced by sulfur. The phosphate linker can also be modified by the replacement of a linking oxygen with nitrogen (bridged phosphoramidates), sulfur (bridged phosphorothioates), and carbon (bridged methylene-phosphonates).

[0279] The a-thio substituted phosphate moiety is provided to confer stability to RNA and DNA polymers through the unnatural phosphorothioate backbone linkages. Phosphorothioate DNA and RNA have increased nuclease resistance and subsequently a longer half-life in a cellular environment.Attorney Docket No. 063586-568001WO

[0280] In specific embodiments, a modified nucleoside includes an alpha-thio-nucleoside (e.g., 5’-O-(l-thiophosphate)-adenosine, 5’-O-(l-thiophosphate)-cytidine (a-thio-cytidine), 5’-O-(l-thiophosphate)-guanosine, 5’-O-(l-thiophosphate)-uridine, or 5’-O-(l-thiophosphate)-pseudouridine).

[0281] Other internucleoside linkages that may be employed according to the present disclosure, including internucleoside linkages which do not contain a phosphorous atom, are described herein.

[0282] In some embodiments, the sequence may include one or more cytotoxic nucleosides. For example, cytotoxic nucleosides may be incorporated into sequence, such as bifunctional modification. Cytotoxic nucleoside may include, but are not limited to, adenosine arabinoside, 5-azacytidine, 4’-thio-aracytidine, cyclopentenylcytosine, cladribine, clofarabine, cytarabine, cytosine arabinoside, 1 -(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl)-cytosine, decitabine, 5-fluorouracil, fludarabine, floxuridine, gemcitabine, a combination of tegafur and uracil, tegafur ((RS)-5-fluoro-l-(tetrahydrofuran-2-yl)pyrimidine-2,4(lH,3H)-dione), troxacitabine, tezacitabine, 2’-deoxy-2’-methylidenecytidine (DMDC), and 6-mercaptopurine. Additional examples include fludarabine phosphate, N4-behenoyl-l-beta-D-arabinofuranosylcytosine, N4-octadecyl- 1 -beta-D-arabinofuranosylcytosine, N4-palmitoyl- 1 -(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine, and P-4055 (cytarabine 5’-elaidic acid ester).

[0283] In some embodiments, the sequence includes one or more post-transcriptional modifications e.g., capping, cleavage, polyadenylation, splicing, poly- A sequence, methylation, acylation, phosphorylation, methylation of lysine and arginine residues, acetylation, and nitrosylation of thiol groups and tyrosine residues, etc). The one or more post-transcriptional modifications can be any post-transcriptional modification, such as any of the more than one hundred different nucleoside modifications that have been identified in RNA (Rozenski, J, Crain, P, and McCloskey, J. (1999). The RNA Modification Database: 1999 update. Nucl Acids Res 27: 196-197) In some embodiments, the first isolated nucleic acid comprises messenger RNA (mRNA). In some embodiments, the mRNA comprises at least one nucleoside selected from the group consisting of pyridin-4-one ribonucleoside, 5 -aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3 -methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinom ethylpseudouridine, 5-taurinomethyl-2 -thio-uridine, l-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-l-methyl-pseudouridine, 2 -thio- 1 -methyl-Attorney Docket No. 063586-568001WO

[0284] pseudouridine, 1 -methyl- 1 -deaza-pseudouridine, 2-thio- 1 -methyl- 1 -deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, and 4-methoxy-2 -thiopseudouridine. In some embodiments, the mRNA comprises at least one nucleoside selected from the group consisting of 5 -aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-l-methyl-pseudoisocytidine, 4-thio-l-methyl-l-deaza-pseudoisocytidine, 1 -methyl- 1-deaza-pseudoisocyti dine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, and 4-methoxy-l-methyl-pseudoisocytidine. In some embodiments, the mRNA comprises at least one nucleoside selected from the group consisting of 2-aminopurine, 2, 6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2, 6-diaminopurine, 1 -methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-m ethyladenine, 2-methylthio-adenine, and 2-m ethoxy-adenine. In some embodiments, mRNA comprises at least one nucleoside selected from the group consisting of inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-m ethylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, l-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, andN2,N2-dimethyl-6-thio-guanosine.

[0285] The sequence may or may not be uniformly modified along the entire length of the molecule. For example, one or more or all types of nucleotides (e.g., naturally-occurring nucleotides, purine or pyrimidine, or any one or more or all of A, G, U, C, I, pU) may or may not be uniformly modified in the sequence, or in a given predetermined sequence region thereof. In some embodiments, the sequence includes a pseudouridine. In some embodiments, the sequence includes an inosine, which may aid in the immune system characterizing the sequence as endogenous versus viral RNAs. The incorporation of inosine may also mediate improved RNA stability / reduced degradation. See for example, Yu, Z. et al. (2015) RNAAttorney Docket No. 063586-568001WO

[0286] editing by AD ARI marks dsRNA as “self’. Cell Res. 25, 1283-1284, which is incorporated by reference in its entirety.

[0287] In some embodiments, one or more of the nucleotides of an RNA guide comprises a 2’-O-methyl phosphorothioate modification. In some embodiments, each of the first three nucleotides of the RNA guide comprises a 2’-O-methyl phosphorothioate modification. In some embodiments, each of the last four nucleotides of the RNA guide comprises a 2’-O-methyl phosphorothioate modification. In some embodiments, each of the first to last, second to last, and third to last nucleotides of the RNA guide comprises a 2’-O-methyl phosphorothioate modification, and wherein the last nucleotide of the RNA guide is unmodified. In some embodiments, each of the first three nucleotides of the RNA guide comprises a 2’-O-methyl phosphorothioate modification, and each of the first to last, second to last, and third to last nucleotides of the RNA guide comprises a 2’-O-methyl phosphorothioate modification.

[0288] When a gene editing system disclosed herein comprises nucleic acids encoding the CRISPR nuclease disclosed herein, e.g., mRNA molecules, such nucleic acid molecules may contain any of the modifications disclosed herein, where applicable. In specific examples, the gRNAs in association with the CRISPR nucleases disclosed herein (regardless of the target) may contain 1-3 (e.g., 1, 2, or 3) 2’-O-methylated bases and 1-3 (e.g., 1, 2, or 3) phosphorothioate bonds at the 5’ end, at the 3’ end, or both. In some instances, the gRNA may have no 2’-O-methylated base at the 5’ end.

[0289] C. Gene Editing Systems Comprising an RNA Guide and a CRISPR Nuclease or Nucleic Acid(s) Encoding Such

[0290] Aspects of the present disclosure provide a gene editing system comprising: (a) a guide RNA targeting the UBE3A-ATS gene or a nucleic acid encoding such, and (b) a CRISPR nuclease or a nucleic acid encoding such. In some embodiments, the gene editing system provided herein may comprise: (a) a nucleic acid encoding the guide RNA as disclosed herein, and / or (b) a nucleic acid encoding the CRISPR nuclease as also disclosed herein. In some examples, one or both of the encoding nucleic acids are located on one or more vectors. In some specific examples, the nucleic acid encoding the guide RNA and the nucleic acid encoding the CRISPR nuclease are located on one vector, for example, an AAV vector.

[0291] Exemplary Gene Editing Systems Targeting UBE3A-ATS

[0292] In some embodiments, the gene editing systems targeting the UBE3A-ATS comprisesAttorney Docket No. 063586-568001WO

[0293] (a) a CRISPR nuclease polypeptide as disclosed herein (e.g., Nuclease C or a variant thereof such as Cl, C2, and C3, or Nuclease D or a variant thereof such as DI, or a Cas9 nuclease ) or a nucleic acid encoding such), and (b) a gRNA as also disclosed herein (e.g., those provided in Table 4, Table 6, or Table 7 below such as C2_EX5_G4 or C2_S1_G7.6) or a nucleic acid encoding such.

[0294] In some embodiments, the 7 / / 77G4-47Vtargeting gene editing system comprises the CRISPR nuclease polypeptide (e.g., Nuclease C or a variant thereof such as Cl, C2, and C3, or Nuclease D or a variant thereof such as DI, or a Cas9 nuclease ) or a nucleic acid encoding such and the gRNA (e.g., those provided in Table 4, Table 6, or Table 7 such as C2_EX5_G4 or C2 S1 G7.6,), which may form a ribonucleoprotein complex (RNP), which can be delivered to host cells for gene editing.

[0295] In other instances, the CRISPR nuclease-encoding nucleic acid may be a messenger RNA molecule. A gene editing system comprising such a messenger RNA molecule may be formulated into a composition, which comprises one or more lipid excipients. In some examples, the lipid excipients may form lipid nanoparticles (LNPs), which associate with, or encapsulate, components of the gene editing system (e.g., the mRNA and optionally the gRNA (e.g., those provided in Table 4, Table 6, or Table 7 such as C2_EX5_G4 or C2_S1_G7.6).

[0296] In other embodiments, the UBE3A-A / ^targeting gene editing system may comprise a nucleic acid encoding the CRISPR nuclease polypeptide. In some instances, the nucleic acid encoding the CRISPR nuclease polypeptide may be located in a vector (e.g., a DNA plasmid). In some examples, the nucleic acid encoding the CRISPR nuclease polypeptide may be located in a genetically modified viral genome (e.g., a genetically modified adeno-associated viral (AAV) genome, or a genetically modified adenoviral vector (AdV) genome), which may be encapsulated by a viral envelop or capsid. In some examples, such a vector or viral genome may be designed to produce both the CRISPR nuclease polypeptide and the gRNA (e.g., those provided in Table 4, Table 6, or Table 7 such as C2_EX5_G4 or C2_S1_G7.6).

[0297] In some embodiments, the UBE3A-A / ^'-targeting gene editing system disclosed herein comprises a genetically modified viral particle comprising a viral capsid or viral envelop encapsulating a genetically modified viral genome. In some instances, the viral particle is derived from a capsid virus such as AAV. In some instances, the genetically modified viral particle (e.g., an AAV viral particle) is replication-defective. As used herein, a genetically modified viral genome refers to viral genomic nucleic acid that is genetically modified relative to the wild-type viral genome to incorporate one or more genes of interest (here a gene encoding any of the CRISPR nuclease polypeptides disclosed herein and optionally a geneAttorney Docket No. 063586-568001WO

[0298] encoding any of the UBE3A-ATSA r Q m gRNAs as also disclosed herein). Such a genetically modified viral genome can deliver the gene(s) of interest (GO I) to host cells, where the proteins or nucleic acids encoded by the GOIs are expressed. The viral genomic nucleic acid can be further modified to remove viral elements not necessary for assembly of the viral genome into viral particles. Depending upon the type of the viral particle (e.g., derived from a DNA virus or RNA virus), the viral genomic nucleic acid in the genetically modified viral particle may be a DNA molecule (e.g., a double-strand DNA (dsDNA) or a single-strand DNA (ssDNA)) or an RNA molecule.

[0299] In some examples, the genetically engineered viral genome comprises a first nucleic acid encoding the CRISPR nuclease polypeptide as disclosed herein or a complementary sequence thereof and a second nucleic acid encoding the gRNA as also disclosed herein or a complementary sequence thereof. The first nucleic acid can be in operable linkage to a first promoter and the second nucleic acid encoding the gRNA can be in operable linkage to a second promoter. In some instances, the first promoter and the second promoter are different promoters, for example, the first promoter is a synapsin promoter or a Ula promoter or and the second promoter is a U6 promoter. In one example, the first promoter can be a synapsin promoter (e.g., a human synapsin or hSyn promoter) and the second promoter is a U6 promoter. In some instances, the first and second promoters can be in opposite orientation (see illustration in FIG. 13A).

[0300] In some examples, the first nucleic acid encoding the CRISPR nuclease polypeptide may further comprise a nucleotide sequence encoding one or more miRNA binding sites. The miRNA binding site-coding sequence may be either downstream to or upstream to the coding sequence for the CRISPR nuclease polypeptide. microRNAs are small, single-stranded, noncoding RNA molecules that modulates mRNA translation. miRNAs typically have 19-25 nucleotides in length and can bind to particular regions in a mRNA via base-pairing to inhibit mRNA translation to proteins. The regions in mRNA that bind miRNAs are the miRNA binding sites. In some instances, a miRNA can destabilize a mRNA via, e.g., degrading the mRNA or shortening the polyA tail of the mRNA. Alternatively, a miRNA may block translation.

[0301] In some instances, the miRNA binding sites in the viral genome can be binding sites for one or more tissue-specific miRNAs, which are selectively expressed or enriched in particular tissues. Due to the inhibitory activity of the miRNAs in the specific tissues, expression of the Casl2i2 nuclease polypeptide would be inhibited in such specific tissues, allowing for detargeting the specific tissues. Tissue-specific miRNAs can be found in public microRNAAttorney Docket No. 063586-568001WO

[0302] databases, for example, the TSmiRNA database.

[0303] In some instances, the first nucleic acid may also comprise a polyA signal sequence (e.g., the polyA signal sequence from bovine growth factor or bGH) downstream to the coding sequence for the CRISPR nuclease polypeptide. Exemplary sequences of the polyA signal sequence are provided in Table 8 above. In some instances, the transcript (mRNA) encoded by the first nucleic acid, driven by the first promoter (e.g., synapsin), may comprise, from 5’ to 3’, coding region for the CRISPR nuclease polypeptide, and the polyA signal.

[0304] In some specific examples, the CRISPR nuclease polypeptide encoded by the first nucleic acid may comprise the amino acid sequence of SEQ ID NO: 3, which may be encoded by the nucleotide sequence of SEQ ID NO: 1151 or 1152. Such a CRISPR nuclease polypeptide may further comprise an NLS (e.g., SEQ ID NO: 1156) located at the C-terminus. In some instances, the NLS may be connected to the nuclease moiety via a peptide linker (e.g., SEQ ID NO: 1158). Alternatively, or in addition, the gRNA encoded by the second nucleic acid may comprise a spacer sequence of SEQ ID NO: 457 or 711. In some instances, the gRNA encoded by the second nucleic acid may be C2 EX5 G4 (SEQ ID NO: 458). In other instances, the gRNA encoded by the second nucleic acid may be C2 S1 G7.6 (SEQ ID NO: 712).

[0305] In some specific examples, the CRISPR nuclease polypeptide encoded by the first nucleic acid may comprise the amino acid sequence of SEQ ID NO: 1153, which may be encoded by the nucleotide sequence of SEQ ID NO: 1154. Such a CRISPR nuclease polypeptide may further comprise an NLS (e.g., SEQ ID NO: 1156) located at the C-terminus. In some instances, the NLS may be connected to the nuclease moiety via a peptide linker (e.g., SEQ ID NO: 1158). Alternatively, or in addition, the gRNA encoded by the second nucleic acid may comprise a spacer sequence of SEQ ID NO: 457 or 711. In some instances, the gRNA encoded by the second nucleic acid may be C2 EX5 G4 (SEQ ID NO: 458). In other instances, the gRNA encoded by the second nucleic acid may be C2 S1 G7.6 (SEQ ID NO: 712).

[0306] In some embodiments, the first promoter (e.g., human synapsin promoter) and the second promoter (e.g., U6) in the genetically modified viral genome disclosed herein can be in opposite orientation, which means that the transcription of the CRISPR nuclease polypeptide driven by the first promoter and transcription of the gRNA driven by the second promoter are in opposite directions. See illustration in FIG. 13A. When the viral genome is single-stranded, such a viral genome would comprise: (a) the first nucleic acid (comprising coding sequence for the CRISPR nuclease and optionally a polyA signal), and (b) complementary sequences of theAttorney Docket No. 063586-568001WO

[0307] second nucleic acid encoding the gRNA coding sequence. Alternatively, the single-stranded viral genome may comprise (a) the second nucleic acid encoding the gRNA, and (b) a complementary sequence of the first nucleic acid. In either case, (a) and (b) each may be in operable linkage to a promoter (e.g., the first and second promoters disclosed herein). In some instances, a transcription terminator sequence can be included downstream to the gRNA coding sequence to terminate transcription of the gRNA driven by the second promoter as disclosed herein.

[0308] When the viral genome is double-stranded, the first nucleic acid (comprising coding sequence for the CRISPR nuclease and optionally a polyA signal) in operable linkage to the first promoter and the second nucleic acid (comprising a coding sequence for the gRNA and optionally a terminator sequence) in operable linkage to the second promoter would be located on opposite strands.

[0309] In one specific example, the genetically modified viral genome comprises, from 5’ to 3’, the human synapsin promoter, a nucleotide sequence encoding the CRISPR nuclease polypeptide, the polyA signal sequence, a nucleotide sequence complementary to the coding sequence for the gRNA (e.g., C2_EX5_G4 (SEQ ID NO: 458) or C2_S1_G7.6 (SEQ ID NO: 712)), and a sequence complementary to the U6 promoter. In some instances, a complementary sequence of the transcription terminator sequence may be located 5’ of the complementary sequence for the gRNA coding sequence to terminate transcription of the gRNA. Such a genetically modified viral genome may be an ssDNA viral genome, for example, an AAV viral genome. Examples of such viral construct designs are provided in FIG. 13A. AAV constructs having the orientation of the two promoters for driving expression of the CRISPR nuclease and guide RNA can result in enhanced expression of the guide RNAs in neuron cells, which would be expected to improve gene editing efficiency.

[0310] In other specific examples, the genetically modified viral genome comprises, from 5’ to 3’, a hSyn promoter, a nucleotide sequence encoding one or more NLSs (e.g., three), a nucleotide sequence encoding the CRISPR nuclease polypeptide followed by an NLS, a polyA signal sequence, a nucleotide sequence complementary to the coding sequence for the gRNA, and a nucleotide sequence complementary to the U6 promoter. In some instances, a complementary sequence of a transcription terminator sequence may be located 5’ of the complementary sequence for the gRNA coding sequence to terminate transcription of the gRNA. Such a genetically modified viral genome may be an ssDNA viral genome, for example, an AAV viral genome.

[0311] In yet other specific examples, the genetically modified viral genome comprises, fromAttorney Docket No. 063586-568001WO

[0312] 5’ to 3’, a hSyn promoter, a nucleotide sequence encoding the CRISPR nuclease polypeptide followed by a peptide linker and an NLS, a polyA signal sequence, a nucleotide sequence complementary to the coding sequence for the gRNA, and a nucleotide sequence complementary to the U6 promoter. In some instances, a complementary sequence of a transcription terminator sequence may be located 5’ of the complementary sequence for the gRNA coding sequence to terminate transcription of the gRNA. Such a genetically modified viral genome may be an ssDNA viral genome, for example, an AAV viral genome.

[0313] In other examples, the genetically modified viral genome (single-stranded) may comprise a complementary sequence of any of the above-disclosed genomic designs. In yet other examples, the genetically modified viral genome disclosed herein may be a doublestranded molecule comprising one strand with any of the above-disclosed genomic designs and a complementary strand thereof.

[0314] The genetically modified viral genome disclosed herein may further comprise viral genomic elements necessary for producing and / or packaging the viral genomic nucleic acid into the viral particle, for example, packaging signals and terminal repeats. Such viral genomic elements for use in viral particle-mediated gene delivery systems are well known in the art.

[0315] The genetically modified viral particle disclosed herein can be prepared by conventional methods. For example, a viral vector (a DNA vector) comprising the elements in the viral genome disclosed herein can be delivered into packaging cells, which are engineered to produce viral proteins needed for producing the viral genomic nucleic acids and viral particle assembly. Alternatively, the viral vector comprising the elements in the viral vectors disclosed herein can be delivered into host cells, together with DNA plasmids for producing the viral proteins. Viral particles produced in the packaging cells or host cells can then be collected.

[0316] As used herein, the term “viral vector” refers to a DNA plasmid or construct comprising the elements contained in the genetically modified viral genome as disclosed herein for use in producing viral particles comprising the genetically modified viral genome. Any of the viral vectors such as AAV vectors is within the scope of the present disclosure.

[0317] Genetically Modified AAV Particles

[0318] In some instances, the genetically modified viral particle for use in the UBE3A-ATS-targeting gene editing system and method disclosed herein is an AAV particle. AAV is a small non-enveloped virus having a single-stranded linear DNA genome. Recombinant AAVs have emerged as one of the most effective vehicles for gene delivery due to their ability to transduceAttorney Docket No. 063586-568001WO

[0319] a variety of mammalian cells and their non-pathogenicity and low immunogenicity in humans. The genome of an AAV is a single-stranded DNA chain (ssDNA), which can be either positive (+)-or negative (-)-sensed. The AAV genome contains inverted terminal report (ITR) sequences at both ends of the DNA strand and two open reading frames, rep and cap, encoding the Rep protein and the capsid proteins, respectively. The ITR sequence in a naturally-occurring AAV genome is about 145 bp long and capable of forming a hairpin, allowing for self-priming and synthesis of the second DNA strand. The ITR sequence also plays a role in efficient packaging of the AAV genome into capsid to form a fully assembled AAV virus. The rep gene encodes Rep proteins, which enable viral DNA replication and integration into the host genome. The cap gene produces three overlapping messenger RNA sequences coding for three capsid proteins, VP1, VP2, and VP3. Typically, an AAV capsid is composed of a mixture of VP1, VP2, and VP3 arranged in icosahedral symmetry. AAV virus of different serotypes contain different capsid proteins.

[0320] The ITR sequences contained in the AAV genome and AAV vectors for producing the AAV particles may be derived from a naturally-occurring AAV genome. In some embodiments, the ITR sequences can be naturally-occurring. In other embodiments, the ITR sequences can be modified relative to the naturally-occurring counterpart, for example, an internal ITR lacking a terminal resolution site. The ITR sequences for use in the AAV vectors disclosed herein may be derived from any serotype of AAV virus capable of infecting neuron cells. In some examples, the ITRs can be derived from AAV2. Exemplar ITR sequences for use in the AAV vectors are provided in Table 8 above.

[0321] The AAV particles disclosed herein are of a serotype that can infect neuron cells, for example, AAV2, AAV9, or AAVrhlO. In some instances, the genetically modified AAV particle as disclosed herein is an AAV2 particle comprising AAV2 capsid proteins. In other instances, the genetically modified AAV particle as disclosed herein is an AAV9 particle comprising AAV9 capsid proteins. In some examples, the capsid of the AAV9 viral particle comprises blood-brain barrier (BBB)-penetrant capsid proteins such as those known in the art.

[0322] To produce AAV viral particles, any of the AAV vectors disclosed herein may be delivered to a suitable host cell, such as a packaging host cell, for producing AAV viral particles following routine practice. In some examples, the host cells are mammalian cells. Examples include, but are not limited to, A549, WEHI, 3T3, 10T1 / 2, BHK, MDCK, COS 1, COS 7, BSC 1, BSC 40, BMT 10, VERO, WI38, HeLa, 293 cells (which express functional adenoviral El), Saos, C2C12, L cells, HT1080, HepG2 and primary fibroblast, hepatocyte and myoblast cells.Attorney Docket No. 063586-568001WO

[0323] In some embodiments, one or more vectors carrying AAV rep gene and / or AAV cap gene may be introduced into the host cell together with the AAV vector. In some instances, the rep gene may be of the same serotype as the serotype of the ITRs in the AAV vector.

[0324] Alternatively, the rep gene may be from a cross-complementing serotype relative to the serotype of the ITR sequences. The AAV vector and the one or more vectors carrying the rep gene and the cap gene may be introduced into the host cell by a conventional method.

[0325] In some embodiment, the host cell may stably express capsid proteins such as the AAV2 or AAV9 capsid proteins (e.g., blood-brain barrier (BBB)-penetrant capsid proteins) disclosed herein under the control of a suitable promoter. In some instances, the capsid proteins may be under the control of an inducible promoter. Alternatively, or in addition, the host cell may stably express the Rep protein under the control of a suitable promoter. In some examples, expression of the Rep protein may be under the control of an inducible promoter.

[0326] In some embodiment, an AAV vector can be introduced into a packaging host cell, which may stably express both a Rep protein and capsid proteins such as the AAV2 or AAV9 capsid proteins (e.g., blood-brain barrier (BBB)-penetrant capsid proteins) disclosed herein. The packaging host cell may also have helper functions in order to package the recombinant AAV viral particles as disclosed herein. In some examples, these functions may be supplied by a herpesvirus. In some examples, the necessary helper functions can be provided by a human or non-human primate adenovirus, such as those known in the art, e.g., those available from the American Type Culture Collection (ATCC), Manassas, Va. (US).

[0327] AAV replication uses the ITR elements to generate complementary strands and the packaging machinery recognizes the ITR structures, which exist on both strands. As such, the population of AAV particles generated from host cells or packaging host cells contain a mixture of (+) and (-) strand genomes.

[0328] Any of the genetically modified viral particles such as AAV particles and any of the viral vectors such as AAV DNA vectors disclosed herein are also within the scope of the present disclosure.

[0329] I). CRISPR Nuclease-gRNA Complexes

[0330] In some embodiments, one or more guide RNAs targeting UBE3A-ATS can be complexed with the CRISPR nuclease disclosed herein to form a ribonucleoprotein (RNP) complex. In some embodiments, complexation of the one or more guide RNAs and CRISPR nuclease occurs at a temperature lower than about any one of 20°C, 21 °C, 22°C, 23 °C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C,Attorney Docket No. 063586-568001WO

[0331] 39°C, 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 50°C, or 55°C. In some embodiments, the one or more guide RNAs does not dissociate from the CRISPR nuclease at about 37°C over an incubation period of at least about any one of lOmins, 15mins, 20mins, 25mins, 30mins, 35mins, 40mins, 45mins, 50mins, 55mins, Ihr, 2hr, 3hr, 4hr, or more hours.

[0332] In some embodiments, the one or more guide RNAs and CRISPR nuclease are complexed in a complexation buffer. In some embodiments, the CRISPR nuclease is stored in a buffer that is replaced with a complexation buffer to form a complex with the one or more guide RNAs. In some embodiments, the CRISPR nuclease is stored in a complexation buffer.

[0333] In some embodiments, the complexation buffer has a pH in a range of about 7.3 to 8.6. In one embodiment, the pH of the complexation buffer is about 7.3. In one embodiment, the pH of the complexation buffer is about 7.4. In one embodiment, the pH of the complexation buffer is about 7.5. In one embodiment, the pH of the complexation buffer is about 7.6. In one embodiment, the pH of the complexation buffer is about 7.7. In one embodiment, the pH of the complexation buffer is about 7.8. In one embodiment, the pH of the complexation buffer is about 7.9. In one embodiment, the pH of the complexation buffer is about 8.0. In one embodiment, the pH of the complexation buffer is about 8.1. In one embodiment, the pH of the complexation buffer is about 8.2. In one embodiment, the pH of the complexation buffer is about 8.3. In one embodiment, the pH of the complexation buffer is about 8.4. In one embodiment, the pH of the complexation buffer is about 8.5. In one embodiment, the pH of the complexation buffer is about 8.6.

[0334] In some embodiments, the CRISPR nuclease can be overexpressed and complexed with the one or more guide RNAs in a host cell prior to purification as described herein. In other embodiments, mRNA or DNA encoding the CRISPR nuclease can be introduced into a cell so that the CRISPR nuclease is expressed in the cell. In some embodiments, the one or more guide RNAs, or nucleic acids encoding the guide RNA, is also introduced into the cell, whether simultaneously, separately, or sequentially from a single mRNA or DNA construct, such that the ribonucleoprotein complex is formed in the cell. In some instances, the cell can be a target cell (e.g., a neuron) in which editing of the UBE3A-ATS gene is intended.

[0335] II. Methods for Genetic Editing of a UBE3A-ATS Gene

[0336] The disclosure also provides methods of genetically editing the UBE3A-ATS gene in target cells, including, for example, neurons.

[0337] In some instances, the methods comprise introducing any of the gene editing systems disclosed herein into cultured target cells (in vitro editing). For example, UBE3A-A 7iS'-targetingAttorney Docket No. 063586-568001WO

[0338] guide RNAs and a CRISPR nuclease such as a CRISPR nuclease provided herein can be introduced into a population of cultured cells. Alternatively, the methods comprise introducing the gene editing system into a subject, e.g., a human patient, to achieve editing of UBE3A-ATS in vivo.

[0339] The UBE3A-ATS -targeting guide RNAs and CRISPR nuclease can form a ribonucleoprotein complex, which can be introduced into target cells. Alternatively, the UBE3A-ATS -targeting guide RNA and CRISPR nuclease can be encoded by a nucleic acid vector(s), which can be introduced into the target cells. In another example, an mRNA molecule encoding the CRISPR nuclease can be introduced into target cells. Alternatively, or in addition, the guide RNAs can be introduced directly into the target cells.

[0340] Any of the gene editing systems disclosed herein may be used to genetically engineer a UBE3A-ATS gene in target cells of interest (e.g., neurons, such as motor neurons). The gene editing system may comprise guide RNAs and a CRISPR nuclease such as those provided in this disclosure. In some embodiments, the guide RNAs each comprise a spacer sequence specific to a target sequence in the UBE3A-ATS gene, e.g., specific to a sequence within a Cluster 2 exonic region of UBE3A-ATS or an intronic region of UBE3A-ATS. In some embodiments, the guide RNAs each comprise a spacer sequence specific to a target sequence in the intronic region of the UBE3A-ATS gene, and wherein the spacer sequence targets segment 1 or segment 2 of the intronic region of the UBE3A-ATS gene and not segment 3 of the UBE 3 A-ATS gene.

[0341] A. Delivery of Gene Editing System

[0342] Components of any of the gene editing systems disclosed herein may be formulated, for example, including a carrier, such as a carrier and / or a polymeric carrier, e.g., a liposome, and delivered by known methods to target cells (e.g., a prokaryotic, eukaryotic, plant, mammalian, etc.). In some embodiments, the target cells are neurons. In some embodiments, the target cells are motor neurons. Such methods include, but are not limited to, transfection (e.g., lipid-mediated, cationic polymers, calcium phosphate, dendrimers); electroporation or other methods of membrane disruption (e.g., nucleofection), viral delivery (e.g., lentivirus, retrovirus, adenovirus, adeno-associated virus (AAV)), microinjection, microprojectile bombardment (“gene gun”), fugene, direct sonic loading, cell squeezing, optical transfection, protoplast fusion, impalefection, magnetofection, exosome-mediated transfer, lipid nanoparticle-mediated transfer, and any combination thereof.

[0343] In some embodiments, the method comprises delivering one or more nucleic acids (e.g.,Attorney Docket No. 063586-568001WO

[0344] nucleic acids encoding the CRISPR nuclease such as a CRISPR nuclease disclosed herein, one or more guide RNAs also disclosed herein, etc.), one or more transcripts thereof, and / or a preformed guide RNA / CRISPR nuclease complex to target cells. In some instances, a guide RNA and an RNA (e.g., mRNA) encoding a CRISPR nuclease are delivered together in a single composition. Alternatively, guide RNAs and an RNA (e.g., mRNA) encoding a CRISPR nuclease are delivered in separate compositions. In some embodiments, the guide RNAs and the RNA encoding the CRISPR nuclease delivered in separate compositions are delivered using the same delivery technology. In other embodiments, the guide RNAs and the RNA encoding the CRISPR nuclease are delivered in separate compositions and are delivered using different delivery technologies.

[0345] Exemplary intracellular delivery methods, include, but are not limited to: viruses, such as AAV, or virus-like agents; chemical-based transfection methods, such as those using calcium phosphate, dendrimers, liposomes, lipid nanoparticles, or cationic polymers (e.g., DEAE-dextran or polyethylenimine); non-chemical methods, such as microinjection, electroporation, cell squeezing, sonoporation, optical transfection, impalefection, protoplast fusion, bacterial conjugation, delivery of plasmids or transposons; particle-based methods, such as using a gene gun, magnectofection or magnet assisted transfection, particle bombardment; and hybrid methods, such as nucleofection.

[0346] In some embodiments, a lipid nanoparticle comprises an mRNA encoding a CRISPR nuclease (e.g., those provided in this disclosure), guide RNAs, or an mRNA encoding the CRISPR nuclease and the guide RNAs can be used for delivering the gene editing components to target cells such as to liver cells.

[0347] Effectiveness of UBE3A-ATS editing in the target cells can be examined via conventional technology and / or those provided in Examples below.

[0348] B. Genetically Modified Cells

[0349] Any of the gene editing systems disclosed herein can be delivered to a variety of cells to genetically edit the UBE3A-ATS gene, which can lead to substantially reduced or no pathology associated with a mutation in the maternal allele of the UBE3A. In some embodiments, the target cells can be cultured cells or a co-culture of two or more types of cells. In some examples, the target cells can be obtained from a living organism (e.g., a mammal such as a human subject) and maintained in a cell culture.

[0350] In some embodiments, the cell can be a single-cellular organism. For example, the cell can be a prokaryotic cell. In some examples, the cell is a bacterial cell or derived from aAttorney Docket No. 063586-568001WO

[0351] bacterial cell. In other examples, the cell is an archaeal cell or derived from an archaeal cell.

[0352] In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a plant cell or derived from a plant cell. In some embodiments, the cell is a fungal cell or derived from a fungal cell. In some embodiments, the cell is an animal cell or derived from an animal cell. In some embodiments, the cell is an invertebrate cell or derived from an invertebrate cell. In some embodiments, the cell is a vertebrate cell or derived from a vertebrate cell. In some embodiments, the cell is a mammalian cell or derived from a mammalian cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is a zebra fish cell. In some embodiments, the cell is a rodent cell.

[0353] In some embodiments, the cell is derived from a cell line. A wide variety of cell lines for tissue culture are known in the art. Examples of cell lines include, but are not limited to, HEK293T, MF7, K562, HeLa, CHO, and transgenic varieties thereof. Cell lines are available from a variety of sources known to those with skill in the art (see, e.g., the American Type Culture Collection (ATCC) (Manassas, Va.)). In some embodiments, the cell is an immortal or immortalized cell.

[0354] In some embodiments, the cell is a primary cell. In some embodiments, the cell is a stem cell such as a totipotent stem cell (e.g., omnipotent), a pluripotent stem cell, a multipotent stem cell, an oligopotent stem cell, or an unipotent stem cell. In some embodiments, the cell is an induced pluripotent stem cell (iPSC) or derived from an iPSC. In some embodiments, the cell is a differentiated cell. For example, in some embodiments, the differentiated cell is a liver cell (e.g., a hepatocyte), a biliary cell (e.g., a cholangiocyte), a stellate cell, a Kupffer cell, a liver sinusoidal endothelial cell, a muscle cell (e.g., a myocyte), a fat cell (e.g., an adipocyte), a bone cell (e.g., an osteoblast, osteocyte, osteoclast), a blood cell (e.g., a monocyte, a lymphocyte, a neutrophil, an eosinophil, a basophil, a macrophage, a erythrocyte, or a platelet), a nerve cell (e.g., a neuron), an epithelial cell, an immune cell (e.g., a lymphocyte, a neutrophil, a monocyte, or a macrophage), a fibroblast, or a sex cell. In some embodiments, the cell is a terminally differentiated cell. For example, in some embodiments, the terminally differentiated cell is a neuronal cell, for example a motoneuronal cell. In some embodiments, the cell is a mammalian cell, e.g., a human cell or a murine cell. In some embodiments, the murine cell is derived from a wild-type mouse, an immunosuppressed mouse, or a disease-specific mouse model. In some embodiments, the cell is a cell within a living tissue, organ, or organism.

[0355] Any of the genetically modified cells produced using any of the gene editing system disclosed herein is also within the scope of the present disclosure. Such modified cells may comprise a disrupted UBE3A-ATS gene. In some embodiments, the edited cell may exhibit aAttorney Docket No. 063586-568001WO

[0356] reduced level of expression of a UBE3A transcript relative to an unmodified cell without a mutation in the maternal copy of UBE3A. In some embodiments, expression level of a UBE3A-ATS transcript is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the expression level of the same transcript in a control cell. In some embodiments, the control cell is a cell that has not been administered a genetic system disclosed herein. In some embodiments, the control cell is a cell without modification to the UBE3A-ATS locus. In some embodiments, the edited cell may exhibit a similar level of expression of a UBE3A transcript relative to an unmodified cell without a mutation in the maternal copy of UBE3A.

[0357] Further aspects of the present disclosure provide ex vivo cells produced by any one of the methods disclosed herein. In some embodiments, an ex vivo cell comprises a deletion in the UBE3A-ATS .

[0358] C. Therapeutic Applications

[0359] Any of the gene editing systems or modified cells (e.g., modified neurons) generated using such a gene editing system as disclosed herein may be used for treating a disease associated with a mutation in the maternal copy of UBE3A, such as Angelman syndrome. In some embodiments, treating Angelman syndrome comprises preventing, ameliorating, or delaying progression of one or more symptoms of Angelman syndrome.

[0360] In some embodiments, provided herein is a method for treating a target disease associated with a mutation in the maternal copy of the UBE3A gene. The method may comprise administering to a subject (e.g., a human patient) in need of the treatment any of the gene editing systems disclosed herein. The gene editing system may be delivered to a specific tissue (e.g., nerve tissue) or specific type of cells (e.g., neurons) where the gene edit is needed. The gene editing system may comprise LNPs encompassing one or more of the components, one or more vectors (e.g., viral vectors) encoding one or more of the components, or a combination thereof. In some embodiments, the one or more vectors comprise one or more plasmids. In some embodiments, the one or more vectors comprise one or more viral vectors. In some embodiments, the one or more viral vectors comprise an adeno associated viral (AAV) vector (e.g., a recombinant AAV (rAAV) vector), a lentiviral vector, or an adenoviral vector. Components of the gene editing system may be formulated to form a pharmaceutical composition, which may further comprise one or more pharmaceutically acceptable carriers.

[0361] Aspects of the disclosure relate to methods of treating Angelman syndrome. In someAttorney Docket No. 063586-568001WO

[0362] embodiments, a method of treating Angelman syndrome comprises administering a gene editing system described herein to a subject.

[0363] Aspects of the disclosure relate to methods of editing a UBE3A-ATS gene in a cell (e.g., a neuron). In some embodiments, a method of editing a UBE3A-ATS gene in a cell comprises administering a gene editing system described herein to a subject.

[0364] In some embodiments, provided herein is a composition comprising the gene editing system disclosed herein or components thereof. Such a composition can be a pharmaceutical composition. A pharmaceutical composition that is useful may be prepared, packaged, or sold in a formulation for a suitable delivery route, e.g., parenteral, intra-lesional, intra-organ or another route of administration. A pharmaceutical composition of the disclosure may be prepared, packaged, or sold in bulk, as a single unit dose, or as a plurality of single unit doses. As used herein, a “unit dose” is discrete amount of the pharmaceutical composition (e.g., the gene editing system or components thereof), which would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.

[0365] A formulation of a pharmaceutical composition suitable for parenteral administration may comprise the active agent (e.g., the gene editing system or components thereof or the modified cells) combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such a formulation may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Some injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multi-dose containers containing a preservative. Some formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Some formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.

[0366] The pharmaceutical composition may be in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the cells, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulation may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or saline. Other acceptable diluents and solvents include, but are not limited to, Ringer’s solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides. Other parentally-administrable formulations which that are usefulAttorney Docket No. 063586-568001WO

[0367] include those which may comprise the cells in a packaged form, in a liposomal preparation, or as a component of a biodegradable polymer system. Some compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.

[0368] In some embodiments, a method disclosed herein reduces one or more pathological manifestations of a mutation in the maternal copy of the UBE3A gene. In some embodiments, a method disclosed herein decreases the level of a UBE3A-ATS transcript.

[0369] In some embodiments, a method disclosed herein decreases the level of a UBE3A-ATS transcript relative to an untreated control cell. In some embodiments, a method disclosed herein decreases the level of a UBE3A-ATS transcript in a cell by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or by 100% relative to an untreated control cell. In some embodiments, the control cell is a neuron.

[0370] In some embodiments, a method disclosed herein increases the level of UBE3A in a cell relative to a level of UBE3A in an untreated control cell. In some embodiments, a method disclosed herein increases the level of UBE3A RNA transcript in a cell relative to a level of UBE3A RNA transcript in an untreated control cell. In some embodiments, a method disclosed herein increases the level of a UBE3A RNA transcript in a cell by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, by at least 100%, by at least 110%, by at least 120%, by at least 130%, by at least 140%, by at least 150%, by at least 160%, by at least 170%, by at least 180%, by at least 190%, or by at least 200% relative to an untreated control cell. In some embodiments, a method disclosed herein increases the level of UBE3A protein in a cell relative to a level of UBE3A protein in an untreated control cell. In some embodiments, a method disclosed herein increases the level of a UBE3A protein in a cell by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, by at least 100%, by at least 110%, by at least 120%, by at least 130%, by at least 140%, by at least 150%, by at least 160%, by at least 170%, by at least 180%, by at least 190%, or by at least 200%. In some embodiments the control cell is a neuron.

[0371] In some embodiments, the method reduces hyperexcitability in a neuron relative to an untreated control neuron (e.g., a neuron not treated with a gene editing system describedAttorney Docket No. 063586-568001WO

[0372] herein).

[0373] In some embodiments, the method reduces the mean firing rate of a neuron relative to an untreated control neuron.

[0374] III. Kits for Genetic Editing of UBE3A-ATS Gene and Alleviating Target Diseases The present disclosure also provides kits that can be used, for example, to carry out a gene editing method described herein for editing of the UBE3A-ATS gene as disclosed herein. In some embodiments, the kits include guide RNAs and a CRISPR nuclease (e.g., a CRISPR nuclease provided herein). In some embodiments, the kits include guide RNAs and the CRISPR nuclease. In other embodiments, the kits include a polynucleotide that encodes CRISPR nuclease, and optionally the polynucleotide is comprised within a vector, e.g., as described herein. In some embodiments, the kits include a polynucleotide that encodes a guide RNA disclosed herein. The CRISPR nuclease (or polynucleotide encoding the CRISPR nuclease) and a guide RNA (e.g., or a polynucleotide encoding the guide RNA) can be packaged within the same or other vessel within a kit or can be packaged in separate vials or other vessels, the contents of which can be mixed prior to use.

[0375] The CRISPR nuclease and a guide RNA can be packaged within the same or other vessel within a kit or can be packaged in separate vials or other vessels, the contents of which can be mixed prior to use. The kits can additionally include, optionally, a buffer and / or instructions for use of the guide RNA or guides and CRISPR nuclease.

[0376] General techniques

[0377] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as Molecular Cloning: A Laboratory Manual, second edition (Sambrook, et al., 1989) Cold Spring Harbor Press;

[0378] Oligonucleotide Synthesis (M. J. Gait, ed. 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J. E. Cellis, ed., 1989) Academic Press; Animal Cell Culture (R. I. Freshney, ed. 1987); Introuction to Cell and Tissue Culture (J. P. Mather and P. E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J. B. Griffiths, and D. G. Newell, eds. 1993-8) J. Wiley and Sons; Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (D. M. Weir and C. C. Blackwell, eds.): Gene Transfer Vectors for Mammalian Cells (J. M. Miller and M. P.Attorney Docket No. 063586-568001WO

[0379] Calos, eds., 1987); Current Protocols in Molecular Biology (F. M. Ausubel, et al. eds. 1987); PCR: The Polymerase Chain Reaction, (Mullis, et al., eds. 1994); Current Protocols in Immunology (J. E. Coligan et al., eds., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C. A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: a practice approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal antibodies: a practical approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J. D. Capra, eds. Harwood Academic Publishers, 1995); DNA Cloning: A practical Approach, Volumes I and II (D.N. Glover ed. 1985); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds.(1985»; Transcription and Translation (B.D. Hames & S.J. Higgins, eds. (1984»; Animal Cell Culture (R.I. Freshney, ed. (1986»; Immobilized Cells and Enzymes (IRL Press, (1986»; and B. Perbal, A practical Guide To Molecular Cloning (1984); F.M. Ausubel etal. (eds.).

[0380] Without further elaboration, it is believed that one skilled in the art can, based on the above description, utilize the present disclosure to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications cited herein are incorporated by reference for the purposes or subject matter referenced herein.

[0381] EXAMPLES

[0382] While the present disclosure has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the disclosure. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit, and scope of the present disclosure. All such modifications are intended to be within the scope of the disclosure.

[0383] Example 1 - Disruption of UBE3A-ATS in HEK293 Using CRISPR Nucleases

[0384] This example describes the identification and screening of CRISPR nucleases and guides for disruption of UBE3A-ATS in two distinct regions: the Cluster 2 Exon region (consisting of 7 exons) and the intronic region that spans the 3’ end of Cluster 2 exons and the 3’ end of UBE3A on the opposite strand (FIG. 1).Attorney Docket No. 063586-568001WO

[0385] UBE3A-ATS Cluster 2 Exonic Region

[0386] Computational Identification and production of guides targeting the Cluster 2 Exon region of VBE3A-ATS

[0387] Guides were designed by tiling the genomic sequence of the Cluster 2 exonic region (chrl5: 25,266,431 - 25,278,884) of the UBE3A-ATS gene, located within the larger host gene SNHG14 (NCBI ref: NC_000015.10), for PAM sequences for C2 and DI (Table 3). The target sequences are designated as a 20-bp target adjacent to the 5’ PAM. All PAMs that overlapped completely or partially with Cluster 2 exons were included and 4 target sequences with identical off-target matches elsewhere in the genome were excluded, resulting in 146 filtered targets. Plasmids encoding the guide RNA were generated by Integrated DNA Technologies. The plasmids consist of a DNA guide sequence that is positioned downstream of a U6 promoter to enable expression in mammalian cells. Numbers of target sequences within the cluster 2 exonic region for Nuclease C2 and Nuclease DI are provided in Table 3 below. Exemplary target sequences within the cluster 2 exonic region are provided in Table 4 below.

[0388] Table 3. In Silico Identification of Target Sequences within Cluster 2 Exon Region PAM # of Target Nuclease PAM Sequence** Region targeted

[0389] position* Sequences C2 5’ NTTN Cluster 2 Exon 97

[0390] DI 5’ NTTR Cluster 2 Exon 49

[0391]

[0392] *PAM position is relative to target sequence; **N is A, G, C or T; R is A or G

[0393] Table 4. Sequences of guides targeting the Cluster 2 Exon region of UBE3A-ATS Guide Target DNA Sequence Spacer gRNA PAM

[0394] Name* Sequence for gRNA Sequence Sequence CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CTCTACATC GTCCTTTTATA CUCUACAUC AUAGGUAUUA DI Ex TGTCCCTTA GGTATTAAACA UGUCCCUUA

[0395] TTTG AACAACCUCU

[0396] 1_G1 GA (SEQ ID ACCTCTACATC GA (SEQ ID ACAUCUGUCCC NO: 10) TGTCCCTTAGA NO: 12)

[0397] UUAGA (SEQ ID (SEQ ID NO: 11)

[0398] NO: 13) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AGAAGGCTT GTCCTTTTATA AGAAGGCUU AUAGGUAUUA DI Ex CCTGAAGCT GGTATTAAACA CCUGAAGCU

[0399] CTTG AACAACAGAA

[0400] 1_G3 GT (SEQ ID ACAGAAGGCTT GU (SEQ ID

[0401] GGCUUCCUGA NO: 14) CCTGAAGCTGT NO: 16)

[0402] AGCUGU (SEQ (SEQ ID NO: 15)

[0403]

[0404] ID NO: 17)Attorney Docket No. 063586-568001WO

[0405] Guide Target DNA Sequence Spacer gRNA PAM

[0406] Name* Sequence for gRNA Sequence Sequence CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU ATGAAAGAC GTCCTTTTATA AUGAAAGAC AUAGGUAUUA DI Ex ATAGTACTC GGTATTAAACA AUAGUACUC

[0407] ATTG AACAACAUGA

[0408] 1_G4 CC (SEQ ID ACATGAAAGAC CC (SEQ ID AAGACAUAGU NO: 18) ATAGTACTCCC NO: 20)

[0409] ACUCCC (SEQ (SEQ ID NO: 19)

[0410] ID NO: 21) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TTGATGAAA GTCCTTTTATA UUGAUGAAA AUAGGUAUUA DI Ex GACATAGTA GGTATTAAACA GACAUAGUA

[0411] ATTA AACAACUUGA

[0412] 1_G5 CT (SEQ ID ACTTGATGAAA CU (SEQ ID UGAAAGACAU NO: 22) GACATAGTACT NO: 24)

[0413] AGUACU (SEQ (SEQ ID NO: 23)

[0414] ID NO: 25) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TTTCTCACC GTCCTTTTATA UUUCUCACC AUAGGUAUUA DI Ex AAATCAGAA GGTATTAAACA AAAUCAGAA

[0415] ATTA AACAACUUUC

[0416] 1_G6 GA (SEQ ID ACTTTCTCACC GA (SEQ ID UCACCAAAUC NO: 26) AAATCAGAAGA NO: 28)

[0417] AGAAGA (SEQ (SEQ ID NO: 27)

[0418] ID NO: 29) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AGGCATTAT GTCCTTTTATA AGGCAUUAU AUAGGUAUUA DI Ex TTCTCACCA GGTATTAAACA UUCUCACCA

[0419] TTTA AACAACAGGC

[0420] 1_G7 AA (SEQ ID ACAGGCATTAT AA (SEQ ID AUUAUUUCUC NO: 30) TTCTCACCAAA NO: 32)

[0421] ACCAAA (SEQ (SEQ ID NO: 31)

[0422] ID NO: 33) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AAGGACACC GTCCTTTTATA AAGGACACC AUAGGUAUUA DI Ex TGGGTGCTG GGTATTAAACA UGGGUGCUG

[0423] ATTA AACAACAAGG

[0424] 1_G8 TC (SEQ ID ACAAGGACACC UC (SEQ ID ACACCUGGGU NO: 34) TGGGTGCTGTC NO: 36)

[0425] GCUGUC (SEQ (SEQ ID NO: 35)

[0426] ID NO: 37) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU ATGAAAATG GTCCTTTTATA AUGAAAAUG AUAGGUAUUA DI Ex CTCTTGACA GGTATTAAACA CUCUUGACA

[0427] TTTA AACAACAUGA

[0428] 1_G9 CC (SEQ ID ACATGAAAATG CC (SEQ ID AAAUGCUCUU NO: 38) CTCTTGACACC NO: 40)

[0429] GACACC (SEQ (SEQ ID NO: 39)

[0430] ID NO: 41) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU ACAGCACCC GTCCTTTTATA ACAGCACCC AUAGGUAUUA DI Ex AGGTGTCCT GGTATTAAACA AGGUGUCCU

[0431] GTTG AACAACACAG

[0432] 1 G10 TT (SEQ ID ACACAGCACCC UU (SEQ ID CACCCAGGUG NO: 42) AGGTGTCCTTT NO: 44)

[0433] UCCUUU (SEQ (SEQ ID NO: 43)

[0434]

[0435] ID NO: 45)Attorney Docket No. 063586-568001WO

[0436] Guide Target DNA Sequence Spacer gRNA PAM

[0437] Name* Sequence for gRNA Sequence Sequence CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TGACTGGGA GTCCTTTTATA UGACUGGGA AUAGGUAUUA DI Ex CAGTTGACA GGTATTAAACA CAGUUGACA

[0438] GTTG AACAACUGAC

[0439] 1 G11 GC (SEQ ID ACTGACTGGGA GC (SEQ ID UGGGACAGUU NO: 46) CAGTTGACAGC NO: 48)

[0440] GACAGC (SEQ (SEQ ID NO: 47)

[0441] ID NO: 49) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU GCCTGTTGT GTCCTTTTATA GCCUGUUGU AUAGGUAUUA DI Ex GACTGGGAC GGTATTAAACA GACUGGGAC

[0442] TTTG AACAACGCCU

[0443] 1 G12 AG (SEQ ID ACGCCTGTTGT AG (SEQ ID GUUGUGACUG NO: 50) GACTGGGACAG NO: 52)

[0444] GGACAG (SEQ (SEQ ID NO: 51)

[0445] ID NO: 53) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU GATGATGAT GTCCTTTTATA GAUGAUGAU AUAGGUAUUA DI Ex ATGGAAGAA GGTATTAAACA AUGGAAGAA

[0446] CTTA AACAACGAUG

[0447] 1 G13 AA (SEQ ID ACGATGATGAT AA (SEQ ID AUGAUAUGGA NO: 54) ATGGAAGAAAA NO: 56)

[0448] AGAAAA (SEQ (SEQ ID NO: 55)

[0449] ID NO: 57) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU ACACCAATG GTCCTTTTATA ACACCAAUG AUAGGUAUUA DI Ex CATCCTAGC GGTATTAAACA CAUCCUAGC

[0450] CTTG AACAACACACC

[0451] 1 G14 AT (SEQ ID ACACACCAATG AU (SEQ ID AAUGCAUCCU NO: 58) CATCCTAGCAT NO: 60)

[0452] AGCAU (SEQ ID (SEQ ID NO: 59)

[0453] NO: 61) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TAATAGAAT GTCCTTTTATA UAAUAGAAU AUAGGUAUUA DI Ex GGCACATCT GGTATTAAACA GGCACAUCU

[0454] TTTA AACAACUAAU

[0455] 2_G1 CT (SEQ ID ACTAATAGAAT CU (SEQ ID AGAAUGGCAC NO: 62) GGCACATCTCT NO: 64)

[0456] AUCUCU (SEQ (SEQ ID NO: 63)

[0457] ID NO: 65) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU GGTGGGAGT GTCCTTTTATA GGUGGGAGU AUAGGUAUUA DI Ex CTTCCATAG GGTATTAAACA CUUCCAUAG

[0458] CTTA AACAACGGUG

[0459] 2_G2 CT (SEQ ID ACGGTGGGAGT CU (SEQ ID GGAGUCUUCC NO: 66) CTTCCATAGCT NO: 68)

[0460] AUAGCU (SEQ (SEQ ID NO: 67)

[0461] ID NO: 69) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CCTGAAGGT GTCCTTTTATA CCUGAAGGU AUAGGUAUUA DI Ex GTAAAACTA GGTATTAAACA GUAAAACUA

[0462] ATTA AACAACCCUG

[0463] 2_G3 AT (SEQ ID ACCCTGAAGGT AU (SEQ ID AAGGUGUAAA NO: 70) GTAAAACTAAT NO: 72)

[0464] ACUAAU (SEQ (SEQ ID NO: 71)

[0465]

[0466] ID NO: 73)Attorney Docket No. 063586-568001WO

[0467] Guide Target DNA Sequence Spacer gRNA PAM

[0468] Name* Sequence for gRNA Sequence Sequence CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AAGTTCAGA GTCCTTTTATA AAGUUCAGA AUAGGUAUUA DI Ex TTACCTGAA GGTATTAAACA UUACCUGAA

[0469] ATTG AACAACAAGU

[0470] 2_G4 GG(SEQID ACAAGTTCAGA GG (SEQ ID UCAGAUUACC NO: 74) TTACCTGAAGG NO: 76)

[0471] UGAAGG(SEQ (SEQ ID NO: 75)

[0472] ID NO: 77) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CCGACGTGT GTCCTTTTATA CCGACGUGU AUAGGUAUUA DI Ex ATATTCTAT GGTATTAAACA AUAUUCUAU

[0473] TTTA AACAACCCGAC

[0474] 2_G5 CT (SEQ ID ACCCGACGTGT CU (SEQ ID GUGUAUAUUC NO: 78) ATATTCTATCT NO: 80)

[0475] UAUCU (SEQ ID (SEQ ID NO: 79)

[0476] NO: 81) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TAAAAGATC GTCCTTTTATA UAAAAGAUC AUAGGUAUUA DI Ex AGTAGCTTC GGTATTAAACA AGUAGCUUC

[0477] ATTA AACAACUAAA

[0478] 2_G6 CT (SEQ ID ACTAAAAGATC CU (SEQ ID AGAUCAGUAG NO: 82) AGTAGCTTCCT NO: 84)

[0479] CUUCCU (SEQ (SEQ ID NO: 83)

[0480] ID NO: 85) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TGTATTTCA GTCCTTTTATA UGUAUUUCA AUAGGUAUUA DI Ex GTAAGACAT GGTATTAAACA GUAAGACAU

[0481] ATTG AACAACUGUA

[0482] 2_G7 GC (SEQ ID ACTGTATTTCA GC (SEQ ID UUUCAGUAAG NO: 86) GTAAGACATGC NO: 88)

[0483] ACAUGC (SEQ (SEQ ID NO: 87)

[0484] ID NO: 89) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TTGTGTATTT GTCCTTTTATA UUGUGUAUU AUAGGUAUUA DI Ex CAGTAAGAC GGTATTAAACA UCAGUAAGA

[0485] CTTA AACAACUUGU

[0486] 2_G8 A (SEQ ID NO: ACTTGTGTATTT CA (SEQ ID GUAUUUCAGU

[0487] 90) CAGTAAGACA NO: 92)

[0488] AAGACA (SEQ (SEQ ID NO: 91)

[0489] ID NO: 93) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AGCTATGGA GTCCTTTTATA AGCUAUGGA AUAGGUAUUA DI Ex AGACTCCCA GGTATTAAACA AGACUCCCA

[0490] ATTG AACAACAGCU

[0491] 2_G9 CC (SEQ ID ACAGCTATGGA CC (SEQ ID AUGGAAGACU NO: 94) AGACTCCCACC NO: 96)

[0492] CCCACC (SEQ (SEQ ID NO: 95)

[0493] ID NO: 97) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AACAACGGT GTCCTTTTATA AACAACGGU AUAGGUAUUA DI Ex TGCAGGGAC GGTATTAAACA UGCAGGGAC

[0494] CTTA AACAACAACA

[0495] 3_G1 AG (SEQ ID ACAACAACGGT AG (SEQ ID ACGGUUGCAG NO: 98) TGCAGGGACAG NO: 100)

[0496] GGACAG (SEQ (SEQ ID NO: 99)

[0497]

[0498] ID NO: 101)Attorney Docket No. 063586-568001WO

[0499] Guide Target DNA Sequence Spacer gRNA PAM

[0500] Name* Sequence for gRNA Sequence Sequence CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CCTCTGTGA GTCCTTTTATA CCUCUGUGA AUAGGUAUUA DI Ex CAACACCAG GGTATTAAACA CAACACCAG

[0501] CTTG AACAACCCUCU

[0502] 3_G2 AG (SEQ ID ACCCTCTGTGA AG (SEQ ID GUGACAACAC NO: 102) CAACACCAGAG NO: 104) CAGAG(SEQID (SEQ ID NO: 103)

[0503] NO: 105) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AATTCACTG GTCCTTTTATA AAUUCACUG AUAGGUAUUA DI Ex CAGCATGCC GGTATTAAACA CAGCAUGCC

[0504] GTTA AACAACAAUU

[0505] 3_G3 TG (SEQ ID ACAATTCACTG UG (SEQ ID CACUGCAGCA NO: 106) CAGCATGCCTG NO: 108)

[0506] UGCCUG (SEQ (SEQ ID NO: 107)

[0507] ID NO: 109) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CAGGGACAG GTCCTTTTATA CAGGGACAG AUAGGUAUUA DI Ex AGGATCAGT GGTATTAAACA AGGAUCAGU

[0508] GTTG AACAACCAGG

[0509] 3_G4 TA (SEQ ID ACCAGGGACAG UA (SEQ ID GACAGAGGAU NO: 110) AGGATCAGTTA NO: 112)

[0510] CAGUUA (SEQ (SEQ ID NO: 111)

[0511] ID NO: 113) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CCAGAATAG GTCCTTTTATA CCAGAAUAG AUAGGUAUUA DI Ex CATCCTTAA GGTATTAAACA CAUCCUUAA

[0512] CTTA AACAACCCAG

[0513] 3_G5 AC (SEQ ID ACCCAGAATAG AC (SEQ ID AAUAGCAUCC NO: 114) CATCCTTAAAC NO: 116)

[0514] UUAAAC (SEQ (SEQ ID NO: 115)

[0515] ID NO: 117) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TAAACCCTT GTCCTTTTATA UAAACCCUU AUAGGUAUUA DI Ex ACCAGAATA GGTATTAAACA ACCAGAAUA

[0516] CTTG AACAACUAAA

[0517] 3_G6 GC (SEQ ID ACTAAACCCTT GC (SEQ ID CCCUUACCAGA NO: 118) ACCAGAATAGC NO: 120)

[0518] AUAGC (SEQ ID (SEQ ID NO: 119)

[0519] NO: 121) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TCTTGTAAA GTCCTTTTATA UCUUGUAAA AUAGGUAUUA DI Ex CCCTTACCA GGTATTAAACA CCCUUACCA

[0520] GTTG AACAACUCUU

[0521] 3_G7 GA (SEQ ID ACTCTTGTAAA GA (SEQ ID GUAAACCCUU NO: 122) CCCTTACCAGA NO: 124)

[0522] ACCAGA (SEQ (SEQ ID NO: 123)

[0523] ID NO: 125) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CGTTGTCTT GTCCTTTTATA CGUUGUCUU AUAGGUAUUA DI Ex GTAAACCCT GGTATTAAACA GUAAACCCU

[0524] TTTA AACAACCGUU

[0525] 3_G8 TA (SEQ ID ACCGTTGTCTT UA (SEQ ID GUCUUGUAAA NO: 126) GTAAACCCTTA NO: 128)

[0526] CCCUUA (SEQ (SEQ ID NO: 127)

[0527]

[0528] ID NO: 129)Attorney Docket No. 063586-568001WO

[0529] Guide Target DNA Sequence Spacer gRNA PAM

[0530] Name* Sequence for gRNA Sequence Sequence CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU ACTGATCCT GTCCTTTTATA ACUGAUCCU AUAGGUAUUA DI Ex CTGTCCCTG GGTATTAAACA CUGUCCCUG

[0531] TTTA AACAACACUG

[0532] 3_G9 CA (SEQ ID ACACTGATCCT CA (SEQ ID AUCCUCUGUCC NO: 130) CTGTCCCTGCA NO: 132)

[0533] CUGCA (SEQ ID (SEQ ID NO: 131)

[0534] NO: 134) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TCACAGAGG GTCCTTTTATA UCACAGAGG AUAGGUAUUA DI Ex CAAGTGCTA GGTATTAAACA CAAGUGCUA

[0535] GTTG AACAACUCAC

[0536] 3 G10 CC (SEQ ID ACTCACAGAGG CC (SEQ ID AGAGGCAAGU NO: 135) CAAGTGCTACC NO: 137)

[0537] GCUACC (SEQ (SEQ ID NO: 136)

[0538] ID NO: 138) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AACACTGAT GTCCTTTTATA AACACUGAU AUAGGUAUUA DI Ex GGTAAAGTG GGTATTAAACA GGUAAAGUG

[0539] CTTA AACAACAACA

[0540] 4_G1 GA (SEQ ID ACAACACTGAT GA (SEQ ID CUGAUGGUAA NO: 139) GGTAAAGTGGA NO: 141)

[0541] AGUGGA (SEQ (SEQ ID NO: 140)

[0542] ID NO: 142) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CCAGAGATG GTCCTTTTATA CCAGAGAUG AUAGGUAUUA DI Ex GTTTCCTTA GGTATTAAACA GUUUCCUUA

[0543] CTTA AACAACCCAG

[0544] 4_G2 AA (SEQ ID ACCCAGAGATG AA (SEQ ID AGAUGGUUUC NO: 143) GTTTCCTTAAA NO: 145)

[0545] CUUAAA (SEQ (SEQ ID NO: 144)

[0546] ID NO: 146) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU GATCAAATA GTCCTTTTATA GAUCAAAUA AUAGGUAUUA DI Ex TGCTTACCA GGTATTAAACA UGCUUACCA

[0547] CTTG AACAACGAUC

[0548] 4_G3 GA (SEQ ID ACGATCAAATA GA (SEQ ID AAAUAUGCUU NO: 147) TGCTTACCAGA NO: 149)

[0549] ACCAGA (SEQ (SEQ ID NO: 148)

[0550] ID NO: 150) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CCATCAGTG GTCCTTTTATA CCAUCAGUG AUAGGUAUUA DI Ex TTTAAGGAA GGTATTAAACA UUUAAGGAA

[0551] TTTA AACAACCCAUC

[0552] 4_G4 AC (SEQ ID ACCCATCAGTG AC (SEQ ID AGUGUUUAAG NO: 151) TTTAAGGAAAC NO: 153)

[0553] GAAAC (SEQ ID (SEQ ID NO: 152)

[0554] NO: 154) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AGTGGTGTC GTCCTTTTATA AGUGGUGUC AUAGGUAUUA DI Ex AGTTTCTCC GGTATTAAACA AGUUUCUCC

[0555] GTTG AACAACAGUG

[0556] 4_G5 CT (SEQ ID ACAGTGGTGTC CU (SEQ ID GUGUCAGUUU NO: 155) AGTTTCTCCCT NO: 157)

[0557] CUCCCU (SEQ (SEQ ID NO: 156)

[0558]

[0559] ID NO: 158)Attorney Docket No. 063586-568001WO

[0560] Guide Target DNA Sequence Spacer gRNA PAM

[0561] Name* Sequence for gRNA Sequence Sequence CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CCCTGTTGT GTCCTTTTATA CCCUGUUGU AUAGGUAUUA DI Ex TCAGGGAGA GGTATTAAACA UCAGGGAGA

[0562] TTTA AACAACCCCUG

[0563] 4_G6 AA (SEQ ID ACCCCTGTTGT AA (SEQ ID UUGUUCAGGG NO: 159) TCAGGGAGAAA NO: 161)

[0564] AGAAA (SEQ ID (SEQ ID NO: 160)

[0565] NO: 162) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CAGAAAAGA GTCCTTTTATA CAGAAAAGA AUAGGUAUUA DI Ex CTGTGGAGG GGTATTAAACA CUGUGGAGG

[0566] TTTA AACAACCAGA

[0567] 4_G7 AA (SEQ ID ACCAGAAAAGA AA (SEQ ID AAAGACUGUG NO: 163) CTGTGGAGGAA NO: 165)

[0568] GAGGAA (SEQ (SEQ ID NO: 164)

[0569] ID NO: 166) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TTCAGGGAG GTCCTTTTATA UUCAGGGAG AUAGGUAUUA DI Ex AAACTGACA GGTATTAAACA AAACUGACA

[0570] GTTG AACAACUUCA

[0571] 4_G9 CC (SEQ ID ACTTCAGGGAG CC (SEQ ID GGGAGAAACU NO: 167) AAACTGACACC NO: 169)

[0572] GACACC (SEQ (SEQ ID NO: 168)

[0573] ID NO: 170) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AAAGTTCAC GTCCTTTTATA AAAGUUCAC AUAGGUAUUA DI Ex AGGAGACCA GGTATTAAACA AGGAGACCA

[0574] GTTG AACAACAAAG

[0575] 5_G1 AA (SEQ ID ACAAAGTTCAC AA (SEQ ID UUCACAGGAG NO: 171) AGGAGACCAAA NO: 173)

[0576] ACCAAA (SEQ (SEQ ID NO: 172)

[0577] ID NO: 174) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AATCCTGGT GTCCTTTTATA AAUCCUGGU AUAGGUAUUA DI Ex TGAAAGTTC GGTATTAAACA UGAAAGUUC

[0578] CTTA AACAACAAUC

[0579] 5_G2 AC (SEQ ID ACAATCCTGGT AC (SEQ ID CUGGUUGAAA NO: 175) TGAAAGTTCAC NO: 177)

[0580] GUUCAC (SEQ (SEQ ID NO: 176)

[0581] ID NO: 178) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU ACACCAGCA GTCCTTTTATA ACACCAGCA AUAGGUAUUA DI Ex CAGCTGACA GGTATTAAACA CAGCUGACA

[0582] GTTG AACAACACACC

[0583] 5_G5 CA (SEQ ID ACACACCAGCA CA (SEQ ID AGCACAGCUG NO: 179) CAGCTGACACA NO: 181)

[0584] ACACA (SEQ ID (SEQ ID NO: 180)

[0585] NO: 182) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TCCTCCTCC GTCCTTTTATA uccuccucc AUAGGUAUUA DI Ex CCTTAGATA GGTATTAAACA CCUUAGAUA

[0586] CTTA AACAACUCCUC

[0587] 5_G8 AG (SEQ ID ACTCCTCCTCC AG (SEQ ID CUCCCCUUAGA NO: 183) CCTTAGATAAG NO: 185)

[0588] UAAG(SEQID (SEQ ID NO: 184)

[0589]

[0590] NO: 186)Attorney Docket No. 063586-568001WO

[0591] Guide Target DNA Sequence Spacer gRNA PAM

[0592] Name* Sequence for gRNA Sequence Sequence CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU TTGACACCA GTCCTTTTATA UUGACACCA AUAGGUAUUA DI Ex GCACAGCTG GGTATTAAACA GCACAGCUG

[0593] CTTG AACAACUUGA

[0594] 5_G9 AC (SEQ ID ACTTGACACCA AC (SEQ ID CACCAGCACAG NO: 187) GCACAGCTGAC NO: 189)

[0595] CUGAC (SEQ ID (SEQ ID NO: 188)

[0596] NO: 190) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CTGCAGGTT GTCCTTTTATA CUGCAGGUU AUAGGUAUUA DI Ex AAAAGCTGA GGTATTAAACA AAAAGCUGA

[0597] TTTG AACAACCUGC

[0598] 6_G1 AA (SEQ ID ACCTGCAGGTT AA (SEQ ID AGGUUAAAAG NO: 191) AAAAGCTGAAA NO: 193)

[0599] CUGAAA (SEQ (SEQ ID NO: 192)

[0600] ID NO: 194) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU AAAGCTGAA GTCCTTTTATA AAAGCUGAA AUAGGUAUUA DI Ex ACAACTTCA GGTATTAAACA ACAACUUCA

[0601] GTTA AACAACAAAG

[0602] 6_G2 AG (SEQ ID ACAAAGCTGAA AG (SEQ ID CUGAAACAAC NO: 195) ACAACTTCAAG NO: 197)

[0603] UUCAAG (SEQ (SEQ ID NO: 196)

[0604] ID NO: 198) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU CTGAGATAG GTCCTTTTATA CUGAGAUAG AUAGGUAUUA DI Ex AAGGCCTGG GGTATTAAACA AAGGCCUGG

[0605] TTTG AACAACCUGA

[0606] 7_G1 AA (SEQ ID ACCTGAGATAG AA (SEQ ID GAUAGAAGGC NO: 199) AAGGCCTGGAA NO: 201)

[0607] CUGGAA (SEQ (SEQ ID NO: 200)

[0608] ID NO: 202) CUUGUUGUAU CTTGTTGTATAT AUGUCCUUUU GCTACTCAC GTCCTTTTATA GCUACUCAC AUAGGUAUUA DI Ex CCCTGTTCT GGTATTAAACA CCCUGUUCU

[0609] CTTA AACAACGCUA

[0610] 7_G2 CT (SEQ ID ACGCTACTCAC CU (SEQ ID CUCACCCCUGU NO: 203) CCCTGTTCTCT NO: 205)

[0611] UCUCU (SEQ ID (SEQ ID NO: 204)

[0612] NO: 206) AGAAAUCCGU AGAAATCCGTC GCTCTACAT GCUCUACAU CUUUCAUUGA TTTCATTGACG

[0613] C2_Ex CTGTCCCTT CUGUCCCUU CGGGCUCUAC ATTT GGCTCTACATC

[0614] 1_G1 AG (SEQ ID AG (SEQ ID AUCUGUCCCU TGTCCCTTAG NO: 207) NO: 209) UAG(SEQID (SEQ ID NO: 208)

[0615] NO: 210) AGAAAUCCGU AGAAATCCGTC ATTAAAGGA AUUAAAGGA CUUUCAUUGA TTTCATTGACG

[0616] C2_Ex CACCTGGGT CACCUGGGU CGGAUUAAAG TTTC GATTAAAGGAC

[0617] 1_G2 GC (SEQ ID GC (SEQ ID GACACCUGGG ACCTGGGTGC NO: 211) NO: 213) UGC (SEQ ID (SEQ ID NO: 212)

[0618]

[0619] NO: 214)Attorney Docket No. 063586-568001WO

[0620] Guide Target DNA Sequence Spacer gRNA PAM

[0621] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC CATTAAAGG CAUUAAAGG CUUUCAUUGA TTTCATTGACG

[0622] C2_Ex ACACCTGGG ACACCUGGG CGGCAUUAAA TTTT GCATTAAAGGA

[0623] 1_G3 TG (SEQ ID UG (SEQ ID GGACACCUGG CACCTGGGTG NO: 215) NO: 217) GUG(SEQID (SEQ ID NO: 216)

[0624] NO: 218) AGAAAUCCGU AGAAATCCGTC TCATTAAAG UCAUUAAAG CUUUCAUUGA TTTCATTGACG

[0625] C2_Ex GACACCTGG GACACCUGG CGGUCAUUAA ATTT GTCATTAAAGG

[0626] 1_G4 GT (SEQ ID GU (SEQ ID AGGACACCUG ACACCTGGGT NO: 219) NO: 221) GGU (SEQ ID (SEQ ID NO: 220)

[0627] NO: 222) AGAAAUCCGU AGAAATCCGTC CTGAAGCTG CUGAAGCUG CUUUCAUUGA TTTCATTGACG

[0628] C2_Ex TGATGCTAG UGAUGCUAG CGGCUGAAGC CTTC GCTGAAGCTGT

[0629] 1_G6 GA (SEQ ID GA (SEQ ID UGUGAUGCUA GATGCTAGGA NO: 223) NO: 225) GGA (SEQ ID (SEQ ID NO: 224)

[0630] NO: 226) AGAAAUCCGU AGAAATCCGTC AGAAGGCTT AGAAGGCUU CUUUCAUUGA TTTCATTGACG

[0631] C2_Ex CCTGAAGCT CCUGAAGCU CGGAGAAGGC CTTG GAGAAGGCTTC

[0632] 1_G7 GT (SEQ ID GU (SEQ ID UUCCUGAAGC CTGAAGCTGT NO: 14) NO: 16) UGU (SEQ ID (SEQ ID NO: 227)

[0633] NO: 228) AGAAAUCCGU AGAAATCCGTC ATGAAAGAC AUGAAAGAC CUUUCAUUGA TTTCATTGACG

[0634] C2_Ex ATAGTACTC AUAGUACUC CGGAUGAAAG ATTG GATGAAAGACA

[0635] 1_G8 CC (SEQ ID CC (SEQ ID ACAUAGUACU TAGTACTCCC NO: 18) NO: 20) CCC (SEQ ID (SEQ ID NO: 229)

[0636] NO: 230) AGAAAUCCGU AGAAATCCGTC TTGATGAAA UUGAUGAAA CUUUCAUUGA TTTCATTGACG

[0637] C2_Ex GACATAGTA GACAUAGUA CGGUUGAUGA ATTA GTTGATGAAAG

[0638] 1_G9 CT (SEQ ID CU (SEQ ID AAGACAUAGU ACATAGTACT NO: 22) NO: 24) ACU (SEQ ID (SEQ ID NO: 231)

[0639] NO: 232) AGAAAUCCGU AGAAATCCGTC ATTATTGAT AUUAUUGAU CUUUCAUUGA TTTCATTGACG

[0640] C2_Ex GAAAGACAT GAAAGACAU CGGAUUAUUG TTTC GATTATTGATG

[0641] 1 G10 AG (SEQ ID AG (SEQ ID AUGAAAGACA AAAGACATAG NO: 233) NO: 235) UAG(SEQID (SEQ ID NO: 234)

[0642] NO: 236) AGAAAUCCGU AGAAATCCGTC TCACCAAAT UCACCAAAU CUUUCAUUGA TTTCATTGACG

[0643] C2_Ex CAGAAGATT CAGAAGAUU CGGUCACCAA TTTC GTCACCAAATC

[0644] 1 G12 TC (SEQ ID UC (SEQ ID AUCAGAAGAU AGAAGATTTC NO: 237) NO: 239) UUC (SEQ ID (SEQ ID NO: 238)

[0645] NO: 240) C2_Ex CTCACCAAA AGAAATCCGTC CUCACCAAA AGAAAUCCGU ATTT

[0646]

[0647] 1 G13 TCAGAAGAT TTTCATTGACG UCAGAAGAU CUUUCAUUGAAttorney Docket No. 063586-568001WO

[0648] Guide Target DNA Sequence Spacer gRNA PAM

[0649] Name* Sequence for gRNA Sequence Sequence TT (SEQ ID GCTCACCAAAT UU (SEQ ID CGGCUCACCAA NO: 241) CAGAAGATTT NO: 243) AUCAGAAGAU (SEQ ID NO: 242) UU (SEQ ID NO:

[0650] 244) AGAAAUCCGU AGAAATCCGTC TTTCTCACC UUUCUCACC CUUUCAUUGA TTTCATTGACG

[0651] C2_Ex AAATCAGAA AAAUCAGAA CGGUUUCUCA ATTA GTTTCTCACCA

[0652] 1 G14 GA (SEQ ID GA (SEQ ID CCAAAUCAGA AATCAGAAGA NO: 26) NO: 28) AGA (SEQ ID (SEQ ID NO: 245)

[0653] NO: 246) AGAAAUCCGU AGAAATCCGTC AGGCATTAT AGGCAUUAU CUUUCAUUGA TTTCATTGACG

[0654] C2_Ex TTCTCACCA UUCUCACCA CGGAGGCAUU TTTA GAGGCATTATT

[0655] 1 G15 AA (SEQ ID AA (SEQ ID AUUUCUCACC TCTCACCAAA NO: 30) NO: 32) AAA (SEQ ID (SEQ ID NO: 247)

[0656] NO: 248) AGAAAUCCGU AGAAATCCGTC AAGGACACC AAGGACACC CUUUCAUUGA TTTCATTGACG

[0657] C2_Ex TGGGTGCTG UGGGUGCUG CGGAAGGACA ATTA GAAGGACACCT

[0658] 1 G16 TC (SEQ ID UC (SEQ ID CCUGGGUGCU GGGTGCTGTC NO: 34) NO: 36) GUC (SEQ ID (SEQ ID NO: 249)

[0659] NO: 250) AGAAAUCCGU AGAAATCCGTC TAAGGCATT UAAGGCAUU CUUUCAUUGA TTTCATTGACG

[0660] C2_Ex ATTTCTCAC AUUUCUCAC CGGUAAGGCA ATTT GTAAGGCATTA

[0661] 1 G17 CA (SEQ ID CA (SEQ ID UUAUUUCUCA TTTCTCACCA NO: 251) NO: 253) CCA (SEQ ID (SEQ ID NO: 252)

[0662] NO: 254) AGAAAUCCGU AGAAATCCGTC GATGATGAT GAUGAUGAU CUUUCAUUGA TTTCATTGACG

[0663] C2_Ex ATGGAAGAA AUGGAAGAA CGGGAUGAUG CTTA GGATGATGATA

[0664] 1 G19 AA (SEQ ID AA (SEQ ID AUAUGGAAGA TGGAAGAAAA NO: 54) NO: 56) AAA (SEQ ID (SEQ ID NO: 255)

[0665] NO: 256) AGAAAUCCGU AGAAATCCGTC GGCCTGTTG GGCCUGUUG CUUUCAUUGA TTTCATTGACG

[0666] C2_Ex TGACTGGGA UGACUGGGA CGGGGCCUGU CTTT GGGCCTGTTGT

[0667] l_G20 CA (SEQ ID CA (SEQ ID UGUGACUGGG GACTGGGACA NO: 257) NO: 259) ACA (SEQ ID (SEQ ID NO: 258)

[0668] NO: 260) AGAAAUCCGU AGAAATCCGTC GCCTGTTGT GCCUGUUGU CUUUCAUUGA TTTCATTGACG

[0669] C2_Ex GACTGGGAC GACUGGGAC CGGGCCUGUU TTTG GGCCTGTTGTG

[0670] 1 G21 AG (SEQ ID AG (SEQ ID GUGACUGGGA ACTGGGACAG NO: 50) NO: 52) CAG (SEQ ID (SEQ ID NO: 261)

[0671] NO: 262) TGACTGGGA UGACUGGGA AGAAAUCCGU AGAAATCCGTC

[0672] C2_Ex CAGTTGACA CAGUUGACA CUUUCAUUGA GTTG TTTCATTGACG

[0673] 1_G22 GC (SEQ ID GC (SEQ ID CGGUGACUGG

[0674] GTGACTGGGAC

[0675]

[0676] NO: 46) NO: 48) GACAGUUGACAttorney Docket No. 063586-568001WO

[0677] Guide Target DNA Sequence Spacer gRNA PAM

[0678] Name* Sequence for gRNA Sequence Sequence AGTTGACAGC AGC (SEQ ID (SEQ ID NO: 263) NO: 264) AGAAAUCCGU AGAAATCCGTC ACAGCACCC ACAGCACCC CUUUCAUUGA TTTCATTGACG

[0679] C2_Ex AGGTGTCCT AGGUGUCCU CGGACAGCACC GTTG GACAGCACCCA

[0680] 1_G23 TT (SEQ ID UU (SEQ ID CAGGUGUCCU GGTGTCCTTT NO: 42) NO: 44) UU (SEQ ID NO:

[0681] (SEQ ID NO: 265)

[0682] 266) AGAAAUCCGU AGAAATCCGTC CTCTACATC CUCUACAUC CUUUCAUUGA TTTCATTGACG

[0683] C2_Ex TGTCCCTTA UGUCCCUUA CGGCUCUACA TTTG GCTCTACATCT

[0684] 1_G24 GA (SEQ ID GA (SEQ ID UCUGUCCCUU GTCCCTTAGA NO: 10) NO: 12) AGA (SEQ ID (SEQ ID NO: 267)

[0685] NO: 268) AGAAAUCCGU AGAAATCCGTC ATGAAAATG AUGAAAAUG CUUUCAUUGA TTTCATTGACG

[0686] C2_Ex CTCTTGACA CUCUUGACA CGGAUGAAAA TTTA GATGAAAATGC

[0687] 1_G25 CC (SEQ ID CC (SEQ ID UGCUCUUGAC TCTTGACACC NO: 38) NO: 40) ACC (SEQ ID (SEQ ID NO: 269)

[0688] NO: 270) AGAAAUCCGU AGAAATCCGTC ACACCAATG ACACCAAUG CUUUCAUUGA TTTCATTGACG

[0689] C2_Ex CATCCTAGC CAUCCUAGC CGGACACCAA CTTG GACACCAATGC

[0690] 1_G26 AT (SEQ ID AU (SEQ ID UGCAUCCUAG ATCCTAGCAT NO: 58) NO: 60) CAU (SEQ ID (SEQ ID NO: 271)

[0691] NO: 272) AGAAAUCCGU AGAAATCCGTC AGGAAGCCT AGGAAGCCU CUUUCAUUGA TTTCATTGACG

[0692] C2_Ex TCTCAAGTG UCUCAAGUG CGGAGGAAGC CTTC GAGGAAGCCTT

[0693] 1_G27 TG (SEQ ID UG (SEQ ID CUUCUCAAGU CTCAAGTGTG NO: 273) NO: 275) GUG(SEQID (SEQ ID NO: 274)

[0694] NO: 276) AGAAAUCCGU AGAAATCCGTC TCAAGTGTG UCAAGUGUG CUUUCAUUGA TTTCATTGACG

[0695] C2_Ex CATGGGGAG CAUGGGGAG CGGUCAAGUG CTTC GTCAAGTGTGC

[0696] 1 G28 TA (SEQ ID UA (SEQ ID UGCAUGGGGA ATGGGGAGTA NO: 277) NO: 279) GUA (SEQ ID (SEQ ID NO: 278)

[0697] NO: 280) AGAAAUCCGU AGAAATCCGTC ATCAATAAT AUCAAUAAU CUUUCAUUGA TTTCATTGACG

[0698] C2_Ex GAAATCTTC GAAAUCUUC CGGAUCAAUA TTTC GATCAATAATG

[0699] 1 G30 TG (SEQ ID UG (SEQ ID AUGAAAUCUU AAATCTTCTG NO: 281) NO: 283) CUG (SEQ ID (SEQ ID NO: 282)

[0700] NO: 284) AGAAAUCCGU AGAAATCCGTC AATGAAAAT AAUGAAAAU CUUUCAUUGA TTTCATTGACG

[0701] C2_Ex GCTCTTGAC GCUCUUGAC CGGAAUGAAA CTTT GAATGAAAATG

[0702] 1 G31 AC (SEQ ID AC (SEQ ID AUGCUCUUGA CTCTTGACAC NO: 285) NO: 287) CAC (SEQ ID (SEQ ID NO: 286)

[0703]

[0704] NO: 288)Attorney Docket No. 063586-568001WO

[0705] Guide Target DNA Sequence Spacer gRNA PAM

[0706] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC AAGTTCAGA AAGUUCAGA CUUUCAUUGA TTTCATTGACG

[0707] C2_Ex TTACCTGAA UUACCUGAA CGGAAGUUCA ATTG GAAGTTCAGAT

[0708] 2_G1 GG(SEQID GG (SEQ ID GAUUACCUGA TACCTGAAGG NO: 74) NO: 76) AGG(SEQID (SEQ ID NO: 289)

[0709] NO: 290) AGAAAUCCGU AGAAATCCGTC AGATTACCT AGAUUACCU CUUUCAUUGA TTTCATTGACG

[0710] C2_Ex GAAGGTGTA GAAGGUGUA CGGAGAUUAC GTTC GAGATTACCTG

[0711] 2_G2 AA (SEQ ID AA (SEQ ID CUGAAGGUGU AAGGTGTAAA NO: 291) NO: 293) AAA (SEQ ID (SEQ ID NO: 292)

[0712] NO: 294) AGAAAUCCGU AGAAATCCGTC CCTGAAGGT CCUGAAGGU CUUUCAUUGA TTTCATTGACG

[0713] C2_Ex GTAAAACTA GUAAAACUA CGGCCUGAAG ATTA GCCTGAAGGTG

[0714] 2_G3 AT (SEQ ID AU (SEQ ID GUGUAAAACU TAAAACTAAT NO: 70) NO: 72) AAU (SEQ ID (SEQ ID NO: 295)

[0715] NO: 296) AGAAAUCCGU AGAAATCCGTC CCTTAGGTG CCUUAGGUG CUUUCAUUGA TTTCATTGACG

[0716] C2_Ex GGAGTCTTC GGAGUCUUC CGGCCUUAGG ATTC GCCTTAGGTGG

[0717] 2_G4 CA (SEQ ID CA (SEQ ID UGGGAGUCUU GAGTCTTCCA NO: 297) NO: 299) CCA (SEQ ID (SEQ ID NO: 298)

[0718] NO: 300) AGAAAUCCGU AGAAATCCGTC TAGATAGAA UAGAUAGAA CUUUCAUUGA TTTCATTGACG

[0719] C2_Ex TATACACGT UAUACACGU CGGUAGAUAG GTTC GTAGATAGAAT

[0720] 2_G5 CG (SEQ ID CG (SEQ ID AAUAUACACG ATACACGTCG NO: 301) NO: 303) UCG (SEQ ID (SEQ ID NO: 302)

[0721] NO: 304) AGAAAUCCGU AGAAATCCGTC CATAGCTCA CAUAGCUCA CUUUCAUUGA TTTCATTGACG

[0722] C2_Ex ATGTTCTAG AUGUUCUAG CGGCAUAGCU CTTC GCATAGCTCAA

[0723] 2_G6 AT (SEQ ID AU (SEQ ID CAAUGUUCUA TGTTCTAGAT NO: 305) NO: 307) GAU (SEQ ID (SEQ ID NO: 306)

[0724] NO: 308) AGAAAUCCGU AGAAATCCGTC TATAATAGA UAUAAUAGA CUUUCAUUGA TTTCATTGACG

[0725] C2_Ex ATGGCACAT AUGGCACAU CGGUAUAAUA CTTT GTATAATAGAA

[0726] 2_G7 CT (SEQ ID CU (SEQ ID GAAUGGCACA TGGCACATCT NO: 309) NO: 311) UCU (SEQ ID (SEQ ID NO: 310)

[0727] NO: 312) AGAAAUCCGU AGAAATCCGTC ATAATAGAA AUAAUAGAA CUUUCAUUGA TTTCATTGACG

[0728] C2_Ex TGGCACATC UGGCACAUC CGGAUAAUAG TTTT GATAATAGAAT

[0729] 2_G8 TC (SEQ ID UC (SEQ ID AAUGGCACAU GGCACATCTC NO: 313) NO: 315) CUC (SEQ ID (SEQ ID NO: 314)

[0730]

[0731] NO: 316)Attorney Docket No. 063586-568001WO

[0732] Guide Target DNA Sequence Spacer gRNA PAM

[0733] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC TAATAGAAT UAAUAGAAU CUUUCAUUGA TTTCATTGACG

[0734] C2_Ex GGCACATCT GGCACAUCU CGGUAAUAGA TTTA GTAATAGAATG

[0735] 2_G9 CT (SEQ ID CU (SEQ ID AUGGCACAUC GCACATCTCT NO: 62) NO: 64) UCU (SEQ ID (SEQ ID NO: 317)

[0736] NO: 318) AGAAAUCCGU AGAAATCCGTC AGCTATGGA AGCUAUGGA CUUUCAUUGA TTTCATTGACG

[0737] C2_Ex AGACTCCCA AGACUCCCA CGGAGCUAUG ATTG GAGCTATGGAA

[0738] 2_G10 CC (SEQ ID CC (SEQ ID GAAGACUCCC GACTCCCACC NO: 94) NO: 96) ACC (SEQ ID (SEQ ID NO: 319)

[0739] NO: 320) AGAAAUCCGU AGAAATCCGTC GGTGGGAGT GGUGGGAGU CUUUCAUUGA TTTCATTGACG

[0740] C2_Ex CTTCCATAG CUUCCAUAG CGGGGUGGGA CTTA GGGTGGGAGTC

[0741] 2_G11 CT (SEQ ID CU (SEQ ID GUCUUCCAUA TTCCATAGCT NO: 66) NO: 68) GCU (SEQ ID (SEQ ID NO: 321)

[0742] NO: 322) AGAAAUCCGU AGAAATCCGTC TATCTAGAA UAUCUAGAA CUUUCAUUGA TTTCATTGACG

[0743] C2_Ex CATTGAGCT CAUUGAGCU CGGUAUCUAG ATTC GTATCTAGAAC

[0744] 2_G12 AT (SEQ ID AU (SEQ ID AACAUUGAGC ATTGAGCTAT NO: 323) NO: 325) UAU (SEQ ID (SEQ ID NO: 324)

[0745] NO: 326) AGAAAUCCGU AGAAATCCGTC AGTAAGACA AGUAAGACA CUUUCAUUGA TTTCATTGACG

[0746] C2_Ex TGCTGCCAA UGCUGCCAA CGGAGUAAGA TTTC GAGTAAGACAT

[0747] 2_G13 GA (SEQ ID GA (SEQ ID CAUGCUGCCA GCTGCCAAGA NO: 327) NO: 329) AGA (SEQ ID (SEQ ID NO: 328)

[0748] NO: 330) AGAAAUCCGU AGAAATCCGTC ACCGACGTG ACCGACGUG CUUUCAUUGA TTTCATTGACG

[0749] C2_Ex TATATTCTA UAUAUUCUA CGGACCGACG CTTT GACCGACGTGT

[0750] 2_G14 TC (SEQ ID UC (SEQ ID UGUAUAUUCU ATATTCTATC NO: 331) NO: 333) AUC (SEQ ID (SEQ ID NO: 332)

[0751] NO: 334) AGAAAUCCGU AGAAATCCGTC CCGACGTGT CCGACGUGU CUUUCAUUGA TTTCATTGACG

[0752] C2_Ex ATATTCTAT AUAUUCUAU CGGCCGACGU TTTA GCCGACGTGTA

[0753] 2_G17 CT (SEQ ID CU (SEQ ID GUAUAUUCUA TATTCTATCT NO: 78) NO: 80) UCU (SEQ ID (SEQ ID NO: 335)

[0754] NO: 336) AGAAAUCCGU AGAAATCCGTC CAGTAAGAC CAGUAAGAC CUUUCAUUGA TTTCATTGACG

[0755] C2_Ex ATGCTGCCA AUGCUGCCA CGGCAGUAAG ATTT GCAGTAAGACA

[0756] 2_G21 AG (SEQ ID AG (SEQ ID ACAUGCUGCC TGCTGCCAAG NO: 337) NO: 339) AAG(SEQID (SEQ ID NO: 338)

[0757]

[0758] NO: 340)Attorney Docket No. 063586-568001WO

[0759] Guide Target DNA Sequence Spacer gRNA PAM

[0760] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC TATTATAAA UAUUAUAAA CUUUCAUUGA TTTCATTGACG

[0761] C2_Ex AGATCAGTA AGAUCAGUA CGGUAUUAUA ATTC GTATTATAAAA

[0762] 2_G22 GC (SEQ ID GC (SEQ ID AAAGAUCAGU GATCAGTAGC NO: 341) NO: 343) AGC (SEQ ID (SEQ ID NO: 342)

[0763] NO: 344) AGAAAUCCGU AGAAATCCGTC TAAAAGATC UAAAAGAUC CUUUCAUUGA TTTCATTGACG

[0764] C2_Ex AGTAGCTTC AGUAGCUUC CGGUAAAAGA ATTA GTAAAAGATCA

[0765] 2_G23 CT (SEQ ID CU (SEQ ID UCAGUAGCUU GTAGCTTCCT NO: 82) NO: 84) CCU (SEQ ID (SEQ ID NO: 345)

[0766] NO: 346) AGAAAUCCGU AGAAATCCGTC CTTTACCGA CUUUACCGA CUUUCAUUGA TTTCATTGACG

[0767] C2_Ex CGTGTATAT CGUGUAUAU CGGCUUUACC CTTC GCTTTACCGAC

[0768] 2_G24 TC (SEQ ID UC (SEQ ID GACGUGUAUA GTGTATATTC NO: 347) NO: 349) UUC (SEQ ID (SEQ ID NO: 348)

[0769] NO: 350) AGAAAUCCGU AGAAATCCGTC TGTATTTCA UGUAUUUCA CUUUCAUUGA TTTCATTGACG

[0770] C2_Ex GTAAGACAT GUAAGACAU CGGUGUAUUU ATTG GTGTATTTCAG

[0771] 2_G25 GC (SEQ ID GC (SEQ ID CAGUAAGACA TAAGACATGC NO: 86) NO: 88) UGC (SEQ ID (SEQ ID NO: 351)

[0772] NO: 352) AGAAAUCCGU AGAAATCCGTC AACAACGGT AACAACGGU CUUUCAUUGA TTTCATTGACG

[0773] C2_Ex TGCAGGGAC UGCAGGGAC CGGAACAACG CTTA GAACAACGGTT

[0774] 3_G1 AG (SEQ ID AG (SEQ ID GUUGCAGGGA GCAGGGACAG NO: 98) NO: 100) CAG (SEQ ID (SEQ ID NO: 353)

[0775] NO: 354) AGAAAUCCGU AGAAATCCGTC CCTCTGTGA CCUCUGUGA CUUUCAUUGA TTTCATTGACG

[0776] C2_Ex CAACACCAG CAACACCAG CGGCCUCUGU CTTG GCCTCTGTGAC

[0777] 3_G2 AG (SEQ ID AG (SEQ ID GACAACACCA AACACCAGAG NO: 102) NO: 104) GAG (SEQ ID (SEQ ID NO: 355)

[0778] NO: 356) AGAAAUCCGU AGAAATCCGTC ACTGCAGCA ACUGCAGCA CUUUCAUUGA TTTCATTGACG

[0779] C2_Ex TGCCTGTGC UGCCUGUGC CGGACUGCAG ATTC GACTGCAGCAT

[0780] 3_G3 GG(SEQID GG (SEQ ID CAUGCCUGUG GCCTGTGCGG NO: 357) NO: 359) CGG (SEQ ID (SEQ ID NO: 358)

[0781] NO: 360) AGAAAUCCGU AGAAATCCGTC AATTCACTG AAUUCACUG CUUUCAUUGA TTTCATTGACG

[0782] C2_Ex CAGCATGCC CAGCAUGCC CGGAAUUCAC GTTA GAATTCACTGC

[0783] 3_G4 TG (SEQ ID UG (SEQ ID UGCAGCAUGC AGCATGCCTG NO: 106) NO: 108) CUG (SEQ ID (SEQ ID NO: 361)

[0784]

[0785] NO: 362)Attorney Docket No. 063586-568001WO

[0786] Guide Target DNA Sequence Spacer gRNA PAM

[0787] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC CAGGGACAG CAGGGACAG CUUUCAUUGA TTTCATTGACG

[0788] C2_Ex AGGATCAGT AGGAUCAGU CGGCAGGGAC GTTG GCAGGGACAGA

[0789] 3_G5 TA (SEQ ID UA (SEQ ID AGAGGAUCAG GGATCAGTTA NO: 110) NO: 112) UUA (SEQ ID (SEQ ID NO: 363)

[0790] NO: 364) AGAAAUCCGU AGAAATCCGTC CCAGAATAG CCAGAAUAG CUUUCAUUGA TTTCATTGACG

[0791] C2_Ex CATCCTTAA CAUCCUUAA CGGCCAGAAU CTTA GCCAGAATAGC

[0792] 3_G6 AC (SEQ ID AC (SEQ ID AGCAUCCUUA ATCCTTAAAC NO: 114) NO: 116) AAC (SEQ ID (SEQ ID NO: 365)

[0793] NO: 366) AGAAAUCCGU AGAAATCCGTC TAAACCCTT UAAACCCUU CUUUCAUUGA TTTCATTGACG

[0794] C2_Ex ACCAGAATA ACCAGAAUA CGGUAAACCC CTTG GTAAACCCTTA

[0795] 3_G7 GC (SEQ ID GC (SEQ ID UUACCAGAAU CCAGAATAGC NO: 118) NO: 120) AGC (SEQ ID (SEQ ID NO: 367)

[0796] NO: 368) AGAAAUCCGU AGAAATCCGTC TCTTGTAAA UCUUGUAAA CUUUCAUUGA TTTCATTGACG

[0797] C2_Ex CCCTTACCA CCCUUACCA CGGUCUUGUA GTTG GTCTTGTAAAC

[0798] 3_G8 GA (SEQ ID GA (SEQ ID AACCCUUACCA CCTTACCAGA NO: 122) NO: 124) GA (SEQ ID NO:

[0799] (SEQ ID NO: 369)

[0800] 370) AGAAAUCCGU AGAAATCCGTC CGTTGTCTT CGUUGUCUU CUUUCAUUGA TTTCATTGACG

[0801] C2_Ex GTAAACCCT GUAAACCCU CGGCGUUGUC TTTA GCGTTGTCTTG

[0802] 3_G9 TA (SEQ ID UA (SEQ ID UUGUAAACCC TAAACCCTTA NO: 126) NO: 128) UUA (SEQ ID (SEQ ID NO: 371)

[0803] NO: 372) AGAAAUCCGU AGAAATCCGTC AACTGATCC AACUGAUCC CUUUCAUUGA TTTCATTGACG

[0804] C2_Ex TCTGTCCCT UCUGUCCCU CGGAACUGAU ATTT GAACTGATCCT

[0805] 3_G11 GC (SEQ ID GC (SEQ ID CCUCUGUCCCU CTGTCCCTGC NO: 373) NO: 375) GC (SEQ ID NO:

[0806] (SEQ ID NO: 374)

[0807] 376) AGAAAUCCGU AGAAATCCGTC TCACAGAGG UCACAGAGG CUUUCAUUGA TTTCATTGACG

[0808] C2_Ex CAAGTGCTA CAAGUGCUA CGGUCACAGA GTTG GTCACAGAGGC

[0809] 3_G12 CC (SEQ ID CC (SEQ ID GGCAAGUGCU AAGTGCTACC NO: 135) NO: 137) ACC (SEQ ID (SEQ ID NO: 377)

[0810] NO: 378) AGAAAUCCGU AGAAATCCGTC CTATGCCTG CUAUGCCUG CUUUCAUUGA TTTCATTGACG

[0811] C2_Ex TAGATAAAG UAGAUAAAG CGGCUAUGCC ATTC GCTATGCCTGT

[0812] 3 G13 AC (SEQ ID AC (SEQ ID UGUAGAUAAA AGATAAAGAC NO: 379) NO: 381) GAC (SEQ ID (SEQ ID NO: 380)

[0813]

[0814] NO: 382)Attorney Docket No. 063586-568001WO

[0815] Guide Target DNA Sequence Spacer gRNA PAM

[0816] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC CTCCCTGAA CUCCCUGAA CUUUCAUUGA TTTCATTGACG

[0817] C2_Ex CAACAGGGT CAACAGGGU CGGCUCCCUGA GTTT GCTCCCTGAAC

[0818] 4_G2 AA (SEQ ID AA (SEQ ID ACAACAGGGU AACAGGGTAA NO: 383) NO: 385) AA (SEQ ID NO:

[0819] (SEQ ID NO: 384)

[0820] 386) AGAAAUCCGU AGAAATCCGTC AGTGGTGTC AGUGGUGUC CUUUCAUUGA TTTCATTGACG

[0821] C2_Ex AGTTTCTCC AGUUUCUCC CGGAGUGGUG GTTG GAGTGGTGTCA

[0822] 4_G3 CT (SEQ ID CU (SEQ ID UCAGUUUCUC GTTTCTCCCT NO: 155) NO: 157) CCU (SEQ ID (SEQ ID NO: 387)

[0823] NO: 388) AGAAAUCCGU AGAAATCCGTC TCAGTGCCA UCAGUGCCA CUUUCAUUGA TTTCATTGACG

[0824] C2_Ex GGCAGTTGA GGCAGUUGA CGGUCAGUGC ATTT GTCAGTGCCAG

[0825] 4_G6 GT (SEQ ID GU (SEQ ID CAGGCAGUUG GCAGTTGAGT NO: 389) NO: 391) AGU (SEQ ID (SEQ ID NO: 390)

[0826] NO: 392) AGAAAUCCGU AGAAATCCGTC AACACTGAT AACACUGAU CUUUCAUUGA TTTCATTGACG

[0827] C2_Ex GGTAAAGTG GGUAAAGUG CGGAACACUG CTTA GAACACTGATG

[0828] 4_G7 GA (SEQ ID GA (SEQ ID AUGGUAAAGU GTAAAGTGGA NO: 139) NO: 141) GGA (SEQ ID (SEQ ID NO: 393)

[0829] NO: 394) AGAAAUCCGU AGAAATCCGTC CCTTAAACA CCUUAAACA CUUUCAUUGA TTTCATTGACG

[0830] C2_Ex CTGATGGTA CUGAUGGUA CGGCCUUAAA GTTT GCCTTAAACAC

[0831] 4_G9 AA (SEQ ID AA (SEQ ID CACUGAUGGU TGATGGTAAA NO: 395) NO: 397) AAA (SEQ ID (SEQ ID NO: 396)

[0832] NO: 398) AGAAAUCCGU AGAAATCCGTC GATCAAATA GAUCAAAUA CUUUCAUUGA TTTCATTGACG

[0833] C2_Ex TGCTTACCA UGCUUACCA CGGGAUCAAA CTTG GGATCAAATAT

[0834] 4_G10 GA (SEQ ID GA (SEQ ID UAUGCUUACC GCTTACCAGA NO: 147) NO: 149) AGA (SEQ ID (SEQ ID NO: 399)

[0835] NO: 400) AGAAAUCCGU AGAAATCCGTC CCAGAGATG CCAGAGAUG CUUUCAUUGA TTTCATTGACG

[0836] C2_Ex GTTTCCTTA GUUUCCUUA CGGCCAGAGA CTTA GCCAGAGATGG

[0837] 4_G11 AA (SEQ ID AA (SEQ ID UGGUUUCCUU TTTCCTTAAA NO: 143) NO: 145) AAA (SEQ ID (SEQ ID NO: 401)

[0838] NO: 402) AGAAAUCCGU AGAAATCCGTC TACAGAAAA UACAGAAAA CUUUCAUUGA TTTCATTGACG

[0839] C2_Ex GACTGTGGA GACUGUGGA CGGUACAGAA CTTT GTACAGAAAAG

[0840] 4_G12 GG(SEQID GG (SEQ ID AAGACUGUGG ACTGTGGAGG NO: 403) NO: 405) AGG(SEQID (SEQ ID NO: 404)

[0841]

[0842] NO: 406)Attorney Docket No. 063586-568001WO

[0843] Guide Target DNA Sequence Spacer gRNA PAM

[0844] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC ACCATCAGT ACCAUCAGU CUUUCAUUGA TTTCATTGACG

[0845] C2_Ex GTTTAAGGA GUUUAAGGA CGGACCAUCA CTTT GACCATCAGTG

[0846] 4_G13 AA (SEQ ID AA (SEQ ID GUGUUUAAGG TTTAAGGAAA NO: 407) NO: 409) AAA (SEQ ID (SEQ ID NO: 408)

[0847] NO: 410) AGAAAUCCGU AGAAATCCGTC AGGGAGAA AGGGAGAAA CUUUCAUUGA TTTCATTGACG

[0848] C2_Ex ACTGACACC CUGACACCA CGGAGGGAGA GTTC GAGGGAGAAA

[0849] 4_G14 ACT (SEQ ID CU (SEQ ID AACUGACACC CTGACACCACT NO: 411) NO: 413) ACU (SEQ ID (SEQ ID NO: 412)

[0850] NO: 414) AGAAAUCCGU AGAAATCCGTC TTCAGGGAG UUCAGGGAG CUUUCAUUGA TTTCATTGACG

[0851] C2_Ex AAACTGACA AAACUGACA CGGUUCAGGG GTTG GTTCAGGGAGA

[0852] 4_G15 CC (SEQ ID CC (SEQ ID AGAAACUGAC AACTGACACC NO: 167) NO: 169) ACC (SEQ ID (SEQ ID NO: 415)

[0853] NO: 416) AGAAAUCCGU AGAAATCCGTC CCCTGTTGT CCCUGUUGU CUUUCAUUGA TTTCATTGACG

[0854] C2_Ex TCAGGGAGA UCAGGGAGA CGGCCCUGUU TTTA GCCCTGTTGTT

[0855] 4 G16 AA (SEQ ID AA (SEQ ID GUUCAGGGAG CAGGGAGAAA NO: 159) NO: 161) AAA (SEQ ID (SEQ ID NO: 417)

[0856] NO: 418) AGAAAUCCGU AGAAATCCGTC ACCCTGTTG ACCCUGUUG CUUUCAUUGA TTTCATTGACG

[0857] C2_Ex TTCAGGGAG UUCAGGGAG CGGACCCUGU CTTT GACCCTGTTGT

[0858] 4_G17 AA (SEQ ID AA (SEQ ID UGUUCAGGGA TCAGGGAGAA NO: 419) NO: 421) GAA (SEQ ID (SEQ ID NO: 420)

[0859] NO: 422) AGAAAUCCGU AGAAATCCGTC ACAGAAAAG ACAGAAAAG CUUUCAUUGA TTTCATTGACG

[0860] C2_Ex ACTGTGGAG ACUGUGGAG CGGACAGAAA TTTT GACAGAAAAG

[0861] 4 G19 GA (SEQ ID GA (SEQ ID AGACUGUGGA ACTGTGGAGGA NO: 433) NO: 445) GGA (SEQ ID (SEQ ID NO: 444)

[0862] NO: 446) AGAAAUCCGU AGAAATCCGTC ACTTTGTCT ACUUUGUCU CUUUCAUUGA TTTCATTGACG

[0863] C2_Ex GAAAATACC GAAAAUACC CGGACUUUGU ATTC GACTTTGTCTG

[0864] 5_G1 TA (SEQ ID UA (SEQ ID CUGAAAAUAC AAAATACCTA NO: 447) NO: 449) CUA (SEQ ID (SEQ ID NO: 448)

[0865] NO: 450) AGAAAUCCGU AGAAATCCGTC GTCTGAAAA GUCUGAAAA CUUUCAUUGA TTTCATTGACG

[0866] C2_Ex TACCTACCA UACCUACCA CGGGUCUGAA CTTT GGTCTGAAAAT

[0867] 5_G2 GA (SEQ ID GA (SEQ ID AAUACCUACC ACCTACCAGA NO: 451) NO: 453) AGA (SEQ ID (SEQ ID NO: 452)

[0868]

[0869] NO: 454)Attorney Docket No. 063586-568001WO

[0870] Guide Target DNA Sequence Spacer gRNA PAM

[0871] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC AACCAGGAT AACCAGGAU CUUUCAUUGA TTTCATTGACG

[0872] C2_Ex TTAAGGATG UUAAGGAUG CGGAACCAGG TTTC GAACCAGGATT

[0873] 5_G4 CC (SEQ ID CC (SEQ ID AUUUAAGGAU TAAGGATGCC NO: 455) NO: 457) GCC (SEQ ID (SEQ ID NO: 456)

[0874] NO: 458) AGAAAUCCGU AGAAATCCGTC ACAGGAGAC ACAGGAGAC CUUUCAUUGA TTTCATTGACG

[0875] C2_Ex CAAACAGAT CAAACAGAU CGGACAGGAG GTTC GACAGGAGACC

[0876] 5_G6 AT (SEQ ID AU (SEQ ID ACCAAACAGA AAACAGATAT NO: 459) NO: 461) UAU (SEQ ID (SEQ ID NO: 460)

[0877] NO: 462) AGAAAUCCGU AGAAATCCGTC AATCCTGGT AAUCCUGGU CUUUCAUUGA TTTCATTGACG

[0878] C2_Ex TGAAAGTTC UGAAAGUUC CGGAAUCCUG CTTA GAATCCTGGTT

[0879] 5_G7 AC (SEQ ID AC (SEQ ID GUUGAAAGUU GAAAGTTCAC NO: 175) NO: 177) CAC (SEQ ID (SEQ ID NO: 463)

[0880] NO: 464) AGAAAUCCGU AGAAATCCGTC CAACCAGGA CAACCAGGA CUUUCAUUGA TTTCATTGACG

[0881] C2_Ex TTTAAGGAT UUUAAGGAU CGGCAACCAG CTTT GC AACCAGGAT

[0882] 5_G8 GC (SEQ ID GC (SEQ ID GAUUUAAGGA TTAAGGATGC NO: 465) NO: 467) UGC (SEQ ID (SEQ ID NO: 466)

[0883] NO: 468) AGAAAUCCGU AGAAATCCGTC ACACCAGCA ACACCAGCA CUUUCAUUGA TTTCATTGACG

[0884] C2_Ex CAGCTGACA CAGCUGACA CGGACACCAGC GTTG GACACCAGCAC

[0885] 5_G11 CA (SEQ ID CA (SEQ ID ACAGCUGACA AGCTGACACA NO: 179) NO: 181) CA (SEQ ID NO:

[0886] (SEQ ID NO: 469)

[0887] 470) AGAAAUCCGU AGAAATCCGTC TTGACACCA UUGACACCA CUUUCAUUGA TTTCATTGACG

[0888] C2_Ex GCACAGCTG GCACAGCUG CGGUUGACAC CTTG GTTGACACCAG

[0889] 5_G12 AC (SEQ ID AC (SEQ ID CAGCACAGCU CACAGCTGAC NO: 187) NO: 189) GAC (SEQ ID (SEQ ID NO: 471)

[0890] NO: 472) AGAAAUCCGU AGAAATCCGTC GGCTTGTTG GGCUUGUUG CUUUCAUUGA TTTCATTGACG

[0891] C2_Ex ACACCAGCA ACACCAGCA CGGGGCUUGU CTTT GGGCTTGTTGA

[0892] 5_G13 CA (SEQ ID CA (SEQ ID UGACACCAGC CACCAGCACA NO: 473) NO: 475) ACA (SEQ ID (SEQ ID NO: 474)

[0893] NO: 476) AGAAAUCCGU AGAAATCCGTC TCCTCCTCC uccuccucc CUUUCAUUGA TTTCATTGACG

[0894] C2_Ex CCTTAGATA CCUUAGAUA CGGUCCUCCUC CTTA GTCCTCCTCCC

[0895] 5_G15 AG (SEQ ID AG (SEQ ID CCCUUAGAUA CTTAGATAAG NO: 183) NO: 185) AG (SEQ ID NO:

[0896] (SEQ ID NO: 477)

[0897]

[0898] 478)Attorney Docket No. 063586-568001WO

[0899] Guide Target DNA Sequence Spacer gRNA PAM

[0900] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC GTCTCCTGT GUCUCCUGU CUUUCAUUGA TTTCATTGACG

[0901] C2_Ex GAACTTTCA GAACUUUCA CGGGUCUCCU TTTG GGTCTCCTGTG

[0902] 5 G16 AC (SEQ ID AC (SEQ ID GUGAACUUUC AACTTTCAAC NO: 479) NO: 481) AAC (SEQ ID (SEQ ID NO: 480)

[0903] NO: 482) AGAAAUCCGU AGAAATCCGTC CTTGAAGTT CUUGAAGUU CUUUCAUUGA TTTCATTGACG

[0904] C2_Ex GTTTCAGCT GUUUCAGCU CGGCUUGAAG TTTC GCTTGAAGTTG

[0905] 6_G1 TT (SEQ ID UU (SEQ ID UUGUUUCAGC TTTCAGCTTT NO: 483) NO: 485) UUU (SEQ ID (SEQ ID NO: 484)

[0906] NO: 486) AGAAAUCCGU AGAAATCCGTC AAAGCTGAA AAAGCUGAA CUUUCAUUGA TTTCATTGACG

[0907] C2_Ex ACAACTTCA ACAACUUCA CGGAAAGCUG GTTA GAAAGCTGAAA

[0908] 6_G6 AG (SEQ ID AG (SEQ ID AAACAACUUC CAACTTCAAG NO: 195) NO: 197) AAG(SEQID (SEQ ID NO: 487)

[0909] NO: 488) AGAAAUCCGU AGAAATCCGTC GCTGCAGGT GCUGCAGGU CUUUCAUUGA TTTCATTGACG

[0910] C2_Ex TAAAAGCTG UAAAAGCUG CGGGCUGCAG TTTT GGCTGCAGGTT

[0911] 6_G7 AA (SEQ ID AA (SEQ ID GUUAAAAGCU AAAAGCTGAA NO: 489) NO: 491) GAA (SEQ ID (SEQ ID NO: 490)

[0912] NO: 492) AGAAAUCCGU AGAAATCCGTC TGCTGCAGG UGCUGCAGG CUUUCAUUGA TTTCATTGACG

[0913] C2_Ex TTAAAAGCT UUAAAAGCU CGGUGCUGCA ATTT GTGCTGCAGGT

[0914] 6_G8 GA (SEQ ID GA (SEQ ID GGUUAAAAGC TAAAAGCTGA NO: 493) NO: 495) UGA (SEQ ID (SEQ ID NO: 494)

[0915] NO: 496) AGAAAUCCGU AGAAATCCGTC TATGTGATA UAUGUGAUA CUUUCAUUGA TTTCATTGACG

[0916] C2_Ex TTTTGCTGC UUUUGCUGC CGGUAUGUGA TTTC GTATGTGATAT

[0917] 6_G9 AG (SEQ ID AG (SEQ ID UAUUUUGCUG TTTGCTGCAG NO: 497) NO: 499) CAG (SEQ ID (SEQ ID NO: 498)

[0918] NO: 500) AGAAAUCCGU AGAAATCCGTC CTATGTGAT CUAUGUGAU CUUUCAUUGA TTTCATTGACG

[0919] C2_Ex ATTTTGCTG AUUUUGCUG CGGCUAUGUG TTTT GCTATGTGATA

[0920] 6 G10 CA (SEQ ID CA (SEQ ID AUAUUUUGCU TTTTGCTGCA NO: 501) NO: 503) GCA (SEQ ID (SEQ ID NO: 502)

[0921] NO: 504) AGAAAUCCGU AGAAATCCGTC CTGCAGGTT CUGCAGGUU CUUUCAUUGA TTTCATTGACG

[0922] C2_Ex AAAAGCTGA AAAAGCUGA CGGCUGCAGG TTTG GCTGCAGGTTA

[0923] 6_G11 AA (SEQ ID AA (SEQ ID UUAAAAGCUG AAAGCTGAAA NO: 191) NO: 193) AAA (SEQ ID (SEQ ID NO: 505)

[0924]

[0925] NO: 506)Attorney Docket No. 063586-568001WO

[0926] Guide Target DNA Sequence Spacer gRNA PAM

[0927] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC CATGTTTTG CAUGUUUUG CUUUCAUUGA TTTCATTGACG

[0928] C2_Ex CTGAGATAG CUGAGAUAG CGGCAUGUUU CTTT GCATGTTTTGC

[0929] 7_G3 AA (SEQ ID AA (SEQ ID UGCUGAGAUA TGAGATAGAA NO: 507) NO: 509) GAA (SEQ ID (SEQ ID NO: 508)

[0930] NO: 510) AGAAAUCCGU AGAAATCCGTC ATGTTTTGC AUGUUUUGC CUUUCAUUGA TTTCATTGACG

[0931] C2_Ex TGAGATAGA UGAGAUAGA CGGAUGUUUU TTTC GATGTTTTGCT

[0932] 7_G4 AG (SEQ ID AG (SEQ ID GCUGAGAUAG GAGATAGAAG NO: 511) NO: 513) AAG(SEQID (SEQ ID NO: 512)

[0933] NO: 514) AGAAAUCCGU AGAAATCCGTC TGCTGAGAT UGCUGAGAU CUUUCAUUGA TTTCATTGACG

[0934] C2_Ex AGAAGGCCT AGAAGGCCU CGGUGCUGAG GTTT GTGCTGAGATA

[0935] 7_G5 GG(SEQID GG (SEQ ID AUAGAAGGCC GAAGGCCTGG NO: 515) NO: 517) UGG (SEQ ID (SEQ ID NO: 516)

[0936] NO: 518) AGAAAUCCGU AGAAATCCGTC GCTGAGATA GCUGAGAUA CUUUCAUUGA TTTCATTGACG

[0937] C2_Ex GAAGGCCTG GAAGGCCUG CGGGCUGAGA TTTT GGCTGAGATAG

[0938] 7_G6 GA (SEQ ID GA (SEQ ID UAGAAGGCCU AAGGCCTGGA NO: 519) NO: 521) GGA (SEQ ID (SEQ ID NO: 520)

[0939] NO: 522) AGAAAUCCGU AGAAATCCGTC CTGAGATAG CUGAGAUAG CUUUCAUUGA TTTCATTGACG

[0940] C2_Ex AAGGCCTGG AAGGCCUGG CGGCUGAGAU TTTG GCTGAGATAGA

[0941] 7_G7 AA (SEQ ID AA (SEQ ID AGAAGGCCUG AGGCCTGGAA NO: 199) NO: 201) GAA (SEQ ID (SEQ ID NO: 523)

[0942] NO: 524) AGAAAUCCGU AGAAATCCGTC TCTGAAGTG UCUGAAGUG CUUUCAUUGA TTTCATTGACG

[0943] C2_Ex GAGGATCAG GAGGAUCAG CGGUCUGAAG GTTC GTCTGAAGTGG

[0944] 7_G8 AT (SEQ ID AU (SEQ ID UGGAGGAUCA AGGATCAGAT NO: 525) NO: 527) GAU (SEQ ID (SEQ ID NO: 526)

[0945]

[0946] NO: 528) *The guide name indicates the nuclease that it can be paired with for editing UBE3A-ATS and the specific exon targeted within the region (eg: C2_ex4_G9 is paired with the C2 nuclease and targets exon 4)

[0947] C2 DR sequence: AGAAAUCCGUCUUUCAUUGACGG (SEQ ID NO: 7)

[0948] D 1 DR sequence : CUUGUUGUAUAUGTCCUUUUAUAGGUAUUAAACAAC (SEQ ID NO : 8)

[0949] Guide Screening in HEK293T Cells - Cluster 2 Exonic Region

[0950] UBE3A-ATS disruption at the Cluster 2 exon was assessed by transient co-transfection of plasmids encoding a guide RNA and a CRISPR nuclease in HEK293T cells. Cells were cultured in DMEM containing 10% fetal bovine serum (DIO). Approximately 16 hours prior toAttorney Docket No. 063586-568001WO

[0951] transfection, a cell suspension containing 25,000 cells was seeded in each well of a 96-well plate, resulting in 70-90% confluency at the time of transfection. For each well to be transfected, a mixture of Lipofectamine 2000 and Opti-Mem (Thermo Fisher Scientific) was prepared and incubated at room temperature (Solution 1). A separate mixture containing plasmid expressing nuclease and plasmid expressing guide was prepared (Solution 2).

[0952] Solutions 1 and 2 were mixed by pipetting, and the mixture was incubated at room temperature before being added to 96-well plates seeded with HEK293T cells. Negative control conditions including vehicle only or pmaxGFP (Lonza) were also administered.

[0953] Transfected cells were cultured for 72 hours at 37°C with 5% CO2. Following removal of the culture media, cells were then detached by adding trypLE (Thermo Fisher Scientific), incubating 5 minutes, followed by neutralization with D10 media, and mixing. Cells were then pelleted by centrifugation, resuspended in QuickExtract™ DNA Extraction Solution (Biosearch Technologies) and incubated at 65°C for 15 minutes, 68°C for 15 minutes, and 98°C for 10 minutes.

[0954] Samples were then prepared for Next Generation Sequencing (NGS) by two rounds of PCR. The first round (PCR I) was used to amplify the genomic regions flanking the target site and to add NGS adapters. The second round (PCR II) was used to add NGS indexes. Reactions were then pooled, purified by column purification, and quantified on a fluorometer (Qubit). Sequencing runs were performed using a NovaSeq™ 6000 S2 Reagent Kit vl.5 (100 cycles) and run on a NovaSeq™ 6000 instrument (Illumina®).

[0955] For NGS analysis, the indel mapping function used a sample’s fastq file, the amplicon reference sequence, and the forward primer sequence. For each read, a kmer-scanning algorithm was used to calculate the edit operations (match, mismatch, insertion, deletion) between the read and the reference sequence. In order to remove small amounts of primer dimer present in some samples, the first 30 nt of each read was required to match the reference and reads where over half of the mapping nucleotides are mismatches were filtered out as well. Up to 50,000 reads passing those filters were used for analysis, and reads were counted as an indel read if they contained an insertion or deletion. The % indels was calculated as the number of indel-containing reads divided by the number of reads analyzed (reads passing filters up to 50,000). The QC standard for the minimum number of reads passing filters was 10,000. FIG. 2 highlights the top C2 and DI guides within the Cluster 2 Exonic regions, with indel percentages reaching levels 20% or greater.Attorney Docket No. 063586-568001WO

[0956] UBE3A-ATS Intronic Region

[0957] Computational identification and production of VBE3A-ATS intronic guides

[0958] This strategy differed from the strategy described for Cluster 2 exon guide design above. The UBE3A-ATS intronic region of interest spans from the 3’ end of cluster 2 exons to the 3’ end of UBE3A on the opposite strand (chrl5: 25,278,885 to 25,333,728, GRCh38 build, UCSC Genome Browser). Given the large size of this region, we opted to divide this large region of ~58kb into three segments (coordinates are based on GRCh38 build of chrl5, UCSC Genome Browser): Segment 1 (25,278,885 to 25,296,525), Segment 2 (25,296,526 to 25,316,526), and Segment 3 (25,316,526 to 25,333,728) (FIG.3) to determine which intronic regions were accessible to CRISPR gene editing. Cas9 nuclease and computationally designed guides were used in this assay. Significant gene editing (>20% indels) was identified within Segment 1 and 2, but not Segment 3 (FIG. 4). The success of this screen informed the guide design for C2 and DI in this region. Guides for C2 and DI were designed by tiling the genomic space surrounding each good-cutting Cas9 guides of segment 1 and 2 resulting in 138 target sequences (Table 6). Cas9 guides are shown in Table 7. Plasmids encoding the guide RNA were generated by Integrated DNA Technologies, as is described for the design of exonic guides above. The DNA sequences of guides targeting UBE3A-ATS intronic regions are recorded in Table 6.

[0959] Numbers of target sequences within the intronic region for Nuclease C2 and Nuclease DI are provided in Table 5 below. Exemplary target sequences within the intronic region are provided in Table 6 below.

[0960] Table 5. In Silico Identification of Target sequences within UBE3A-ATS intronic regions * PAM position is relative to target sequence; **N is A, G, C or T; R is A or G

[0961] PAM # of Target Nuclease PAM Sequence** Region targeted

[0962] position* Sequences VBE3A-ATS

[0963] C2 5’ NTTN 72

[0964] intron

[0965] VBE3A-ATS

[0966] DI 5’ NTTR 66

[0967]

[0968] intronAttorney Docket No. 063586-568001WO

[0969] Table 6. Sequences of guides targeting the intronic region of UBE3A-ATS

[0970] Guide Target DNA Sequence Spacer gRNA PAM

[0971] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC CTCGAGGAT CUCGAGGAU CUUUCAUUGA TTTCATTGACG

[0972] C2_S1_ AGTTTCACTG AGUUUCACU CGGCUCGAGG CTTC GCTCGAGGAT

[0973] G5.1 A (SEQ ID NO: GA (SEQ ID AUAGUUUCAC AGTTTCACTGA

[0974] 529) NO: 531) UGA (SEQ ID (SEQ ID NO: 530)

[0975] NO: 532) AGAAAUCCGU AGAAATCCGTC CACTGACTTC CACUGACUU CUUUCAUUGA TTTCATTGACG

[0976] C2_S1_ ATCTTATCCT CAUCUUAUC CGGCACUGAC GTTT GCACTGACTTC

[0977] G5.2 (SEQ ID NO: CU (SEQ ID UUCAUCUUAU ATCTTATCCT

[0978] 533) NO: 535) CCU (SEQ ID (SEQ ID NO: 534)

[0979] NO: 536) AGAAAUCCGU AGAAATCCGTC ATCTTATCCT AUCUUAUCC CUUUCAUUGA TTTCATTGACG

[0980] C2_S1_ CTTTGTGCCA UCUUUGUGC CGGAUCUUAU CTTC GATCTTATCCT

[0981] G5.3 (SEQ ID NO: CA (SEQ ID CCUCUUUGUG CTTTGTGCCA

[0982] 537) NO: 539) CCA (SEQ ID (SEQ ID NO: 538)

[0983] NO: 540) AGAAAUCCGU AGAAATCCGTC TTATCCTTCA UUAUCCUUC CUUUCAUUGA TTTCATTGACG

[0984] C2_S1_ TTCTGTTAAA AUUCUGUUA CGGUUAUCCU ATTT GTTATCCTTCA

[0985] G10.1 (SEQ ID NO: AA (SEQ ID UCAUUCUGUU TTCTGTTAAA

[0986] 541) NO: 543) AAA (SEQ ID (SEQ ID NO: 542)

[0987] NO: 544) AGAAATCCGTC AGAAAUCCGU ACAGAATGA TTTCATTGACG ACAGAAUGA CUUUCAUUGA

[0988] C2_S1_ AGGATAAAA GACAGAATGA AGGAUAAAA CGGACAGAAU TTTA

[0989] G10.2 AT (SEQ ID AGGATAAAAA AU (SEQ ID GAAGGAUAAA NO: 545) T (SEQ ID NO: NO: 547) AAU (SEQ ID 546) NO: 548) AGAAAUCCGU AGAAATCCGTC AACTAGTTTA AACUAGUUU CUUUCAUUGA TTTCATTGACG

[0990] C2_S1_ CAGTCCCACC ACAGUCCCAC CGGAACUAGU GTTG GAACTAGTTTA GIO.3 (SEQ ID NO: C (SEQ ID NO: UUACAGUCCC CAGTCCCACC

[0991] 549) 551) ACC (SEQ ID (SEQ ID NO: 550)

[0992] NO: 552) AGAAAUCCGU AGAAATCCGTC GTGGGACTGT GUGGGACUG CUUUCAUUGA TTTCATTGACG

[0993] C2_S1_ AAACTAGTTC UAAACUAGU CGGGUGGGAC GTTG GGTGGGACTGT

[0994] G10.4 (SEQ ID NO: UC (SEQ ID UGUAAACUAG AAACTAGTTC

[0995] 553) NO: 555) UUC (SEQ ID (SEQ ID NO: 554)

[0996] NO: 556) AGAAAUCCGU AGAAATCCGTC AAGTAGTGT AAGUAGUGU CUUUCAUUGA TTTCATTGACG

[0997] C2_S1_ AACATTTGTT AACAUUUGU CGGAAGUAGU GTTA GAAGTAGTGT GIO.5 G (SEQ ID NO: UG (SEQ ID GUAACAUUUG AACATTTGTTG

[0998] 557) NO: 559) UUG (SEQ ID (SEQ ID NO: 558)

[0999] NO: 560)

[1000]

[1001] Attorney Docket No. 063586-568001WO

[1002] Guide Target DNA Sequence Spacer gRNA PAM

[1003] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC ACACTGTTGG ACACUGUUG CUUUCAUUGA TTTCATTGACG

[1004] C2_S1_ TGGGACTGTA GUGGGACUG CGGACACUGU TTTT GACACTGTTGG GIO.6 (SEQ ID NO: UA (SEQ ID UGGUGGGACU TGGGACTGTA

[1005] 561) NO: 563) GUA (SEQ ID (SEQ ID NO: 562)

[1006] NO: 564) AGAAAUCCGU AGAAATCCGTC TTACACTGTT UUACACUGU CUUUCAUUGA TTTCATTGACG

[1007] C2_S1_ GGTGGGACT UGGUGGGAC CGGUUACACU ATTT GTTACACTGTT GIO.7 G (SEQ ID NO: UG (SEQ ID GUUGGUGGGA GGTGGGACTG

[1008] 565) NO: 567) CUG(SEQID (SEQ ID NO: 566)

[1009] NO: 568) AGAAAUCCGU AGAAATCCGTC AACCATCGA AACCAUCGA CUUUCAUUGA TTTCATTGACG

[1010] C2_S1_ GATGATCATA GAUGAUCAU CGGAACCAUC GTTC GAACCATCGA GIO.8 T (SEQ ID NO: AU (SEQ ID GAGAUGAUCA GATGATCATAT

[1011] 569) NO: 571) UAU (SEQ ID (SEQ ID NO: 570)

[1012] NO: 572) AGAAAUCCGU AGAAATCCGTC ACAGTCCCAC ACAGUCCCAC CUUUCAUUGA TTTCATTGACG

[1013] C2_S1_ CAACAGTGT CAACAGUGU CGGACAGUCC GTTT GACAGTCCCAC GIO.9 A (SEQ ID NO: A (SEQ ID NO: CACCAACAGU CAACAGTGTA

[1014] 573) 575) GUA (SEQ ID (SEQ ID NO: 574)

[1015] NO: 576) AGAAAUCCGU AGAAATCCGTC TACACTGTTG UACACUGUU CUUUCAUUGA TTTCATTGACG

[1016] C2_S1_ GTGGGACTGT GGUGGGACU CGGUACACUG TTTT GTACACTGTTG GIO.10 (SEQ ID NO: GU (SEQ ID UUGGUGGGAC GTGGGACTGT

[1017] 577) NO: 579) UGU (SEQ ID (SEQ ID NO: 578)

[1018] NO: 580) AGAAAUCCGU AGAAATCCGTC CCTCCAGGTT CCUCCAGGU CUUUCAUUGA TTTCATTGACG

[1019] C2_S1_ TGTCATATGT UUGUCAUAU CGGCCUCCAG ATTA GCCTCCAGGTT

[1020] G6.1 (SEQ ID NO: GU (SEQ ID GUUUGUCAUA TGTCATATGT

[1021] 581) NO: 583) UGU (SEQ ID (SEQ ID NO: 582)

[1022] NO: 584) AGAAAUCCGU AGAAATCCGTC ACCATTGAGT ACCAUUGAG CUUUCAUUGA TTTCATTGACG

[1023] C2_S1_ ATATTACCTC UAUAUUACC CGGACCAUUG TTTC GACCATTGAGT

[1024] G6.2 (SEQ ID NO: UC (SEQ ID AGUAUAUUAC ATATTACCTC

[1025] 585) NO: 587) CUC (SEQ ID (SEQ ID NO: 586)

[1026] NO: 588)

[1027]

[1028] Attorney Docket No. 063586-568001WO

[1029] Guide Target DNA Sequence Spacer gRNA PAM

[1030] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC ACTCTAAGAT ACUCUAAGA CUUUCAUUGA TTTCATTGACG

[1031] C2_S1_ CAGAACCAA UCAGAACCA CGGACUCUAA TTTG GACTCTAAGAT

[1032] G6.3 A (SEQ ID NO: AA (SEQ ID GAUCAGAACC CAGAACCAAA

[1033] 589) NO: 591) AAA (SEQ ID (SEQ ID NO: 590)

[1034] NO: 592) AGAAAUCCGU AGAAATCCGTC TCACCACTTA UCACCACUU CUUUCAUUGA TTTCATTGACG

[1035] C2_S1_ TATTTAACAT AUAUUUAAC CGGUCACCAC ATTC GTCACCACTTA

[1036] G6.4 (SEQ ID NO: AU (SEQ ID UUAUAUUUAA TATTTAACAT

[1037] 593) NO: 595) CAU (SEQ ID (SEQ ID NO: 594)

[1038] NO: 596) AGAAAUCCGU AGAAATCCGTC CTCTAGCTAG CUCUAGCUA CUUUCAUUGA TTTCATTGACG

[1039] C2_S1_ AATTTCAACT GAAUUUCAA CGGCUCUAGC ATTG GCTCTAGCTAG

[1040] G6.5 (SEQ ID NO: CU (SEQ ID UAGAAUUUCA AATTTCAACT

[1041] 597) NO: 599) ACU (SEQ ID (SEQ ID NO: 598)

[1042] NO: 600) AGAAATCCGTC AGAAAUCCGU TAGCTAGAG TTTCATTGACG UAGCUAGAG CUUUCAUUGA

[1043] C2_S1_ CAATTAGGC GTAGCTAGAG CAAUUAGGC CGGUAGCUAG ATTC

[1044] G6.6 AA (SEQ ID CAATTAGGCA AA (SEQ ID AGCAAUUAGG NO: 601) A (SEQ ID NO: NO: 603) CAA (SEQ ID 602) NO: 604) AGAAAUCCGU AGAAATCCGTC AACTACTATG AACUACUAU CUUUCAUUGA TTTCATTGACG

[1045] C2_S1_ TTAAATATAA GUUAAAUAU CGGAACUACU TTTC GAACTACTATG

[1046] G6.7 (SEQ ID NO: AA (SEQ ID AUGUUAAAUA TTAAATATAA

[1047] 605) NO: 607) UAA (SEQ ID (SEQ ID NO: 606)

[1048] NO: 608) AGAAAUCCGU AGAAATCCGTC ACCTGGCAA ACCUGGCAA CUUUCAUUGA TTTCATTGACG

[1049] C2_S1_ ATCTGTTCCT AUCUGUUCC CGGACCUGGC CTTT GACCTGGCAA

[1050] G3.1 C (SEQ ID NO: UC (SEQ ID AAAUCUGUUC ATCTGTTCCTC

[1051] 609) NO: 611) CUC (SEQ ID (SEQ ID NO: 610)

[1052] NO: 612) AGAAAUCCGU AGAAATCCGTC GCCAGGTAA GCCAGGUAA CUUUCAUUGA TTTCATTGACG

[1053] C2_S1_ AGCGTTGGTT AGCGUUGGU CGGGCCAGGU ATTT GGCCAGGTAA

[1054] G3.2 G (SEQ ID NO: UG (SEQ ID AAAGCGUUGG AGCGTTGGTTG

[1055] 613) NO: 615) UUG (SEQ ID (SEQ ID NO: 614)

[1056] NO: 616) AGAAATCCGTC AGAAAUCCGU CTCAGAAAT TTTCATTGACG CUCAGAAAU CUUUCAUUGA

[1057] C2_S1_ GAAGGAGAG GCTCAGAAAT GAAGGAGAG CGGCUCAGAA GTTC

[1058] G3.3 AG (SEQ ID GAAGGAGAGA AG (SEQ ID AUGAAGGAGA NO: 617) G (SEQ ID NO: NO: 619) GAG (SEQ ID

[1059]

[1060] 618) NO: 620)Attorney Docket No. 063586-568001WO

[1061] Guide Target DNA Sequence Spacer gRNA PAM

[1062] Name* Sequence for gRNA Sequence Sequence AGAAATCCGTC AGAAAUCCGU CCTAGACAA TTTCATTGACG CCUAGACAA CUUUCAUUGA

[1063] C2_S1_ ACAAAAGCT GCCTAGACAA ACAAAAGCU CGGCCUAGAC CTTT

[1064] G3.4 GA (SEQ ID ACAAAAGCTG GA (SEQ ID AAACAAAAGC NO: 621) A (SEQ ID NO: NO: 623) UGA (SEQ ID 622) NO: 624) AGAAAUCCGU AGAAATCCGTC TGAGGAACA UGAGGAACA CUUUCAUUGA TTTCATTGACG

[1065] C2_S1_ GATTTGCCAG GAUUUGCCA CGGUGAGGAA TTTC GTGAGGAACA

[1066] G3.5 G (SEQ ID NO: GG (SEQ ID CAGAUUUGCC GATTTGCCAGG

[1067] 625) NO: 627) AGG (SEQ ID (SEQ ID NO: 626)

[1068] NO: 628) AGAAAUCCGU AGAAATCCGTC TCTCTCCTTC ucucuccuuc CUUUCAUUGA TTTCATTGACG

[1069] C2_S1_ ATTTCTGAGG AUUUCUGAG CGGUCUCUCC CTTC GTCTCTCCTTC

[1070] G3.6 (SEQ ID NO: G (SEQ ID NO: UUCAUUUCUG ATTTCTGAGG

[1071] 629) 631) AGG (SEQ ID (SEQ ID NO: 630)

[1072] NO: 632) AGAAAUCCGU AGAAATCCGTC TTCTCTCTCC uucucucucc CUUUCAUUGA TTTCATTGACG

[1073] C2_S1_ TTCATTTCTG UUCAUUUCU CGGUUCUCUC GTTC GTTCTCTCTCC

[1074] G3.7 (SEQ ID NO: G (SEQ ID NO: UCCUUCAUUU TTCATTTCTG

[1075] 633) 635) CUG(SEQID (SEQ ID NO: 634)

[1076] NO: 636) AGAAAUCCGU AGAAATCCGTC TGTTTGTCTA UGUUUGUCU CUUUCAUUGA TTTCATTGACG

[1077] C2_S1_ GGAAAGTTCT AGGAAAGUU CGGUGUUUGU CTTT GTGTTTGTCTA

[1078] G3.8 (SEQ ID NO: CU (SEQ ID CUAGGAAAGU GGAAAGTTCT

[1079] 637) NO: 639) UCU (SEQ ID (SEQ ID NO: 638)

[1080] NO: 640) AGAAAUCCGU AGAAATCCGTC CCTGGCAAAT CCUGGCAAA CUUUCAUUGA TTTCATTGACG

[1081] C2_S1_ CTGTTCCTCA UCUGUUCCU CGGCCUGGCA TTTA GCCTGGCAAAT

[1082] G3.9 (SEQ ID NO: CA (SEQ ID AAUCUGUUCC CTGTTCCTCA

[1083] 641) NO: 643) UCA (SEQ ID (SEQ ID NO: 642)

[1084] NO: 644) AGAAAUCCGU AGAAATCCGTC ATTTCTGAGG AUUUCUGAG CUUUCAUUGA TTTCATTGACG

[1085] C2_S1_ AACAGATTTG GAACAGAUU CGGAUUUCUG CTTC GATTTCTGAGG

[1086] G3.10 (SEQ ID NO: UG (SEQ ID AGGAACAGAU AACAGATTTG

[1087] 645) NO: 647) UUG (SEQ ID (SEQ ID NO: 646)

[1088] NO: 648) AGAAAUCCGU AGAAATCCGTC ACTGATTCTT ACUGAUUCU CUUUCAUUGA TTTCATTGACG

[1089] C2_S1_ TCTTCTGCCT UUCUUCUGC CGGACUGAUU GTTC GACTGATTCTT

[1090] G7.1 (SEQ ID NO: CU (SEQ ID CUUUCUUCUG TCTTCTGCCT

[1091] 649) NO: 651) CCU (SEQ ID (SEQ ID NO: 650)

[1092]

[1093] NO: 652)Attorney Docket No. 063586-568001WO

[1094] Guide Target DNA Sequence Spacer gRNA PAM

[1095] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC AAGATATGTC AAGAUAUGU CUUUCAUUGA TTTCATTGACG

[1096] C2_S1_ AACTGAGATT CAACUGAGA CGGAAGAUAU CTTG GAAGATATGTC

[1097] G7.2 (SEQ ID NO: UU (SEQ ID GUCAACUGAG AACTGAGATT

[1098] 653) NO: 655) AUU (SEQ ID (SEQ ID NO: 654)

[1099] NO: 656) AGAAAUCCGU AGAAATCCGTC ACATATCTTC ACAUAUCUU CUUUCAUUGA TTTCATTGACG

[1100] C2_S1_ AAGTTCACTG CAAGUUCAC CGGACAUAUC GTTG GACATATCTTC

[1101] G7.3 (SEQ ID NO: UG (SEQ ID UUCAAGUUCA AAGTTCACTG

[1102] 657) NO: 659) CUG(SEQID (SEQ ID NO: 658)

[1103] NO: 700) AGAAAUCCGU AGAAATCCGTC CTCAGACTGG CUCAGACUG CUUUCAUUGA TTTCATTGACG

[1104] C2_S1_ ATAATCTCAG GAUAAUCUC CGGCUCAGAC GTTG GCTCAGACTGG

[1105] G7.4 (SEQ ID NO: AG (SEQ ID UGGAUAAUCU ATAATCTCAG

[1106] 701) NO: 703) CAG(SEQID (SEQ ID NO: 702)

[1107] NO: 704) AGAAAUCCGU AGAAATCCGTC TCCAGTCTGA UCCAGUCUG CUUUCAUUGA TTTCATTGACG

[1108] C2_S1_ GCAACAAAG AGCAACAAA CGGUCCAGUC ATTA GTCCAGTCTGA

[1109] G7.5 G (SEQ ID NO: GG (SEQ ID UGAGCAACAA GCAACAAAGG

[1110] 705) NO: 707) AGG (SEQ ID (SEQ ID NO: 706)

[1111] NO: 708) AGAAAUCCGU AGAAATCCGTC GTATGAGAG GUAUGAGAG CUUUCAUUGA TTTCATTGACG

[1112] C2_S1_ ATGCTGTTCT AUGCUGUUC CGGGUAUGAG ATTG GGTATGAGAG

[1113] G7.6 A (SEQ ID NO: UA (SEQ ID AGAUGCUGUU ATGCTGTTCTA

[1114] 709) NO: 711) CUA (SEQ ID (SEQ ID NO: 710)

[1115] NO: 712) AGAAAUCCGU AGAAATCCGTC TTTGTTGCTC UUUGUUGCU CUUUCAUUGA TTTCATTGACG

[1116] C2_S1_ AGTTTTCTTC CAGUUUUCU CGGUUUGUUG GTTC GTTTGTTGCTC

[1117] G7.7 (SEQ ID NO: UC (SEQ ID CUCAGUUUUC AGTTTTCTTC

[1118] 713) NO: 715) UUC (SEQ ID (SEQ ID NO: 714)

[1119] NO: 716) AGAAAUCCGU AGAAATCCGTC TACAGTTCTT UACAGUUCU CUUUCAUUGA TTTCATTGACG

[1120] C2_S1_ TGTTGCTCAG UUGUUGCUC CGGUACAGUU GTTC GTACAGTTCTT

[1121] G7.8 (SEQ ID NO: AG (SEQ ID CUUUGUUGCU TGTTGCTCAG

[1122] 717) NO: 719) CAG(SEQID (SEQ ID NO: 718)

[1123] NO: 720) AGAAAUCCGU AGAAATCCGTC CTCAGTTTTC CUCAGUUUU CUUUCAUUGA TTTCATTGACG

[1124] C2_S1_ TTCATTTTTT CUUCAUUUU CGGCUCAGUU GTTG GCTCAGTTTTC

[1125] G7.9 (SEQ ID NO: UU (SEQ ID UUCUUCAUUU TTCATTTTTT

[1126] 721) NO: 723) UUU (SEQ ID (SEQ ID NO: 722)

[1127]

[1128] NO: 724)Attorney Docket No. 063586-568001WO

[1129] Guide Target DNA Sequence Spacer gRNA PAM

[1130] Name* Sequence for gRNA Sequence Sequence AGAAATCCGTC AGAAAUCCGU AAAAAATAT TTTCATTGACG AAAAAAUAU CUUUCAUUGA

[1131] C2_S1_ AGCACTTGA GAAAAAATAT AGCACUUGA CGGAAAAAAU TTTA

[1132] G9.1 GG (SEQ ID AGCACTTGAG GG (SEQ ID AUAGCACUUG NO: 725) G (SEQ ID NO: NO: 727) AGG (SEQ ID 726) NO: 728) AGAAAUCCGU AGAAATCCGTC AGGCTGGGC AGGCUGGGC CUUUCAUUGA TTTCATTGACG

[1133] C2_S1_ ATGGTGGCCC AUGGUGGCC CGGAGGCUGG CTTG GAGGCTGGGC

[1134] G9.2 T (SEQ ID NO: CU (SEQ ID GCAUGGUGGC ATGGTGGCCCT

[1135] 729) NO: 731) CCU (SEQ ID (SEQ ID NO: 730)

[1136] NO: 732) AGAAAUCCGU AGAAATCCGTC TATATATAAT UAUAUAUAA CUUUCAUUGA TTTCATTGACG

[1137] C2_S1_ ATATATAAA UAUAUAUAA CGGUAUAUAU ATTA GTATATATAAT

[1138] G9.3 A (SEQ ID NO: AA (SEQ ID AAUAUAUAUA ATATATAAAA

[1139] 733) NO: 735) AAA (SEQ ID (SEQ ID NO: 734)

[1140] NO: 736) AGAAAUCCGU AGAAATCCGTC ATATATATTA AUAUAUAUU CUUUCAUUGA TTTCATTGACG

[1141] C2_S1_ TATATATAAT AUAUAUAUA CGGAUAUAUA TTTT GATATATATTA

[1142] G9.4 (SEQ ID NO: AU (SEQ ID UUAUAUAUAU TATATATAAT

[1143] 737) NO: 739) AAU (SEQ ID (SEQ ID NO: 738)

[1144] NO: 740) AGAAAUCCGU AGAAATCCGTC AGGGCCACC AGGGCCACC CUUUCAUUGA TTTCATTGACG

[1145] C2_S1_ ATGCCCAGCC AUGCCCAGCC CGGAGGGCCA ATTG GAGGGCCACC

[1146] G9.5 T (SEQ ID NO: U (SEQ ID NO: CCAUGCCCAG ATGCCCAGCCT

[1147] 741) 743) CCU (SEQ ID (SEQ ID NO: 742)

[1148] NO: 744) AGAAAUCCGU AGAAATCCGTC TGTTATTGAT UGUUAUUGA CUUUCAUUGA TTTCATTGACG

[1149] C2_S2_ TTCTAGTTTT UUUCUAGUU CGGUGUUAUU CTTC GTGTTATTGAT

[1150] Gl.l (SEQ ID NO: UU (SEQ ID GAUUUCUAGU TTCTAGTTTT

[1151] 745) NO: 747) UUU (SEQ ID (SEQ ID NO: 746)

[1152] NO: 748) AGAAAUCCGU AGAAATCCGTC ATTTCTAGTT AUUUCUAGU CUUUCAUUGA TTTCATTGACG

[1153] C2_S2_ TTATTCCATT UUUAUUCCA CGGAUUUCUA ATTG GATTTCTAGTT

[1154] G1.2 (SEQ ID NO: UU (SEQ ID GUUUUAUUCC TTATTCCATT

[1155] 749) NO: 751) AUU (SEQ ID (SEQ ID NO: 750)

[1156] NO: 752) AGAAAUCCGU AGAAATCCGTC CTAGTTTTAT CUAGUUUUA CUUUCAUUGA TTTCATTGACG

[1157] C2_S2_ TCCATTGTGA UUCCAUUGU CGGCUAGUUU ATTT GCTAGTTTTAT

[1158] G1.3 (SEQ ID NO: GA (SEQ ID UAUUCCAUUG TCCATTGTGA

[1159] 753) NO: 755) UGA (SEQ ID (SEQ ID NO: 754)

[1160]

[1161] NO: 756)Attorney Docket No. 063586-568001WO

[1162] Guide Target DNA Sequence Spacer gRNA PAM

[1163] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC TATTCCATTG UAUUCCAUU CUUUCAUUGA TTTCATTGACG

[1164] C2_S2_ TGATCACAG GUGAUCACA CGGUAUUCCA GTTT GTATTCCATTG

[1165] G1.4 A (SEQ ID NO: GA (SEQ ID UUGUGAUCAC TGATCACAGA

[1166] 757) NO: 759) AGA (SEQ ID (SEQ ID NO: 758)

[1167] NO: 760) AGAAAUCCGU AGAAATCCGTC CATTGTGATC CAUUGUGAU CUUUCAUUGA TTTCATTGACG

[1168] C2_S2_ ACAGAAGAT CACAGAAGA CGGCAUUGUG ATTC GCATTGTGATC

[1169] G1.5 A (SEQ ID NO: UA (SEQ ID AUCACAGAAG ACAGAAGATA

[1170] 761) NO: 763) AUA (SEQ ID (SEQ ID NO: 762)

[1171] NO: 764) AGAAAUCCGU AGAAATCCGTC GTATAATCGC GUAUAAUCG CUUUCAUUGA TTTCATTGACG

[1172] C2_S2_ AGTCTATTAA CAGUCUAUU CGGGUAUAAU TTTT GGTATAATCGC

[1173] G1.6 (SEQ ID NO: AA (SEQ ID CGCAGUCUAU AGTCTATTAA

[1174] 765) NO: 767) UAA (SEQ ID (SEQ ID NO: 766)

[1175] NO: 768) AGAAAUCCGU AGAAATCCGTC ATTAAGTCTT AUUAAGUCU CUUUCAUUGA TTTCATTGACG

[1176] C2_S2_ GTGGCCTAAC UGUGGCCUA CGGAUUAAGU ATTT GATTAAGTCTT

[1177] G1.7 (SEQ ID NO: AC (SEQ ID CUUGUGGCCU GTGGCCTAAC

[1178] 769) NO: 771) AAC (SEQ ID (SEQ ID NO: 770)

[1179] NO: 772) AGAAAUCCGU AGAAATCCGTC GAGAATGTTC GAGAAUGUU CUUUCAUUGA TTTCATTGACG

[1180] C2_S2_ CAAGTGCAA CCAAGUGCA CGGGAGAAUG GTTG GGAGAATGTTC

[1181] G1.8 T (SEQ ID NO: AU (SEQ ID UUCCAAGUGC CAAGTGCAAT

[1182] 773) NO: 775) AAU (SEQ ID (SEQ ID NO: 774)

[1183] NO: 776) AGAAAUCCGU AGAAATCCGTC TGGTGCTATT UGGUGCUAU CUUUCAUUGA TTTCATTGACG

[1184] C2_S2_ AGGTGAAGT UAGGUGAAG CGGUGGUGCU ATTC GTGGTGCTATT

[1185] G1.9 A (SEQ ID NO: UA (SEQ ID AUUAGGUGAA AGGTGAAGTA

[1186] 777) NO: 779) GUA (SEQ ID (SEQ ID NO: 778)

[1187] NO: 780) AGAAAUCCGU AGAAATCCGTC TCTATATGTC UCUAUAUGU CUUUCAUUGA TTTCATTGACG

[1188] C2_S2_ TGTTAAGTCC CUGUUAAGU CGGUCUAUAU ATTC GTCTATATGTC

[1189] G1.10 (SEQ ID NO: CC (SEQ ID GUCUGUUAAG TGTTAAGTCC

[1190] 781) NO: 783) UCC (SEQ ID (SEQ ID NO: 782)

[1191] NO: 784) AGAAAUCCGU AGAAATCCGTC ACGTTTCCTG ACGUUUCCU CUUUCAUUGA TTTCATTGACG

[1192] C2_S2_ TTCCTTACTG GUUCCUUAC CGGACGUUUC GTTG GACGTTTCCTG

[1193] Gl.ll (SEQ ID NO: UG (SEQ ID CUGUUCCUUA TTCCTTACTG

[1194] 785) NO: 787) CUG(SEQID (SEQ ID NO: 786)

[1195]

[1196] NO: 788)Attorney Docket No. 063586-568001WO

[1197] Guide Target DNA Sequence Spacer gRNA PAM

[1198] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC ACAGACATA ACAGACAUA CUUUCAUUGA TTTCATTGACG

[1199] C2_S2_ TAGAGAATA UAGAGAAUA CGGACAGACA CTTA GACAGACATA

[1200] G1.13 CT (SEQ ID CU (SEQ ID UAUAGAGAAU TAGAGAATACT NO: 789) NO: 791) ACU (SEQ ID (SEQ ID NO: 790)

[1201] NO: 792) AGAAAUCCGU AGAAATCCGTC TCAATTGCAC UCAAUUGCA CUUUCAUUGA TTTCATTGACG

[1202] C2_S2_ TTGGAACATT CUUGGAACA CGGUCAAUUG ATTC GTCAATTGCAC GE 14 (SEQ ID NO: UU (SEQ ID CACUUGGAAC TTGGAACATT

[1203] 793) NO: 795) AUU (SEQ ID (SEQ ID NO: 794)

[1204] NO: 796) AGAAAUCCGU AGAAATCCGTC ATAAATGTTA AUAAAUGUU CUUUCAUUGA TTTCATTGACG

[1205] C2_S2_ ATAGACTGC AAUAGACUG CGGAUAAAUG CTTA GATAAATGTTA

[1206] G1.15 G (SEQ ID NO: CG(SEQID UUAAUAGACU ATAGACTGCG

[1207] 797) NO: 799) GCG(SEQID (SEQ ID NO: 798)

[1208] NO: 800) AGAAAUCCGU AGAAATCCGTC TTCTGTTATC UUCUGUUAU CUUUCAUUGA TTTCATTGACG

[1209] C2_S2_ TTTTGTAAGA CUUUUGUAA CGGUUCUGUU ATTG GTTCTGTTATC

[1210] G2.1 (SEQ ID NO: GA (SEQ ID AUCUUUUGUA TTTTGTAAGA

[1211] 801) NO: 803) AGA (SEQ ID (SEQ ID NO: 802)

[1212] NO: 804) AGAAAUCCGU AGAAATCCGTC TAGAACATTT UAGAACAUU CUUUCAUUGA TTTCATTGACG

[1213] C2_S2_ TGCCCTCAGA UUGCCCUCA CGGUAGAACA TTTC GTAGAACATTT

[1214] G2.2 (SEQ ID NO: GA (SEQ ID UUUUGCCCUC TGCCCTCAGA

[1215] 805) NO: 807) AGA (SEQ ID (SEQ ID NO: 806)

[1216] NO: 808) AGAAAUCCGU AGAAATCCGTC AATGCCAAC AAUGCCAAC CUUUCAUUGA TTTCATTGACG

[1217] C2_S2_ GTATTTCTCA GUAUUUCUC CGGAAUGCCA CTTA GAATGCCAAC

[1218] G2.3 C (SEQ ID NO: AC (SEQ ID ACGUAUUUCU GTATTTCTCAC

[1219] 809) NO: 811) CAC (SEQ ID (SEQ ID NO: 810)

[1220] NO: 812) AGAAAUCCGU AGAAATCCGTC CTCACTTATT CUCACUUAU CUUUCAUUGA TTTCATTGACG

[1221] C2_S2_ GTTTACTGCT UGUUUACUG CGGCUCACUU ATTT GCTCACTTATT

[1222] G2.4 (SEQ ID NO: CU (SEQ ID AUUGUUUACU GTTTACTGCT

[1223] 813) NO: 815) GCU (SEQ ID (SEQ ID NO: 814)

[1224] NO: 816) AGAAAUCCGU AGAAATCCGTC TTTACTGCTT UUUACUGCU CUUUCAUUGA TTTCATTGACG

[1225] C2_S2_ TTGGATTTAC UUUGGAUUU CGGUUUACUG ATTG GTTTACTGCTT

[1226] G2.5 (SEQ ID NO: AC (SEQ ID CUUUUGGAUU TTGGATTTAC

[1227] 817) NO: 819) UAC (SEQ ID (SEQ ID NO: 818)

[1228]

[1229] NO: 820)Attorney Docket No. 063586-568001WO

[1230] Guide Target DNA Sequence Spacer gRNA PAM

[1231] Name* Sequence for gRNA Sequence Sequence AGAAAUCCGU AGAAATCCGTC ACATATGATT ACAUAUGAU CUUUCAUUGA TTTCATTGACG

[1232] C2_S2_ TGATTCTTTC UUGAUUCUU CGGACAUAUG ATTT GACATATGATT

[1233] G2.6 (SEQ ID NO: UC (SEQ ID AUUUGAUUCU TGATTCTTTC

[1234] 821) NO: 823) UUC (SEQ ID (SEQ ID NO: 822)

[1235] NO: 824) AGAAAUCCGU AGAAATCCGTC TCCTTACAAT UCCUUACAA CUUUCAUUGA TTTCATTGACG

[1236] C2_S2_ GTAATTCAAA UGUAAUUCA CGGUCCUUAC CTTA GTCCTTACAAT

[1237] G2.7 (SEQ ID NO: AA (SEQ ID AAUGUAAUUC GTAATTCAAA

[1238] 825) NO: 827) AAA (SEQ ID (SEQ ID NO: 826)

[1239] NO: 828) AGAAAUCCGU AGAAATCCGTC AACTTAAATT AACUUAAAU CUUUCAUUGA TTTCATTGACG

[1240] C2_S2_ GGCATCAGTT UGGCAUCAG CGGAACUUAA ATTG GAACTTAAATT

[1241] G2.8 (SEQ ID NO: UU (SEQ ID AUUGGCAUCA GGCATCAGTT

[1242] 829) NO: 831) GUU (SEQ ID (SEQ ID NO: 830)

[1243] NO: 832) AGAAAUCCGU AGAAATCCGTC GCATCAGTTT GCAUCAGUU CUUUCAUUGA TTTCATTGACG

[1244] C2_S2_ GAATTACATT UGAAUUACA CGGGCAUCAG ATTG GGCATCAGTTT

[1245] G2.9 (SEQ ID NO: UU (SEQ ID UUUGAAUUAC GAATTACATT

[1246] 833) NO: 835) AUU (SEQ ID (SEQ ID NO: 834)

[1247] NO: 836) AGAAAUCCGU AGAAATCCGTC CATTGTAAGG CAUUGUAAG CUUUCAUUGA TTTCATTGACG

[1248] C2_S2_ ATAAGAGAT GAUAAGAGA CGGCAUUGUA ATTA GCATTGTAAGG

[1249] G2.10 A (SEQ ID NO: UA (SEQ ID AGGAUAAGAG ATAAGAGATA

[1250] 837) NO: 839) AUA (SEQ ID (SEQ ID NO: 838)

[1251] NO: 840) AGAAAUCCGU AGAAATCCGTC AGTCTGAGG AGUCUGAGG CUUUCAUUGA TTTCATTGACG

[1252] C2_S2_ GCAAAATGTT GCAAAAUGU CGGAGUCUGA TTTA GAGTCTGAGG

[1253] G2.ll C (SEQ ID NO: UC (SEQ ID GGGCAAAAUG GCAAAATGTTC

[1254] 841) NO: 843) UUC (SEQ ID (SEQ ID NO: 842)

[1255] NO: 844) AGAAAUCCGU AGAAATCCGTC TAGAAATCTT UAGAAAUCU CUUUCAUUGA TTTCATTGACG

[1256] C2_S2_ ACAAAAGAT UACAAAAGA CGGUAGAAAU GTTC GTAGAAATCTT

[1257] G2.12 A (SEQ ID NO: UA (SEQ ID CUUACAAAAG ACAAAAGATA

[1258] 845) NO: 847) AUA (SEQ ID (SEQ ID NO: 846)

[1259] NO: 848) AGAAATCCGTC AGAAAUCCGU CAAAAGATA TTTCATTGACG CAAAAGAUA CUUUCAUUGA

[1260] C2_S2_ ACAGAACAA GCAAAAGATA ACAGAACAA CGGCAAAAGA CTTA

[1261] G2.13 TT (SEQ ID ACAGAACAAT UU (SEQ ID UAACAGAACA NO: 849) T (SEQ ID NO: NO: 851) AUU (SEQ ID

[1262]

[1263] 850) NO: 852)Attorney Docket No. 063586-568001WO

[1264] Guide Target DNA Sequence Spacer gRNA PAM

[1265] Name* Sequence for gRNA Sequence Sequence CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU ACTCTAAGAT ACUCUAAGA AGGTATTAAAC AUAGGUAUUA

[1266] D1 S1- CAGAACCAA UCAGAACCA

[1267] TTTG AACACTCTAAG AACAACACUC

[1268] G6.1 A (SEQ ID NO: AA (SEQ ID ATCAGAACCA UAAGAUCAGA

[1269] 589) NO: 591)

[1270] AA (SEQ ID NO: ACCAAA (SEQ 853) ID NO: 854) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TATTTAACAT UAUUUAACA AGGTATTAAAC AUAGGUAUUA

[1271] D1 S1- AGTAGTTGA UAGUAGUUG

[1272] CTTA AACTATTTAAC AACAACUAUU

[1273] G6.2 A (SEQ ID NO: AA (SEQ ID ATAGTAGTTGA UAACAUAGUA

[1274] 855) NO: 857)

[1275] A (SEQ ID NO: GUUGAA (SEQ 856) ID NO: 858) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU ACATAGTAGT ACAUAGUAG AGGTATTAAAC AUAGGUAUUA

[1276] D1 S1- TGAAATTCTA UUGAAAUUC

[1277] TTTA AACACATAGT AACAACACAU

[1278] G6.3 (SEQ ID NO: UA (SEQ ID AGTTGAAATTC AGUAGUUGAA

[1279] 859) NO: 861)

[1280] TA (SEQ ID NO: AUUCUA (SEQ 860) ID NO: 862) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU AAATTCTAGC AAAUUCUAG AGGTATTAAAC AUAGGUAUUA

[1281] D1 S1- TAGAGCAATT CUAGAGCAA

[1282] GTTG AACAAATTCTA AACAACAAAU

[1283] G6.4 (SEQ ID NO: UU (SEQ ID GCTAGAGCAA UCUAGCUAGA

[1284] 863) NO: 865)

[1285] TT (SEQ ID NO: GCAAUU (SEQ 864) ID NO: 866) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CCTAATTGCT CCUAAUUGC AGGTATTAAAC AUAGGUAUUA

[1286] D1 S1- CTAGCTAGA UCUAGCUAG

[1287] CTTG AACCCTAATTG AACAACCCUA

[1288] G6.5 A (SEQ ID NO: AA (SEQ ID CTCTAGCTAGA AUUGCUCUAG

[1289] 867) NO: 869)

[1290] A (SEQ ID NO: CUAGAA (SEQ 868) ID NO: 870) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CTCTAGCTAG CUCUAGCUA AGGTATTAAAC AUAGGUAUUA

[1291] D1 S1- AATTTCAACT GAAUUUCAA

[1292] ATTG AACCTCTAGCT AACAACCUCU

[1293] G6.6 (SEQ ID NO: CU (SEQ ID AGAATTTCAAC AGCUAGAAUU

[1294] 597) NO: 599)

[1295] T (SEQ ID NO: UCAACU (SEQ 871) ID NO: 872) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU AATATAAGT AAUAUAAGU AGGTATTAAAC AUAGGUAUUA

[1296] D1 S1- GGTGAGAAT GGUGAGAAU

[1297] GTTA AACAATATAA AACAACAAUA

[1298] G6.7 GG (SEQ ID GG (SEQ ID GTGGTGAGAA UAAGUGGUGA NO: 873) NO: 875)

[1299] TGG(SEQID GAAUGG (SEQ

[1300]

[1301] NO: 874) ID NO: 876)Attorney Docket No. 063586-568001WO

[1302] Guide Target DNA Sequence Spacer gRNA PAM

[1303] Name* Sequence for gRNA Sequence Sequence CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TTTTGGTTCT UUUUGGUUC AGGTATTAAAC AUAGGUAUUA

[1304] D1 S1- GATCTTAGAG UGAUCUUAG

[1305] CTTG AACTTTTGGTT AACAACUUUU

[1306] G6.8 (SEQ ID NO: AG (SEQ ID CTGATCTTAGA GGUUCUGAUC

[1307] 877) NO: 879)

[1308] G (SEQ ID NO: UUAGAG (SEQ 878) ID NO: 880) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU GTTCTGATCT GUUCUGAUC AGGTATTAAAC AUAGGUAUUA

[1309] D1 S1- TAGAGTCAA UUAGAGUCA

[1310] TTTG AACGTTCTGAT AACAACGUUC

[1311] G6.9 A (SEQ ID NO: AA (SEQ ID CTTAGAGTCAA UGAUCUUAGA

[1312] 881) NO: 883)

[1313] A (SEQ ID NO: GUCAAA (SEQ 882) ID NO: 884) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU GAGTCAAAG GAGUCAAAG AGGTATTAAAC AUAGGUAUUA

[1314] D1 S1- CTTTTTACTT CUUUUUACU

[1315] CTTA AACGAGTCAA AACAACGAGU

[1316] G6.10 T (SEQ ID NO: UU (SEQ ID AGCTTTTTACT CAAAGCUUUU

[1317] 885) NO: 887)

[1318] TT (SEQ ID NO: UACUUU (SEQ 886) ID NO: 888) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TCTAGGAAA UCUAGGAAA AGGTATTAAAC AUAGGUAUUA

[1319] D1 S1- GTTCTTCTCT GUUCUUCUC

[1320] TTTG AACTCTAGGA AACAACUCUA

[1321] G3.1 C (SEQ ID NO: UC (SEQ ID AAGTTCTTCTC GGAAAGUUCU

[1322] 889) NO: 891)

[1323] TC (SEQ ID NO: UCUCUC (SEQ 890) ID NO: 892) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TTTGTCTAGG UUUGUCUAG AGGTATTAAAC AUAGGUAUUA

[1324] D1 S1- AAAGTTCTTC GAAAGUUCU

[1325] TTTG AACTTTGTCTA AACAACUUUG

[1326] G3.2 (SEQ ID NO: UC (SEQ ID GGAAAGTTCTT UCUAGGAAAG

[1327] 893) NO: 895)

[1328] C (SEQ ID NO: UUCUUC (SEQ 894) ID NO: 896) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU GCATTTTTTT GCAUUUUUU AGGTATTAAAC AUAGGUAUUA

[1329] D1 S1- CCTTGCAGCA UCCUUGCAG

[1330] GTTG AACGCATTTTT AACAACGCAU

[1331] G3.3 (SEQ ID NO: CA (SEQ ID TTCCTTGCAGC UUUUUUCCUU

[1332] 897) NO: 899)

[1333] A (SEQ ID NO: GCAGCA (SEQ 898) ID NO: 900) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TCCTCTTTGT UCCUCUUUG AGGTATTAAAC AUAGGUAUUA

[1334] D1 S1- GCCATATTTT UGCCAUAUU

[1335] CTTA AACTCCTCTTT AACAACUCCU

[1336] G5.1 (SEQ ID NO: UU (SEQ ID GTGCCATATTT CUUUGUGCCA

[1337] 901) NO: 903)

[1338] T (SEQ ID NO: UAUUUU (SEQ

[1339]

[1340] 902) ID NO: 904)Attorney Docket No. 063586-568001WO

[1341] Guide Target DNA Sequence Spacer gRNA PAM

[1342] Name* Sequence for gRNA Sequence Sequence CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TCCAGTCTGA UCCAGUCUG AGGTATTAAAC AUAGGUAUUA

[1343] D1 S1- GCAACAAAG AGCAACAAA

[1344] ATTA AACTCCAGTCT AACAACUCCA

[1345] G7.1 G (SEQ ID NO: GG (SEQ ID GAGCAACAAA GUCUGAGCAA

[1346] 705) NO: 707)

[1347] GG (SEQ ID NO: CAAAGG(SEQ 905) ID NO: 906)

[1348] CUUGUUGUAU CTTGTTGTATA AUGUCCUUUU TTGCTCAGTT TGTCCTTTTAT UUGCUCAGU AUAGGUAUUA

[1349] D1 S1- TTCTTCATTT AGGTATTAAAC UUUCUUCAU

[1350] TTTG AACAACUUGC

[1351] G7.2 (SEQ ID NO: AACTTGCTCAG UU (SEQ ID UCAGUUUUCU

[1352] 907) TTTTCTTCATTT NO: 909)

[1353] UCAUUU (SEQ (SEQ ID NO: 908)

[1354] ID NO: 910) CUUGUUGUAU CTTGTTGTATA AUGUCCUUUU CTCAGTTTTC TGTCCTTTTAT CUCAGUUUU AUAGGUAUUA

[1355] D1 S1- TTCATTTTTT AGGTATTAAAC CUUCAUUUU

[1356] GTTG AACAACCUCA

[1357] G7.3 (SEQ ID NO: AACCTCAGTTT UU (SEQ ID GUUUUCUUCA

[1358] 721) TCTTCATTTTTT NO: 723)

[1359] UUUUUU (SEQ (SEQ ID NO: 911)

[1360] ID NO: 912) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TTGCTCAGAC UUGCUCAGA AGGTATTAAAC AUAGGUAUUA

[1361] D1 S1- TGGATAATCT CUGGAUAAU

[1362] TTTG AACTTGCTCAG AACAACUUGC

[1363] G7.4 (SEQ ID NO: CU (SEQ ID ACTGGATAATC UCAGACUGGA

[1364] 913) NO: 915)

[1365] T (SEQ ID NO: UAAUCU (SEQ 914) ID NO: 916) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CTCAGACTGG CUCAGACUG AGGTATTAAAC AUAGGUAUUA

[1366] D1 S1- ATAATCTCAG GAUAAUCUC

[1367] GTTG AACCTCAGACT AACAACCUCA

[1368] G7.5 (SEQ ID NO: AG (SEQ ID GGATAATCTCA GACUGGAUAA

[1369] 701) NO: 703)

[1370] G (SEQ ID NO: UCUCAG(SEQ 917) ID NO: 918) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU ACATATCTTC ACAUAUCUU AGGTATTAAAC AUAGGUAUUA

[1371] D1 S1- AAGTTCACTG CAAGUUCAC

[1372] GTTG AACACATATCT AACAACACAU

[1373] G7.6 (SEQ ID NO: UG (SEQ ID TCAAGTTCACT AUCUUCAAGU

[1374] 657) NO: 659)

[1375] G (SEQ ID NO: UCACUG(SEQ 919) ID NO: 920) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TATATATAAT UAUAUAUAA AGGTATTAAAC AUAGGUAUUA

[1376] D1 S1- ATATATAAA UAUAUAUAA

[1377] ATTA AACTATATATA AACAACUAUA

[1378] G9.1 A (SEQ ID NO: AA (SEQ ID ATATATATAAA UAUAAUAUAU

[1379] 733) NO: 735)

[1380] A (SEQ ID NO: AUAAAA (SEQ

[1381]

[1382] 921) ID NO: 922)Attorney Docket No. 063586-568001WO

[1383] Guide Target DNA Sequence Spacer gRNA PAM

[1384] Name* Sequence for gRNA Sequence Sequence CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TATATATTAT UAUAUAUUA AGGTATTAAAC AUAGGUAUUA

[1385] D1 S1- ATATATAATT UAUAUAUAA

[1386] TTTA AACTATATATT AACAACUAUA

[1387] G9.2 (SEQ ID NO: UU (SEQ ID ATATATATAAT UAUUAUAUAU

[1388] 923) NO: 925)

[1389] T (SEQ ID NO: AUAAUU (SEQ 924) ID NO: 926) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TATATATAAT UAUAUAUAA AGGTATTAAAC AUAGGUAUUA

[1390] D1 S1- TGAGGGCCA UUGAGGGCC

[1391] ATTA AACTATATATA AACAACUAUA

[1392] G9.3 C (SEQ ID NO: AC (SEQ ID ATTGAGGGCC UAUAAUUGAG

[1393] 927) NO: 929)

[1394] AC (SEQ ID NO: GGCCAC (SEQ 928) ID NO: 930) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CACTACTTTA CACUACUUU AGGTATTAAAC AUAGGUAUUA

[1395] D1 S1- ACAGAATGA AACAGAAUG

[1396] GTTA AACCACTACTT AACAACCACU

[1397] G10.1 A (SEQ ID NO: AA (SEQ ID TAACAGAATG ACUUUAACAG

[1398] 931) NO: 933)

[1399] AA (SEQ ID NO: AAUGAA (SEQ 932) ID NO: 934) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU AACTAGTTTA AACUAGUUU AGGTATTAAAC AUAGGUAUUA

[1400] D1 S1- CAGTCCCACC ACAGUCCCAC

[1401] GTTG AACAACTAGTT AACAACAACU

[1402] G10.2 (SEQ ID NO: C (SEQ ID NO:

[1403] TACAGTCCCAC AGUUUACAGU

[1404] 549) 551)

[1405] C (SEQ ID NO: CCCACC (SEQ 935) ID NO: 936) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CAGTCCCACC CAGUCCCACC AGGTATTAAAC AUAGGUAUUA

[1406] D1 S1- AACAGTGTA AACAGUGUA

[1407] TTTA AACCAGTCCCA AACAACCAGU GIO.3 A (SEQ ID NO: A (SEQ ID NO:

[1408] CCAACAGTGTA CCCACCAACA

[1409] 937) 939)

[1410] A (SEQ ID NO: GUGUAA (SEQ 938) ID NO: 940) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CACTGTTGGT CACUGUUGG AGGTATTAAAC AUAGGUAUUA

[1411] D1 S1- GGGACTGTA UGGGACUGU

[1412] TTTA AACCACTGTTG AACAACCACU

[1413] G10.4 A (SEQ ID NO: AA (SEQ ID GTGGGACTGTA GUUGGUGGGA

[1414] 941) NO: 943)

[1415] A (SEQ ID NO: CUGUAA (SEQ 942) ID NO: 944) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU GTGGGACTGT GUGGGACUG AGGTATTAAAC AUAGGUAUUA

[1416] D1 S1- AAACTAGTTC UAAACUAGU

[1417] GTTG AACGTGGGAC AACAACGUGG GIO.5 (SEQ ID NO: UC (SEQ ID TGTAAACTAGT GACUGUAAAC

[1418] 553) NO: 555)

[1419] TC (SEQ ID NO: UAGUUC (SEQ

[1420]

[1421] 945) ID NO: 946)Attorney Docket No. 063586-568001WO

[1422] Guide Target DNA Sequence Spacer gRNA PAM

[1423] Name* Sequence for gRNA Sequence Sequence CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TCCTTCATTC UCCUUCAUU AGGTATTAAAC AUAGGUAUUA

[1424] D1 S1- TGTTAAAGTA CUGUUAAAG

[1425] TTTA AACTCCTTCAT AACAACUCCU GIO.6 (SEQ ID NO: UA (SEQ ID TCTGTTAAAGT UCAUUCUGUU

[1426] 947) NO: 949)

[1427] A (SEQ ID NO: AAAGUA (SEQ 948) ID NO: 950) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU AAGTAGTGT AAGUAGUGU AGGTATTAAAC AUAGGUAUUA

[1428] D1 S1- AACATTTGTT AACAUUUGU

[1429] GTTA AACAAGTAGT AACAACAAGU GIO.7 G (SEQ ID NO: UG (SEQ ID GTAACATTTGT AGUGUAACAU

[1430] 557) NO: 559)

[1431] TG (SEQ ID NO: UUGUUG (SEQ 951) ID NO: 952) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TTGATTTCTA UUGAUUUCU AGGTATTAAAC AUAGGUAUUA

[1432] D1_S2_ GTTTTATTCC AGUUUUAUU

[1433] GTTA AACTTGATTTC AACAACUUGA

[1434] Gl.l (SEQ ID NO: CC (SEQ ID TAGTTTTATTC UUUCUAGUUU

[1435] 953) NO: 955)

[1436] C (SEQ ID NO: UAUUCC (SEQ 954) ID NO: 956) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU ATTTCTAGTT AUUUCUAGU AGGTATTAAAC AUAGGUAUUA

[1437] D1_S2_ TTATTCCATT UUUAUUCCA

[1438] ATTG AACATTTCTAG AACAACAUUU

[1439] G1.2 (SEQ ID NO: UU (SEQ ID TTTTATTCCAT CUAGUUUUAU

[1440] 749) NO: 751)

[1441] T (SEQ ID NO: UCCAUU (SEQ 957) ID NO: 958) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TTCCATTGTG UUCCAUUGU AGGTATTAAAC AUAGGUAUUA

[1442] D1_S2_ ATCACAGAA GAUCACAGA

[1443] TTTA AACTTCCATTG AACAACUUCC

[1444] G1.3 G (SEQ ID NO: AG (SEQ ID TGATCACAGA AUUGUGAUCA

[1445] 959) NO: 961)

[1446] AG (SEQ ID NO: CAGAAG(SEQ 960) ID NO: 962) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TGATCACAG UGAUCACAG AGGTATTAAAC AUAGGUAUUA

[1447] D1_S2_ AAGATATTTT AAGAUAUUU

[1448] ATTG AACTGATCACA AACAACUGAU

[1449] G1.4 G (SEQ ID NO: UG (SEQ ID GAAGATATTTT CACAGAAGAU

[1450] 963) NO: 965)

[1451] G (SEQ ID NO: AUUUUG (SEQ 964) ID NO: 966) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TATAATCGCA UAUAAUCGC AGGTATTAAAC AUAGGUAUUA

[1452] D1_S2_ GTCTATTAAC AGUCUAUUA

[1453] TTTG AACTATAATCG AACAACUAUA

[1454] G1.5 (SEQ ID NO: AC (SEQ ID CAGTCTATTAA AUCGCAGUCU

[1455] 967) NO: 969)

[1456] C (SEQ ID NO: AUUAAC (SEQ

[1457]

[1458] 968) ID NO: 970)Attorney Docket No. 063586-568001WO

[1459] Guide Target DNA Sequence Spacer gRNA PAM

[1460] Name* Sequence for gRNA Sequence Sequence CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU GAGAATGTTC GAGAAUGUU AGGTATTAAAC AUAGGUAUUA

[1461] D1_S2_ CAAGTGCAA CCAAGUGCA

[1462] GTTG AACGAGAATG AACAACGAGA

[1463] G1.6 T (SEQ ID NO: AU (SEQ ID TTCCAAGTGCA AUGUUCCAAG

[1464] 773) NO: 775)

[1465] AT (SEQ ID NO: UGCAAU (SEQ 971) ID NO: 972) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU AGAATACTAT AGAAUACUA AGGTATTAAAC AUAGGUAUUA

[1466] D1_S2_ TCTGGTGCTA UUCUGGUGC

[1467] ATTG AACAGAATAC AACAACAGAA

[1468] G1.7 (SEQ ID NO: UA (SEQ ID TATTCTGGTGC UACUAUUCUG

[1469] 973) NO: 975)

[1470] TA (SEQ ID NO: GUGCUA (SEQ 974) ID NO: 976) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU GGTGAAGTA GGUGAAGUA AGGTATTAAAC AUAGGUAUUA

[1471] D1_S2_ TTCTCTATAT UUCUCUAUA

[1472] ATTA AACGGTGAAG AACAACGGUG

[1473] G1.8 G (SEQ ID NO: UG (SEQ ID TATTCTCTATA AAGUAUUCUC

[1474] 977) NO: 979)

[1475] TG (SEQ ID NO: UAUAUG (SEQ 978) ID NO: 980) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU AGTCCAATTC AGUCCAAUU AGGTATTAAAC AUAGGUAUUA

[1476] D1_S2_ ATCTATAGTG CAUCUAUAG

[1477] GTTA AACAGTCCAAT AACAACAGUC

[1478] G1.9 (SEQ ID NO: UG (SEQ ID TCATCTATAGT CAAUUCAUCU

[1479] 981) NO: 983)

[1480] G (SEQ ID NO: AUAGUG (SEQ 982) ID NO: 984) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU ACGTTTCCTG ACGUUUCCU AGGTATTAAAC AUAGGUAUUA

[1481] D1_S2_ TTCCTTACTG GUUCCUUAC

[1482] GTTG AACACGTTTCC AACAACACGU

[1483] G1.10 (SEQ ID NO: UG (SEQ ID TGTTCCTTACT UUCCUGUUCC

[1484] 785) NO: 787)

[1485] G (SEQ ID NO: UUACUG(SEQ 985) ID NO: 986) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CTGATTTTCT CUGAUUUUC AGGTATTAAAC AUAGGUAUUA

[1486] D1_S2_ GACTTATTAT UGACUUAUU

[1487] CTTA AACCTGATTTT AACAACCUGA

[1488] Gl.ll (SEQ ID NO: AU (SEQ ID CTGACTTATTA UUUUCUGACU

[1489] 987) NO: 989)

[1490] T (SEQ ID NO: UAUUAU (SEQ 988) ID NO: 990) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU GACTTAACA GACUUAACA AGGTATTAAAC AUAGGUAUUA

[1491] D1_S2_ GACATATAG GACAUAUAG

[1492] ATTG AACGACTTAAC AACAACGACU GE 12 AG (SEQ ID AG (SEQ ID AGACATATAG UAACAGACAU NO: 991) NO: 993)

[1493] AG (SEQ ID NO: AUAGAG (SEQ

[1494]

[1495] 992) ID NO: 994)Attorney Docket No. 063586-568001WO

[1496] Guide Target DNA Sequence Spacer gRNA PAM

[1497] Name* Sequence for gRNA Sequence Sequence CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU ACAGACATA ACAGACAUA AGGTATTAAAC AUAGGUAUUA

[1498] D1_S2_ TAGAGAATA UAGAGAAUA

[1499] CTTA AACACAGACA AACAACACAG

[1500] G1.13 CT (SEQ ID CU (SEQ ID TATAGAGAAT ACAUAUAGAG NO: 789) NO: 791)

[1501] ACT (SEQ ID AAUACU (SEQ NO: 995) ID NO: 996) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CACTTGGAAC CACUUGGAA AGGTATTAAAC AUAGGUAUUA

[1502] D1_S2_ ATTCTCCAAC CAUUCUCCA

[1503] ATTG AACCACTTGGA AACAACCACU GE 14 (SEQ ID NO: AC (SEQ ID ACATTCTCCAA UGGAACAUUC

[1504] 997) NO: 999)

[1505] C (SEQ ID NO: UCCAAC (SEQ 998) ID NO: 1000) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU GAACATTCTC GAACAUUCU AGGTATTAAAC AUAGGUAUUA

[1506] D1_S2_ CAACATAGA CCAACAUAG

[1507] CTTG AACGAACATTC AACAACGAAC

[1508] G1.15 T (SEQ ID NO: AU (SEQ ID TCCAACATAGA AUUCUCCAAC

[1509] 1001) NO: 1003)

[1510] T (SEQ ID NO: AUAGAU (SEQ 1002) ID NO: 1004) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU ATAGACTGC AUAGACUGC AGGTATTAAAC AUAGGUAUUA

[1511] D1_S2_ GATTATACAA GAUUAUACA

[1512] GTTA AACATAGACT AACAACAUAG

[1513] G1.16 A (SEQ ID NO: AA (SEQ ID GCGATTATACA ACUGCGAUUA

[1514] 1005) NO: 1007)

[1515] AA (SEQ ID NO: UACAAA (SEQ 1006) ID NO: 1008) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TACAAAATAT UACAAAAUA AGGTATTAAAC AUAGGUAUUA

[1516] D1_S2_ CTTCTGTGAT UCUUCUGUG

[1517] ATTA AACTACAAAA AACAACUACA

[1518] G1.17 (SEQ ID NO: AU (SEQ ID TATCTTCTGTG AAAUAUCUUC

[1519] 1009) NO: 1011)

[1520] AT (SEQ ID NO: UGUGAU (SEQ 1010) ID NO: 1012) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TTCTGTTATC UUCUGUUAU AGGTATTAAAC AUAGGUAUUA

[1521] D1_S2_ TTTTGTAAGA CUUUUGUAA

[1522] ATTG AACTTCTGTTA AACAACUUCU

[1523] G2.1 (SEQ ID NO: GA (SEQ ID TCTTTTGTAAG GUUAUCUUUU

[1524] 801) NO: 803)

[1525] A (SEQ ID NO: GUAAGA (SEQ 1013) ID NO: 1014) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TCTTTTGTAA UCUUUUGUA AGGTATTAAAC AUAGGUAUUA

[1526] D1_S2_ GATTTCTAGA AGAUUUCUA

[1527] GTTA AACTCTTTTGT AACAACUCUU

[1528] G2.2 (SEQ ID NO: GA (SEQ ID AAGATTTCTAG UUGUAAGAUU

[1529] 1015) NO: 1017)

[1530] A (SEQ ID NO: UCUAGA (SEQ

[1531]

[1532] 1016) ID NO: 1018)Attorney Docket No. 063586-568001WO

[1533] Guide Target DNA Sequence Spacer gRNA PAM

[1534] Name* Sequence for gRNA Sequence Sequence CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TAAGATTTCT UAAGAUUUC AGGTATTAAAC AUAGGUAUUA

[1535] D1_S2_ AGAACATTTT UAGAACAUU

[1536] TTTG AACTAAGATTT AACAACUAAG

[1537] G2.3 (SEQ ID NO: UU (SEQ ID CTAGAACATTT AUUUCUAGAA

[1538] 1019) NO: 1021)

[1539] T (SEQ ID NO: CAUUUU (SEQ 1020) ID NO: 1022) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CTGCTTTTGG CUGCUUUUG AGGTATTAAAC AUAGGUAUUA

[1540] D1_S2_ ATTTACATAT GAUUUACAU

[1541] TTTA AACCTGCTTTT AACAACCUGC

[1542] G2.4 (SEQ ID NO: AU (SEQ ID GGATTTACATA UUUUGGAUUU

[1543] 1023) NO: 1025)

[1544] T (SEQ ID NO: ACAUAU (SEQ 1024) ID NO: 1026) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU GATTTACATA GAUUUACAU AGGTATTAAAC AUAGGUAUUA

[1545] D1_S2_ TGATTTGATT AUGAUUUGA

[1546] TTTG AACGATTTACA AACAACGAUU

[1547] G2.5 (SEQ ID NO: UU (SEQ ID TATGATTTGAT UACAUAUGAU

[1548] 1027) NO: 1029)

[1549] T (SEQ ID NO: UUGAUU (SEQ 1028) ID NO: 1030) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CATATGATTT CAUAUGAUU AGGTATTAAAC AUAGGUAUUA

[1550] D1_S2_ GATTCTTTCT UGAUUCUUU

[1551] TTTA AACCATATGAT AACAACCAUA

[1552] G2.6 (SEQ ID NO: CU (SEQ ID TTGATTCTTTC UGAUUUGAUU

[1553] 1031) NO: 1033)

[1554] T (SEQ ID NO: CUUUCU (SEQ 1032) ID NO: 1034) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU ATTCTTTCTT AUUCUUUCU AGGTATTAAAC AUAGGUAUUA

[1555] D1_S2_ ATCTCTTATC UAUCUCUUA

[1556] TTTG AACATTCTTTC AACAACAUUC

[1557] G2.7 (SEQ ID NO: UC (SEQ ID TTATCTCTTAT UUUCUUAUCU

[1558] 1035) NO: 1037)

[1559] C (SEQ ID NO: CUUAUC (SEQ 1036) ID NO: 1038) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TCTCTTATCC UCUCUUAUC AGGTATTAAAC AUAGGUAUUA

[1560] D1_S2_ TTACAATGTA CUUACAAUG

[1561] CTTA AACTCTCTTAT AACAACUCUC

[1562] G2.8 (SEQ ID NO: UA (SEQ ID CCTTACAATGT UUAUCCUUAC

[1563] 1039) NO: 1041)

[1564] A (SEQ ID NO: AAUGUA (SEQ 1040) ID NO: 1042) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TCCTTACAAT UCCUUACAA AGGTATTAAAC AUAGGUAUUA

[1565] D1_S2_ GTAATTCAAA UGUAAUUCA

[1566] CTTA AACTCCTTACA AACAACUCCU

[1567] G2.9 (SEQ ID NO: AA (SEQ ID ATGTAATTCAA UACAAUGUAA

[1568] 825) NO: 827)

[1569] A (SEQ ID NO: UUCAAA (SEQ

[1570]

[1571] 1043) ID NO: 1044)Attorney Docket No. 063586-568001WO

[1572] Guide Target DNA Sequence Spacer gRNA PAM

[1573] Name* Sequence for gRNA Sequence Sequence CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CAATGTAATT CAAUGUAAU AGGTATTAAAC AUAGGUAUUA

[1574] D1_S2_ CAAACTGAT UCAAACUGA

[1575] CTTA AACCAATGTA AACAACCAAU

[1576] G2.10 G (SEQ ID NO: UG (SEQ ID ATTCAAACTGA GUAAUUCAAA

[1577] 1045) NO: 1047)

[1578] TG (SEQ ID NO: CUGAUG(SEQ 1046) ID NO: 1048) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TACGCAATTG UACGCAAUU AGGTATTAAAC AUAGGUAUUA

[1579] D1_S2_ AACTTAAATT GAACUUAAA

[1580] TTTG AACTACGCAAT AACAACUACG

[1581] G2.ll (SEQ ID NO: UU (SEQ ID TGAACTTAAAT CAAUUGAACU

[1582] 1049) NO: 1051)

[1583] T (SEQ ID NO: UAAAUU (SEQ 1050) ID NO: 1052) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU AACTTAAATT AACUUAAAU AGGTATTAAAC AUAGGUAUUA

[1584] D1_S2_ GGCATCAGTT UGGCAUCAG

[1585] ATTG AACAACTTAA AACAACAACU

[1586] G2.12 (SEQ ID NO: UU (SEQ ID ATTGGCATCAG UAAAUUGGCA

[1587] 829) NO: 831)

[1588] TT (SEQ ID NO: UCAGUU (SEQ 1053) ID NO: 1054) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU AATTGGCATC AAUUGGCAU AGGTATTAAAC AUAGGUAUUA

[1589] D1_S2_ AGTTTGAATT CAGUUUGAA

[1590] CTTA AACAATTGGC AACAACAAUU

[1591] G2.13 (SEQ ID NO: UU (SEQ ID ATCAGTTTGAA GGCAUCAGUU

[1592] 1055) NO: 1057)

[1593] TT (SEQ ID NO: UGAAUU (SEQ 1056) ID NO: 1058) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU GCATCAGTTT GCAUCAGUU AGGTATTAAAC AUAGGUAUUA

[1594] D1_S2_ GAATTACATT UGAAUUACA

[1595] ATTG AACGCATCAGT AACAACGCAU

[1596] G2.14 (SEQ ID NO: UU (SEQ ID TTGAATTACAT CAGUUUGAAU

[1597] 833) NO: 835)

[1598] T (SEQ ID NO: UACAUU (SEQ 1059) ID NO: 1060) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU AATTACATTG AAUUACAUU AGGTATTAAAC AUAGGUAUUA

[1599] D1_S2_ TAAGGATAA GUAAGGAUA

[1600] TTTG AACAATTACAT AACAACAAUU

[1601] G2.15 G (SEQ ID NO: AG (SEQ ID TGTAAGGATA ACAUUGUAAG

[1602] 1061) NO: 1063)

[1603] AG (SEQ ID NO: GAUAAG (SEQ 1062) ID NO: 1064) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CATTGTAAGG CAUUGUAAG AGGTATTAAAC AUAGGUAUUA

[1604] D1_S2_ ATAAGAGAT GAUAAGAGA

[1605] ATTA AACCATTGTAA AACAACCAUU

[1606] G2.16 A (SEQ ID NO: UA (SEQ ID GGATAAGAGA GUAAGGAUAA

[1607] 837) NO: 839)

[1608] TA (SEQ ID NO: GAGAUA (SEQ

[1609]

[1610] 1065) ID NO: 1066)Attorney Docket No. 063586-568001WO

[1611] Guide Target DNA Sequence Spacer gRNA PAM

[1612] Name* Sequence for gRNA Sequence Sequence CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU TAAGGATAA UAAGGAUAA AGGTATTAAAC AUAGGUAUUA

[1613] D1_S2_ GAGATAAGA GAGAUAAGA

[1614] ATTG AACTAAGGAT AACAACUAAG

[1615] G2.17 AA (SEQ ID AA (SEQ ID AAGAGATAAG GAUAAGAGAU NO: 1067) NO: 1069)

[1616] AAA (SEQ ID AAGAAA (SEQ NO: 1068) ID NO: 1070) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU AGTCTGAGG AGUCUGAGG AGGTATTAAAC AUAGGUAUUA

[1617] D1_S2_ GCAAAATGTT GCAAAAUGU

[1618] TTTA AACAGTCTGA AACAACAGUC

[1619] G2.18 C (SEQ ID NO: UC (SEQ ID GGGCAAAATG UGAGGGCAAA

[1620] 841) NO: 843)

[1621] TTC (SEQ ID AUGUUC (SEQ NO: 1071) ID NO: 1072) CTTGTTGTATA CUUGUUGUAU TGTCCTTTTAT AUGUCCUUUU CAAAAGATA CAAAAGAUA AGGTATTAAAC AUAGGUAUUA

[1622] D1_S2_ ACAGAACAA ACAGAACAA

[1623] CTTA AACCAAAAGA AACAACCAAA

[1624] G2.19 TT (SEQ ID UU (SEQ ID TAACAGAACA AGAUAACAGA NO: 849) NO: 851)

[1625] ATT (SEQ ID ACAAUU (SEQ

[1626]

[1627] NO: 1073) ID NO: 1074) C2 DR sequence: AGAAATCCGTCTTTCATTGACGG (SEQ ID NO: 7)

[1628] DI DR sequence: CTTGTTGTATATGTCCTTTTATAGGTATTAAACAAC (SEQ ID NO: 8)

[1629] Table 7. Sequences of Guides Targeting the Intronic Region of UBE3A-ATS for Use with Cas9.

[1630] Guide Target DNA Sequence Spacer gRNA PAM

[1631] Name* Sequence for gRNA Sequence Sequence GCCACATATGA GCCACAUAUG CAAACCTGGGT ACAAACCUGG TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC GCCACATAT GCCACAUAU TAAAATAAGGC AAGUUAAAAU

[1632] Cas9_Sl GACAAACCT GACAAACCU

[1633] AGG TAGTCCGTTAT AAGGCUAGUC

[1634] _G1 GG(SEQID GG (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1075) NO: 1077) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1635] (SEQ ID NO: CGGUGC (SEQ 1076) ID NO: 1078) CCTGGAGGTAA CCUGGAGGUA TATACTCAAGT AUAUACUCAA TTTAGAGCTAG GUUUUAGAGC CCTGGAGGT CCUGGAGGU AAATAGCAAGT UAGAAAUAGC

[1636] Cas9_Sl AATATACTC AAUAUACUC

[1637] TGG TAAAATAAGGC AAGUUAAAAU

[1638] _G2 AA (SEQ ID AA (SEQ ID TAGTCCGTTAT AAGGCUAGUC NO: 1079) NO: 1081) CAACTTGAAAA CGUUAUCAAC AGTGGCACCGA UUGAAAAAGU

[1639]

[1640] GTCGGTGC GGCACCGAGUAttorney Docket No. 063586-568001WO

[1641] Guide Target DNA Sequence Spacer gRNA PAM

[1642] Name* Sequence for gRNA Sequence Sequence (SEQ ID NO: CGGUGC (SEQ 1080) ID NO: 1082) AGTCAGTGAAA AGUCAGUGAA CTATCCTCGGT ACUAUCCUCG TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC AGTCAGTGA AGUCAGUGA TAAAATAAGGC AAGUUAAAAU

[1643] Cas9_Sl AACTATCCT AACUAUCCU

[1644] AGG TAGTCCGTTAT AAGGCUAGUC

[1645] _G5 CG (SEQ ID CG(SEQID CAACTTGAAAA CGUUAUCAAC NO: 1083) NO: 1085) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1646] (SEQ ID NO: CGGUGC (SEQ 1084) ID NO: 1086) AAAGCCACATA AAAGCCACAU TGACAAACCGT AUGACAAACC TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC AAAGCCACA AAAGCCACA TAAAATAAGGC AAGUUAAAAU

[1647] Cas9_Sl TATGACAAA UAUGACAAA

[1648] TGG TAGTCCGTTAT AAGGCUAGUC

[1649] _G6 CC (SEQ ID CC (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1087) NO: 1089) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1650] (SEQ ID NO: CGGUGC (SEQ 1088) ID NO: 1090) AACAGCATCTC AACAGCAUCU TCATACCAAGT CUCAUACCAA TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC AACAGCATC AACAGCAUC TAAAATAAGGC AAGUUAAAAU

[1651] Cas9_Sl TCTCATACC UCUCAUACC

[1652] TGG TAGTCCGTTAT AAGGCUAGUC

[1653] _G7 AA (SEQ ID AA (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1091) NO: 1093) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1654] (SEQ ID NO: CGGUGC (SEQ 1092) ID NO: 1094) AAAATATAGCA AAAAUAUAGC CTTGAGGCTGT ACUUGAGGCU TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC AAAATATAG AAAAUAUAG TAAAATAAGGC AAGUUAAAAU

[1655] Cas9_Sl CACTTGAGG CACUUGAGG

[1656] GGG TAGTCCGTTAT AAGGCUAGUC

[1657] _G9 CT (SEQ ID CU (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1095) NO: 1097) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1658] (SEQ ID NO: CGGUGC (SEQ

[1659]

[1660] 1096) ID NO: 1098)Attorney Docket No. 063586-568001WO

[1661] Guide Target DNA Sequence Spacer gRNA PAM

[1662] Name* Sequence for gRNA Sequence Sequence AAATCATATGA AAAUCAUAUG TCATCTCGAGT AUCAUCUCGA TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC AAATCATAT AAAUCAUAU TAAAATAAGGC AAGUUAAAAU

[1663] Cas9_Sl GATCATCTC GAUCAUCUC

[1664] TGG TAGTCCGTTAT AAGGCUAGUC GIO GA (SEQ ID GA (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1099) NO: 1101) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1665] (SEQ ID NO: CGGUGC (SEQ 1100) ID NO: 1102) TAAGTCTTGTG UAAGUCUUGU GCCTAACAGGT GGCCUAACAG TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC TAAGTCTTG UAAGUCUUG TAAAATAAGGC AAGUUAAAAU

[1666] Cas9_S2 TGGCCTAAC UGGCCUAAC

[1667] AGG TAGTCCGTTAT AAGGCUAGUC

[1668] _G1 AG (SEQ ID AG (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1103) NO: 1105) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1669] (SEQ ID NO: CGGUGC (SEQ 1104) ID NO: 1106) ACAATAAGTGA ACAAUAAGUG GAAATACGTGT AGAAAUACGU TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC ACAATAAGT ACAAUAAGU TAAAATAAGGC AAGUUAAAAU

[1670] Cas9_S2 GAGAAATAC GAGAAAUAC

[1671] TGG TAGTCCGTTAT AAGGCUAGUC

[1672] _G2 GT (SEQ ID GU (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1107) NO: 1109) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1673] (SEQ ID NO: CGGUGC (SEQ 1108) ID NO: 1110) CTGGGGCAAGC CUGGGGCAAG AACTATGGGGT CAACUAUGGG TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC CTGGGGCAA CUGGGGCAA TAAAATAAGGC AAGUUAAAAU

[1674] Cas9_S2 GCAACTATG GCAACUAUG

[1675] TGG TAGTCCGTTAT AAGGCUAGUC

[1676] _G7 GG(SEQID GG (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1111) NO: 1113) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1677] (SEQ ID NO: CGGUGC (SEQ

[1678]

[1679] 1112) ID NO: 1114)Attorney Docket No. 063586-568001WO

[1680] Guide Target DNA Sequence Spacer gRNA PAM

[1681] Name* Sequence for gRNA Sequence Sequence AACTGGGTATA AACUGGGUAU TCTAAGCTTGT AUCUAAGCUU TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC AACTGGGTA AACUGGGUA TAAAATAAGGC AAGUUAAAAU

[1682] Cas9_S2 TATCTAAGC UAUCUAAGC

[1683] AGG TAGTCCGTTAT AAGGCUAGUC GIO TT (SEQ ID UU (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1115) NO: 1117) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1684] (SEQ ID NO: CGGUGC (SEQ 1116) ID NO: 1118) AGGTGATGACA AGGUGAUGAC CCCCTACCAGT ACCCCUACCAG TTTAGAGCTAG UUUUAGAGCU AAATAGCAAGT AGAAAUAGCA AGGTGATGA AGGUGAUGA TAAAATAAGGC AGUUAAAAUA

[1685] Cas9_S3 CACCCCTAC CACCCCUAC

[1686] TGG TAGTCCGTTAT AGGCUAGUCC

[1687] _G1 CA (SEQ ID CA (SEQ ID CAACTTGAAAA GUUAUCAACU NO: 1119) NO: 1121) AGTGGCACCGA UGAAAAAGUG GTCGGTGC GCACCGAGUC

[1688] (SEQ ID NO: GGUGC (SEQ ID 1120) NO: 1122) TGATAGGAGCT UGAUAGGAGC GAATAGTAGGT UGAAUAGUAG TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC TGATAGGAG UGAUAGGAG TAAAATAAGGC AAGUUAAAAU

[1689] Cas9_S3 CTGAATAGT CUGAAUAGU

[1690] GGG TAGTCCGTTAT AAGGCUAGUC

[1691] _G2 AG (SEQ ID AG (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1123) NO: 1125) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1692] (SEQ ID NO: CGGUGC (SEQ 1124) ID NO: 1126) GGTCATAGGAG GGUCAUAGGA TGTTAGCCCGT GUGUUAGCCC TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC GGTCATAGG GGUCAUAGG TAAAATAAGGC AAGUUAAAAU

[1693] Cas9_S3 AGTGTTAGC AGUGUUAGC

[1694] AGG TAGTCCGTTAT AAGGCUAGUC

[1695] _G3 CC (SEQ ID CC (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1127) NO: 1129) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1696] (SEQ ID NO: CGGUGC (SEQ

[1697]

[1698] 1128) ID NO: 1130)Attorney Docket No. 063586-568001WO

[1699] Guide Target DNA Sequence Spacer gRNA PAM

[1700] Name* Sequence for gRNA Sequence Sequence GGAGTAGGTAT GGAGUAGGUA ATTAGTCTAGT UAUUAGUCUA TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC GGAGTAGGT GGAGUAGGU TAAAATAAGGC AAGUUAAAAU

[1701] Cas9_S3 ATATTAGTC AUAUUAGUC

[1702] AGG TAGTCCGTTAT AAGGCUAGUC

[1703] _G4 TA (SEQ ID UA (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1131) NO: 1133) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1704] (SEQ ID NO: CGGUGC (SEQ 1132) ID NO: 1134) TTGTGGACTAA UUGUGGACUA CATATATCCGT ACAUAUAUCC TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC TTGTGGACT UUGUGGACU TAAAATAAGGC AAGUUAAAAU

[1705] Cas9_S3 AACATATAT AACAUAUAU

[1706] TGG TAGTCCGTTAT AAGGCUAGUC

[1707] _G5 CC (SEQ ID CC (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1135) NO: 1137) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1708] (SEQ ID NO: CGGUGC (SEQ 1136) ID NO: 1138) GGGCACTCATA GGGCACUCAU CATACATGGGT ACAUACAUGG TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC GGGCACTCA GGGCACUCA TAAAATAAGGC AAGUUAAAAU

[1709] Cas9_S3 TACATACAT UACAUACAU

[1710] AGG TAGTCCGTTAT AAGGCUAGUC

[1711] _G6 GG(SEQID GG (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1139) NO: 1141) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1712] (SEQ ID NO: CGGUGC (SEQ 1140) ID NO: 1142) TAGACCCATGG UAGACCCAUG CTCATCAGTGT GCUCAUCAGU TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC TAGACCCAT UAGACCCAU TAAAATAAGGC AAGUUAAAAU

[1713] Cas9_S3 GGCTCATCA GGCUCAUCA

[1714] GGG TAGTCCGTTAT AAGGCUAGUC

[1715] _G7 GT (SEQ ID GU (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1143) NO: 1145) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1716] (SEQ ID NO: CGGUGC (SEQ

[1717]

[1718] 1144) ID NO: 1146)Attorney Docket No. 063586-568001WO

[1719] Guide Target DNA Sequence Spacer gRNA PAM

[1720] Name* Sequence for gRNA Sequence Sequence AGTGCTACCCA AGUGCUACCC TTAGACCCAGT AUUAGACCCA TTTAGAGCTAG GUUUUAGAGC AAATAGCAAGT UAGAAAUAGC AGTGCTACC AGUGCUACC TAAAATAAGGC AAGUUAAAAU

[1721] Cas9_S3 CATTAGACC CAUUAGACC

[1722] TGG TAGTCCGTTAT AAGGCUAGUC

[1723] G8 CA (SEQ ID CA (SEQ ID CAACTTGAAAA CGUUAUCAAC NO: 1147) NO: 1149) AGTGGCACCGA UUGAAAAAGU GTCGGTGC GGCACCGAGU

[1724] (SEQ ID NO: CGGUGC (SEQ

[1725]

[1726] 1148) ID NO: 1150)

[1727] Guide screening in HEK293T cells - UBE3A-ATS Intronic region

[1728] UBE3A-ATS disruption within the intronic region was assessed by RNP electroporation of protein nucleases complexed with synthetic mRNA guides. HEK293 cells were cultured for 48 hours, to a confluency of 75-90% in DMEM (Gibco #10569010) containing 10% FBS (Hyclone, Heat inactivated #SH30071.03). Cells were lifted with TrypLE (Gibco), counted, rinsed with PBS, and resuspended in Lonza SF nucleofection buffer + supplement (Lonza, V4SC-2096) at a concentration of 17,441 cells / pL. 300,000 cells were used per electroporation reaction.

[1729] 138 RNA guides (Table 6) targeting the UBE3A-ATS intronic region: Segment 1 or Segment 2, were tested. Variant Dl / RNA guide RNP complexes were generated by mixing DI (in 20 mM HEPES pH 7.8, 500 mM NaCl, 10 % Glycerol, 0.5 mM TCEP) with RNA guides (in 250 mM NaCl) on ice at a 1 :2.5 molar ratio for 45 minutes. Variant C2 / RNA guide RNP complexes were generated by mixing C2 (in 20 mM HEPES pH 7.8, 750 mM NaCl, 10 % Glycerol, 0.5 mM TCEP) with RNA guides (in 250 mM NaCl) on ice at a 1 :2.5 molar ratio for 45 minutes RNPs were added to each reaction at a final concentration of 10 pM (C2) and 25 pM RNA guide. The cells were electroporated using an electroporation device (program CA- 137, Lonza 4D-nucleofector). Following electroporation, cells were immediately added to prewarmed culture medium and mixed gently by pipetting. The cells were then incubated at 37°C for 72 hours. After 72 hours, cells were harvested with TrypLE (Thermo Fisher Scientific), incubating 5 minutes, followed by D10 media, and mixing. Cells were then pelleted by centrifugation, resuspended in QuickExtract™ DNA Extraction Solution (Biosearch Technologies) and incubated at 65°C for 15 minutes, 68°C for 15 minutes, and 98°C for 10 minutes.

[1730] Samples for Next Generation Sequencing (NGS) were prepared as described above.Attorney Docket No. 063586-568001WO

[1731] FIG. 5 includes all guides showing indel editing greater than 0% within the UBE3A-ATS intronic regions.

[1732] Example 2 - CRISPR Nuclease-Mediated Disruption of UBE3A-ATS in Neurons Human glutamatergic cortical neurons derived from induced pluripotent stem (iPS) cells were purchased from Fujifilm Cellular Dynamics, Inc. (FCDI) and cultured in the laboratory using manufacturer’s protocols. Briefly, 600,000 cells were seeded on 12-well culture plates coated with poly-L-omithine, laminin and fibronectin in complete media containing BrainPhys™ Neuronal Medium (Stem Cell Technologies), iCell Neural Supplement B (FCDI), iCell Nervous System Supplement (FCDI), N2 supplement (Gibco™) and Gentamicin (Gibco™).

[1733] Four days after plating the cells were transduced with a lentivirus expressing a C2 nuclease or a DI nuclease under the synapsin promoter at an MOI of 20. Five days after treatment with nuclease, guide RNAs were transfected into neurons. lOOnM of gRNA per well and 0.5 mL Lipofectamine™ 2000 transfection reagent (Thermo Fisher Scientific) were mixed into 20 mL of Neurobasal media for five minutes (Solutions C and D respectively). Solutions C and D were mixed and incubated for 1 hour. 10X KY buffer was prepared using lOmM kynurenic acid, 0.0025% phenol red, 5mM HEPES, lOOmM magnesium chloride, sodium hydroxide dropwise titrated to a pH of 7.4. Neurons in the 96-well plate were washed and preincubated with IX KY buffer prepared in Neurobasal media (IX NB / KY media). Solutions C+D was added to the 96 well plate (40 mL per well) and allowed to incubate for an additional 4 hours, after which the cells are washed and maintained in fresh media for 10 days.

[1734] For NGS indel analysis, cells were directly resuspended in 40 mL QuickExtract™ DNA Extraction Solution (Biosearch Technologies). Samples were incubated at 65°C for 15 minutes, 68°C for 15 minutes, and 98°C for 10 minutes. DNA harvested from the samples above were used to measure indel % using next generation sequencing methodologies described above.

[1735] For RNA analysis, cells were harvested with RLT Buffer (Qiagen) for RNA extraction. RNA was extracted using the RNEasy Mini kit according to manufacturer protocol. cDNA was generated from the harvested RNA using the iSCRIPT cDNA synthesis kit, following manufacturer protocol. Finally, qualitative real-time PCR (qPCR) reactions, made up of Taqman Gene expression Master Mix (Thermo Fisher) and Taqman probes for UBE3 A (Hs00166580_ml) and PPIA(Hs99999904_ml), were ran using the Bio-Rad CFX Opus 384-well PCR system. The thermocycling conditions used followed the manufacturer’s recommended protocol.Attorney Docket No. 063586-568001WO

[1736] A subset of guides from Cluster 2 Exon pool exhibiting >20% indels and guides from the intronic pool exhibiting >50% indels in Example 1 were chosen as part of the neuronal screen. Both indel % and UBE3A mRNA expression following editing were analyzed. FIGs.

[1737] 6a and 6b shows the UBE3A mRNA fold change and % Indel following editing with nuclease and gRNAs targeting the Cluster 2 Exon region. Similarly, FIG. 7a and FIG. 7b shows the UBE3A mRNA fold change and % Indels following editing with nuclease and gRNAs targeting the Intronic Region. There is poor correlation between indel % and UBE3A mRNA expression of Cluster 2 exon guides specifically (FIG. 8), showing that the highest indel % does not always lead to the best UBE3A expression. More generally speaking, this observation strongly suggests that some, but not all exons, have a larger propensity to lead to UBE3A unsilencing. Specifically, guides within Exon 5, on average, lead to the greatest UBE3A mRNA expression changes and we propose that Exon 5 serves as a “hotspot” for UBE3A-ATS disruption, disrupts UBE3A-ATS in neuron in vitro and in NHP models in vivo by >90%, as assessed by qPCR using a probe spanning an exon junction at exon 4 and 5 (Hs01372957_ml). The same probe is used internally to assess UBE3A mRNA expression. In contrast, there is strong correlation between indel % and UBE3A mRNA expression of intronic guides (FIG. 9), suggesting that within the intronic region, indel % will serve as a good proxy for a guide’s potency to unsilenced paternal UBE3A expression.

[1738] Example 3: Functional Phenotypic Recovery Following Disruption of UBE3A-ATS Cortical glutamatergic neurons were differentiated from induced pluripotent stem (iPS) cells using a protocol based on overexpression of the transcription factor Ngn2 (Zhang 2013, doi.org / 10.1016 / j. neuron.2013.05.029). To determine whether UBE3 A protein restoration mediated by disruption of the UBE3A-ATS could rescue neuronal network function associated with loss of UBE3A expression, Angelman patient-derived Ngn2 cortical neurons were edited with four top performing guides identified from the intronic and exonic screens along with a non-targeting guide control (gNT or GNT), and their spontaneous activity was recorded on an multi-electrode array (MEA) (Axion Biosystems, Maestro pro). The top two guide / nuclease combinations were selected from the previously described exonic and intronic guide screens based on their ability to induce a high percentage of indels in UBE3A-ATS and restore UBE3 A mRNA levels.

[1739] In brief, neurons generated from an iPS line derived from an Angelman Syndrome patient harboring a 2bp deletion in UBE3 A resulting in a loss of maternal UBE3 A expression (UConn stem cell bank, cell line Rx33) were seeded on a 48-well MEA plate in a lOuL dropletAttorney Docket No. 063586-568001WO

[1740] at a density of 7.5xl06cells / mL and maintained in human glutamatergic cortical neuron media. On day 3, cells were transduced with lentiviruses for C2 nuclease or DI nuclease expressed under the synapsin promoter at an MOI of 20 along with lentiviruses for gRNA expressed under the U6 promoter at an MOI of 20. Rat cortical astrocytes (Sartorius) were added to the cultures to support neuronal maturation. MEA recordings were performed twice a week starting at day 7 and continuing until day 45.

[1741] UBE3 A protein was measured 21 days after editing to confirm successful editing outcomes and molecular phenotypic recovery using a Jess automated western blot assay (ProteinSimple) according to manufacturer’s instructions. Editing of UBE3A-ATS using four top gRNA sequences yielded robust recovery of UBE3A protein expression to levels approaching that of neurotypical control neurons (FIG. 10A). Neurons on the MEA underwent an initial period of network maturation during the first 30 days of culture, followed by a stabilization of neuronal network activity that persisted for the remaining lifetime of the culture. Previous experiments determined the expected level of synchrony in neurotypical cultures and identified a hypersynchrony phenotype associated with a loss of UBE3A expression. This hypersynchrony was decreased in edited neurons compared to non-targeting guide treated cells and approached the empirically determined synchrony of neurotypical control patient-derived neurons (n=6 per condition) (FIG. 10B). Area Under Curve (AUC) analysis of the MEA timecourse shows that this reduction in network synchrony is highly significant in edited neurons that achieve substantial UBE3 A protein recovery (one-way ANOVA p<0.0001) (FIG. 10C). A comparison of the degree of UBE3 A protein recovery to reduction in MEA hypersynchrony phenotype as measured by AUC analysis shows that these two variables are correlated (linear regression, r-squared = 0.75) (FIG. 11). Taken together, these results suggest that type V nuclease-mediated disruption of UBE3A-ATS can restore UBE3 A protein expression and reverse neuronal hyperexcitability associated with Angelman Syndrome.

[1742] Example 4: UBE3A Protein Recovery Following Disruption of VBE3A-ATS

[1743] To determine the capacity of guides to restore UBE3 A protein in patient-derived neurons, cortical glutamatergic neurons were differentiated from induced pluripotent stem (iPS) derived from an Angelman patient harboring a type II megadeletion at the UBE3 A locus (UConn stem cell bank, cell line AG2-3). The megadeletion Angelman genotype includes a loss of approximately 5 million base pairs and includes a loss of UBE3A and neighboring genes. Neurons were generated using the protocol as described in Example 3.Attorney Docket No. 063586-568001WO

[1744] In brief, patient-derived neurons were seeded at a density of 150,000 cells / cm2in 12-well plates and cultured in human glutamatergic cortical neuron media. On day 3, cells were transduced with lentiviruses for C2 nuclease or DI nuclease expressed under the synapsin promoter at an MOI of 20 along with lentiviruses for gRNA expressed under the U6 promoter at an MOI of 20. Top guides from FIG. 7A were selected to be used in this assay, along with a non-targeting guide control (gNT or GNT) and with a research-grade ASO (PS.L 4.4 ASO) reported to potently recover UBE3 A in published reports (see, e.g., Dindot et al 2023, Science) and used as a benchmark in this assay. The cells were harvested 20 days after transduction with lentiviruses. UBE3 A protein was measured using a Jess automated western blot assay (ProteinSimple) according to manufacturer’s instructions. Several top nuclease / gRNA combinations were able to recover UBE3 A protein expression to levels close to or at levels of neurotypical control neurons (FIG. 12).

[1745] Example 5: UBE3A Protein Recovery In Vivo Using Top Guides in Humanized UBE3A-ATS Mouse Model

[1746] A humanized UBE3 A- ATS Angelman (AS / hsATS) mouse model was used in this example. This humanized Angelman mouse model combines loss of maternal Ube3a expression with a paternal allele containing a knock-in of the human UBE3A-ATS locus. The humanized Angelman mouse model recapitulates Angelman syndrome-like molecular and behavioral phenotypes and provides a more translationally relevant platform for therapies aimed at unsilencing paternal UBE3A. It enables the testing of human gRNAs disclosed in Examples 1-4.

[1747] The editing efficiency of 2 UBE3 A specific guides was assessed in the humanized mouse model using an AAV vector as a delivery vehicle. The AAV construct comprises AAV2 ITR sequences, a codon-optimized C3 nuclease polypeptide under the control of a human synapsin (hSYN) promoter, and a coding sequence for guide RNA C2_Ex5_G4 or

[1748] C2 S1 G7.6 under the control of a U6 promoter. The AAV construct further comprises a bGH polyA signal sequence, a nucleoplasmin NLS polypeptide sequence, and a peptide linker, which links the nuclease to the NLS. An illustration of this AAV construct is provided in FIG. 13A

[1749] Neonatal animals (postnatal days Pl) were administered AAV particles comprising the AAV construct described above at a dose of 4E11 vg / animal. Animals were euthanized and tissue was harvested 4 weeks post-dosing to evaluate impact on editing and protein recovery in bulk cortex tissue. As shown in FIG. 13B, editing was observed with both gRNAs in bothAttorney Docket No. 063586-568001WO

[1750] wild-type humanized mice (WT / hsATS) and Angelman humanized mice (AS / hsATS), with the C2 S1 G7.6 guide exhibiting greater editing than Cl_Ex5_G4. Furthermore, both guides were able to lead to a 2-3 fold protein recovery compared to vehicle-treated AS / hsATS mice (FIG.

[1751] 13C and 13D)

[1752] OTHER EMBODIMENTS

[1753] All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

[1754] From the above description, one skilled in the art can easily ascertain the essential characteristics of the present disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications of the present disclosure to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.

[1755] EQUIVALENTS

[1756] While several inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and / or structures for performing the function and / or obtaining the results and / or one or more of the advantages described herein, and each of such variations and / or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and / or configurations will depend upon the specific application or applications for which the inventive teachings is / are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and / or methods, if such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.Attorney Docket No. 063586-568001WO

[1757] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.

[1758] All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.

[1759] The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.” The phrase “and / or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and / or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and / or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and / or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

[1760] As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating items in a list, “or” or “and / or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of’ or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[1761] As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elementsAttorney Docket No. 063586-568001WO

[1762] and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and / or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

[1763] It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.

Claims

Attorney Docket No. 063586-568001WOWHAT IS CLAIMED IS:

1. A gene editing system for genetic editing a UBE3 A antisense transcript gene (UBE3A-ATS gene), the gene editing system comprising:(a) a CRISPR nuclease or a first nucleic acid encoding the CRISPR nuclease; and(b) a guide RNA or a second nucleic acid encoding the guide RNA, wherein the guide RNA comprises a spacer sequence that is specific to a target sequence in a UBE3 A antisense transcript gene (UBE3A-ATS gene), and a scaffold sequence recognizable by the CRISPR nuclease;wherein:(i) the target sequence is adjacent to a protospacer adjacent motif (PAM) comprising the motif of 5’-NTTN-3’, optionally 5’-NTTR-3’, in which each N independently is A, T, G, or C, and R is A or G, the PAM being located 5’ to the target sequence, or comprising the motif of 5’-NGG-3’, in which N is A, T, G, or C, the PAM being located 3’ to the target sequence; and(ii) the target sequence is located in a cluster 2 exonic region (chrl5:25,266,431-25,278,884) or an intronic region (chrl5: 25,278,885 to 25,333,728) of the UBE 3 A-ATS gene.

2. The gene editing system of claim 1, wherein the target sequence is located in the cluster 2 exonic region of the UBE3A-ATS gene.

3. The gene editing system of claim 2, wherein the target sequence is located in Exon 5.

4. The gene editing system of claim 2, wherein the target sequence comprises any one of the target sequences set forth in Table 4.

5. The gene editing system of claim 1, wherein the target sequence is located in the intronic region of the UBE3A-ATS gene.

6. The gene editing system of claim 5, wherein the target sequence is located in: (a) segment 1 of the intronic region (chrl5: 25,278,885 to 25,296,525);Attorney Docket No. 063586-568001WO(b) segment 2 of the intronic region (chrl5: 25,296,526 to 25,316,526), or(c) segment 3 of the intronic region (chrl5: 25,316,526 to 25,333,728).

7. The gene editing system of claim 6, wherein the target sequence comprises any one of the target sequences set forth in Table 6.

8. The gene editing system of any one of claims 1-7, wherein the guide RNA comprises the spacer sequence, which is any one of the spacer sequences provided in Table 4 Table 6, or Table 7.

9. The gene editing system of claim 8, wherein the target sequence is set forth below:(i) 5’-AACCAGGATTTAAGGATGCC-3’ (SEQ ID NO: 455); or(ii) 5’- GTATGAGAGATGCTGTTCTA-3’ (SEQ ID NO: 709).

10. The gene editing system of claim 9, wherein the spacer sequence in the guide RNA comprises one of the following sequences:(i) 5’- AACCAGGAUUUAAGGAUGCC -3’ (SEQ ID NO: 457); or(ii) 5’- GUAUGAGAGAUGCUGUUCUA -3’ (SEQ ID NO: 711).

11. The gene editing system of any one of claims 1-10, wherein the CRISPR nuclease comprises an amino acid sequence at least 90% identical to SEQ ID NO: 1, and optionally one or more nuclear localization signals (NLS), one or more peptide likers, or a combination thereof; and wherein the PAM motif is 5’-NTTN-3’, in which each N independent is any one of A, C, G, and T.

12. The gene editing system of claim 11, wherein the CRISPR nuclease is a variant of SEQ ID NO: 1 comprising one or more mutations at positions D581, G624, F626, N840, P868, 1926, VI 030, El 035, and / or SI 046 of SEQ ID NO: 1; optionally wherein the one or more mutations are amino acid substitutions, which optionally are D581R, G624R, F626R, N840R, P868T, I926R, V1030G, E1035R, S1046G, or a combination thereof.

13. The gene editing system of claim 12, wherein the CRISPR nuclease comprises: (i) mutations at positions D581, D911, 1926, and VI 030, which optionally are aminoAttorney Docket No. 063586-568001WOacid substitutions of D581R, D911R, I926R, and V1030G;(ii) mutations at positions D581, 1926, and VI 030, which optionally are amino acid substitutions ofD581R, I926R, and V1030G;(iii) mutations at positions D581, 1926, VI 030, and SI 046, which optionally are amino acid substitutions of D581R, I926R, V1030G, and S1046G;(iv) mutations at positions D581, G624, F626, 1926, V1030, E1035, and S1046, which optionally are amino acid substitutions of D581R, G624R, F626R, I926R, V1030G, E1035R, and S1046G;(v) mutations at positions D581, G624, F626, P868, 1926, V1030, E1035, and S1046, which optionally are amino acid substitutions of D581R, G624R, F626R, P868T, I926R, V1030G, E1035R, and S1046G; or(vi) mutations at positions D581, G624, F626, N840, P868, 1926, V1030, E1035, and S1046, which optionally are amino acid substitutions of D581R, G624R, F626R, N840R, P868T, I926R, V1030G, E1035R, and S1046G.

14. The gene editing system of claim 13, wherein the CRISPR nuclease comprises the amino acid sequence of SEQ ID NO: 3 or 1153.

15. The gene editing system of any one of claims 11-14, wherein the scaffold sequence comprises a sequence that is at least 80% identical to SEQ ID NO: 7; optionally wherein the scaffold sequence comprises the sequence of SEQ ID NO: 7.

16. The gene editing system of any one of claims 1-10, wherein the CRISPR nuclease comprises an amino acid sequence at least 90% identical to SEQ ID NO: 4 and optionally one or more NLSs, one or more peptide linkers or a combination thereof; optionally wherein the CRISPR nuclease comprises the amino acid sequence of SEQ ID NO: 5 and optionally one or more NLSs; and wherein the PAM is 5’-NTTR-3’, in which N is any one of A, C, G, and T and R is A or G.

17. The gene editing system of claim 16, wherein the scaffold sequence comprises a sequence that is at least 80% identical to SEQ ID NO: 8; optionally wherein the scaffold sequence comprises the sequence of SEQ ID NO: 8.

18. The gene editing system of any one of claims 1-10, wherein the CRISPRAttorney Docket No. 063586-568001WOnuclease comprises an amino acid sequence at least 90% identical to SEQ ID NO: 6 and optionally one or more NLSs, one or more peptide linkers or a combination thereof; optionally wherein the CRISPR nuclease comprises the amino acid sequence of SEQ ID NO: 6; and wherein the PAM is 5’-NGG-3’, in which N is any one of A, C, G, and T.

19. The gene editing system of claim 18, wherein the scaffold sequence comprises a sequence that is at least 80% identical to SEQ ID NO: 9; optionally wherein the scaffold sequence comprises the sequence of SEQ ID NO: 9.

20. The gene editing system of claim 1, wherein the guide RNA comprises a sequence set forth in Table 4, Table 6, or Table 7.

21. The gene editing system of claim 20, wherein the guide RNA comprises the sequence of any one of SEQ ID NOs: 458 and 712.

22. The gene editing system of any one of claims 1-21, which comprises the first nucleic acid encoding the CRISPR nuclease; optionally wherein the first nucleic acid is codon optimized.

23. The gene editing system of any one of claims 1-22, which comprises the first nucleic acid encoding the CRISPR nuclease and the second nucleic acid encoding the guide RNA.

24. The gene editing system of claim 23, wherein the first nucleic acid and the second nucleic acid are located on one or more vectors; optionally wherein at least one of the one or more vectors is a viral vector.

25. The gene editing system of claim 23 or claim 24, wherein the first nucleic acid and the second nucleic acid are located on one viral vector, which optionally is adeno-associated virus (AAV) vectors.

26. A gene editing system for genetic editing a UBE3 A antisense transcript gene (UBE3A-ATS gene), the gene editing system comprising a genetically modified viral particle, which comprises a viral capsid encapsulating a viral genome,Attorney Docket No. 063586-568001WOwherein the viral genome comprises a first nucleotide sequence encoding a CRISPR nuclease or a complementary sequence thereof and a second nucleotide sequence encoding a guide RNA or a complementary sequence thereof;wherein the guide RNA comprises a spacer sequence that is specific to a target sequence in a UBE3A antisense transcript gene (UBE3A-ATS gene), and a scaffold sequence recognizable by the CRISPR nuclease; andwherein:(i) the target sequence is adjacent to a protospacer adjacent motif (PAM) comprising the motif of 5’-NTTN-3’, optionally 5’-NTTR-3’, in which each N independently is A, T, G, or C, and R is A or G, the PAM being located 5’ to the target sequence, or comprising the motif of 5’-NGG-3’, in which N is A, T, G, or C, the PAM being located 3’ to the target sequence, and(ii) the target sequence is located in a cluster 2 exonic region (chrl5:25,266,431-25,278,884) or an intronic region (chrl5: 25,278,885 to 25,333,728) of the UBE3A-A TS gene.

27. The gene editing system of claim 24, wherein the CRISPR nuclease is set forth in any one of claims 11-14, 16, and 18.

28. The gene editing system of claim 26 or claim 27, wherein the target sequence is set forth in any one of claims 2-7 and 9.

29. The gene editing system of any one of claims 26-28, wherein the guide RNA is set forth in any one of claims 8, 10, 15, 17, and 18.

30. The gene editing system of any one of claims 26-29, wherein the genetically modified viral particle is an engineered AAV viral particle, which optionally comprises AAV2 capsid or AAV9 capsid.

31. The gene editing system of claim 30, wherein the viral particle is an engineered AAV viral particle comprising AAV9 capsid; optionally wherein the AAV9 capsid comprises blood-brain barrier (BBB)-penetrant capsid proteins.

32. The gene editing system of any one of claims 26-31, wherein the geneticallyAttorney Docket No. 063586-568001WOmodified viral genome is a genetically modified adeno-associated viral (AAV) genome, which comprises inverted terminal repeats (ITRs) at both 5’ and 3’ ends; optionally wherein the ITRs are AAV2 ITRs.

33. The gene editing system of any one of claims 26-32, wherein the genetically engineered viral genome comprises (a) the first nucleotide sequence and a complementary sequence of the second nucleotide sequence, or (b) a complementary sequence of the first nucleotide sequence and the second nucleotide sequence.

34. The gene editing system of any one of claims 26-33, wherein in the genetically modified viral genome, the first nucleotide sequence encoding the CRISPR nuclease polypeptide is in operable linkage to a first promoter and the second nucleotide encoding the gRNA is in operable linkage to a second promoter; optionally wherein the first promoter and the second promoter are different promoters and / or wherein the first and second promoters are in opposite orientation.

35. The gene editing system of claim 34, wherein the first promoter is a human synapsin promoter and the second promoter is a U6 promoter.

36. The gene editing system of claim 34 or claim 35, wherein the complementary sequence of the second nucleotide sequence encoding the gRNA further comprise a transcription terminator sequence downstream to the gRNA-coding sequence.

37. The gene editing system of any one of claims 34-36, wherein the first nucleotide sequence further comprises a polyA signal sequence.

38. The gene editing system of any one of claims 26-37, wherein the first nucleotide sequence encodes the CRISPR nuclease comprising the amino acid sequence of SEQ ID NO: 1153, optionally wherein the first nucleotide sequence comprises the nucleotide sequence of SEQ ID NO: 1154.

39. The gene editing system of claim 38, wherein the CRISPR nuclease further comprises a peptide linker of SEQ ID NO: 1158 and an NLS of SEQ ID NO: 1156.Attorney Docket No. 063586-568001WO40. The gene editing system of any one of claims 26-39, wherein the genetically modified viral genome comprises(a), from 5’ to 3’, a human synapsin promoter, a nucleotide sequence encoding the CRISPR nuclease polypeptide, which optionally is set forth in any one of claims 11-14, a polyA signal sequence, a nucleotide sequence complementary to the coding sequence of the guide RNA, which optionally comprises the nucleotide sequence of SEQ ID NO: 458 or 712, and a nucleotide sequence complementary to a U6 promoter; or(b) a complementary sequence of (a).

41. The gene editing system of any one of claims 26-40, wherein the genetically modified viral genome comprises AAV2 inverted terminal repeats at both the 5’ end and the 3’ end.

42. A pharmaceutical composition comprising the gene editing system of any one of claims 1-41.

43. A guide RNA comprising a spacer sequence that is specific to a target sequence in a UBE3A antisense transcript gene (UBE3A-ATS gene); wherein:(i) the target sequence is adjacent to a protospacer adjacent motif (PAM) comprising the motif of 5’-NTTN-3’, optionally 5’-NTTR-3’, in which each N independently is A, T, G, or C, and R is A or G, the PAM being located 5’ to the target sequence, or the target sequence is adjacent to a PAM comprising the motif a 5’-NGG-3’, in which N is A, T, G, or C, the PAM being located 3’ to the target sequence, and(ii) the target sequence is located in the Cluster 2 exonic region (chrl5: 25,266,431-25,278,884) or the intronic region (chrl5: 25,278,885 to 25,333,728) of the UBE3A-ATS gene.

44. The guide RNA of claim 43, wherein the target sequence is located in the cluster 2 exonic region of the UBE3A-ATS gene; optionally in Exon 5.

45. The guide RNA of claim 41, wherein the target sequence is located in the intronic region of the UBE3A-ATS gene; optionally wherein:(a) the target sequence is located in segment 1 of the intronic region (chrl5:25,278,885 to 25,296,525);Attomey Docket No. 063586-568001WO(b) the target sequence is located in segment 2 of the intronic region (chrl5:25.296.526 to 25,316,526); or(c) the target sequence is not located in segment 3 of the intronic region (chrl5:25.316.526 to 25,333,728).

46. The guide RNA of claim 43, wherein the target sequence comprises any one of the target sequences set forth in Table 4, Table 6, or Table 7.

47. The guide RNA of claim 43, wherein the target sequence is set forth below:(i) 5’-AACCAGGATTTAAGGATGCC-3’ (SEQ ID NO: 455); or (ii) 5’- GTATGAGAGATGCTGTTCTA-3’ (SEQ ID NO: 709).

48. The guide RNA of any one of claims 43-47, wherein the guide RNA further comprises a scaffold sequence.

49. The guide RNA of claim 48, wherein the scaffold sequence comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 7-9.

50. The guide RNA of any one of claims 43-49, wherein the spacer sequence in the guide RNA is any one of the spacer sequences provided in Table 4, Table 6, or Table 7.

51. The guide RNA of claim 50, wherein the spacer sequence in the guide RNA comprises one of the following sequences:(i) 5’- AACCAGGAUUUAAGGAUGCC -3’ (SEQ ID NO: 457); or (ii) 5 ’ - GUAUGAGAGAUGCUGUUCUA -3 ’ (SEQ ID NO : 711 ).

52. The guide RNA of claim 43, wherein the guide RNA comprises a sequence set forth in Table 4, Table 6, or Table 7.

53. The guide RNA of claim 43, wherein the guide RNA comprises the sequence of any one of SEQ ID NOs: 458 and 712.

54. A method of treating Angelman Syndrome comprising administering to a subject in need thereof an effective amount of the gene editing system of any one of claims 1-Attorney Docket No. 063586-568001WO41 or the pharmaceutical composition of claim 42.

55. A method of editing a UBE3A-ATS gene in a cell, comprising contacting the cell with the gene editing system of any one of claims 1-41.

56. The method of claim 55, wherein the cell is a neuronal cell.

57. The method of claim 55 or claim 56, wherein the cell is cultured in vitro.

58. The method of claim 55 or claim 56, wherein the contacting step is performed by administering the gene editing system to a subject comprising the cell.

59. A viral vector, comprising a first nucleic acid comprising a nucleotide sequence encoding a CRISPR nuclease, optionally set forth in any one of claims 11-14, 16, and 18, and a second nucleic acid comprising a nucleotide sequence encoding a guide RNA targeting a human UBE3A antisense transcript gene (UBE3A-ATS gene), optionally wherein the guide RNA is set forth in any one of claims 41-50;wherein the first nucleic acid is in operable linkage to a first promoter and the second nucleic acid is in operable linkage to a second promoter; the first and second promoter optionally being in opposite orientation and different from each other.

60. The viral vector of claim 59, wherein the second nucleic acid further comprises a transcription terminator sequence downstream to the encoding sequence for the gRNA.

61. The viral vector of claim 59 or claim 60, wherein the first promoter is a human synapsin promoter and the second promoter is a U6 promoter.

62. The viral vector of any one of claims 59-61, wherein the first nucleic acid further comprises a polyA signal sequence.

63. The viral vector of any one of claims 59-62, wherein the CRISPR nuclease comprises the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 1153, optionally wherein the nucleotide sequence encoding the CRISPR nuclease comprises SEQ ID NO: 1151, 1152, or 1154; and / orAttorney Docket No. 063586-568001WOwherein the gRNA comprises the nucleotide sequence of SEQ ID NO: 458 or 712.

64. The viral vector of any one of claims 59-63, wherein the viral vector comprises, from 5’ to 3’, a human synapsin promoter, a nucleotide sequence encoding the CRISPR nuclease, which optionally is set forth in any one of claims 11-14, 16, and 18, a polyA signal sequence, a nucleotide sequence complementary to a coding sequence for the guide RNA, and a nucleotide sequence complementary to a U6 promoter; optionally wherein viral vector further comprise a complementary sequence of a transcription terminator 5’ of the complementary sequence of the gRNA coding sequence.

65. The viral vector of claim 64, which is an AAV vector further comprising a 5’ end inverted terminal repeat (ITR) and a 3 ’ end ITR.

66. A kit comprising (i) the guide RNA set forth in any one of claims 41-50 or a nucleic acid encoding the guide RNA and / or (ii) a CRISPR nuclease or a nucleic acid encoding the CRISPR nuclease; optionally wherein the CRISPR nuclease is set forth in any one of claims 11-14, 16, and 18.

67. The kit of claim 66, which comprises one or more components of the gene editing system set forth in any one of claims 1-41, the viral particle set forth in any one of claims 26-41, or the viral vector set forth in any one of claims 59-65.